Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
Through the polyribonucleotide composition of HSV antigen construct, the HSV vaccine was constructed, which solved the problems of prevention and treatment of HSV infection in the prior art, achieved an effective immune response to HSV-1 and HSV-2, and improved defense capabilities .
Patent Information
- Application Number
- CN202380028786.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-19
- Filing Date
- 2023-01-27
- Publication Date
- 2024-11-08
AI Technical Summary
Existing HSV vaccines and treatments are difficult to effectively prevent or treat HSV-1 and HSV-2 infections, especially in the case of lifelong infections, and the problem of high transmission efficiency and prevalence.
A pharmaceutical composition comprising an HSV antigen construct, including a polyribonucleotide encoding the HSV-1 and HSV-2 antigens, is provided for constructing an HSV vaccine to prevent or treat HSV infection by eliciting an immune response against HSV.
By eliciting a strong immune response against HSV, it improves its defense against HSV-1 and HSV-2, potentially reducing infection rate and transmission efficiency, and providing more effective prevention and treatment options.
Smart Images

Figure CN118922194A_ABST
Abstract
Description
Background Art
[0001] Herpes simplex virus (HSV), often referred to simply as herpes, is divided into two types: HSV type 1 (HSV-1, or oral herpes) and HSV type 2 (HSV-2, or genital herpes). According to the World Health Organization, 3.7 billion people under the age of 50 (67% of the global population) are infected with HSV-1. HSV-1 prevalence is highest in Africa and lowest in the Americas. An estimated 491 million people aged 15-49 (13% of the global population) are infected with HSV-2 worldwide. More women than men are infected with HSV-2 because HSV is sexually transmitted more efficiently from male to female than from female to male. The estimated prevalence of HSV-2 infection is highest in Africa, followed by the Americas. The prevalence of HSV-2 has also been shown to increase with age, although historically, the highest number of new infections has occurred in adolescents. Both HSV-1 and HSV-2 infections are lifelong. Summary of the Invention
[0002] The present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) and related technologies (e.g., methods) for delivering specific herpes simplex virus (HSV) antigenic constructs (e.g., HSV-1 antigenic constructs, HSV-2 antigenic constructs, or a combination thereof) to a subject (e.g., a patient). In particular, the present disclosure provides HSV (e.g., HSV-1, HSV-2, or both) vaccine compositions and related technologies (e.g., methods). The present disclosure includes the unexpected discovery that the HSV antigens and antigenic fragments thereof provided in Tables 3-5 below are particularly advantageous for use in preventing or treating HSV, for example, in HSV antigenic constructs and / or HSV vaccines, as further disclosed herein.
[0003] The present disclosure provides, for example, polyribonucleotides encoding one or more HSV antigens (e.g., HSV-1 antigens, HSV-2 antigens, or a combination thereof) or antigenic fragments thereof. In some embodiments, such polyribonucleotides can be part of an RNA construct. In some embodiments, the polyribonucleotides or RNA constructs described herein can be part of a composition (e.g., a pharmaceutical composition, such as an immunogenic composition, such as a vaccine).
[0004] The present disclosure provides polyribonucleotides encoding polypeptides. In some embodiments, the polypeptide comprises one or more herpes simplex virus (HSV) antigens or antigenic fragments thereof.
[0005] In some embodiments, the one or more HSV antigens or antigenic fragments thereof include: (i) an HSV-1 antigen or an antigenic fragment thereof, (ii) an HSV-2 antigen or an antigenic fragment thereof, or (iii) a combination thereof.
[0006] In some embodiments, the polypeptide comprises a single HSV antigen or an antigenic fragment thereof. In some embodiments, the polypeptide comprises a single HSV antigen. In some embodiments, the polypeptide comprises a single HSV antigen.
[0007] In some embodiments, the polypeptide comprises two or more HSV antigens or antigenic fragments thereof. In some embodiments, the polypeptide comprises two or more HSV antigens. In some embodiments, the polypeptide comprises two or more HSV antigenic fragments, wherein each of the two or more HSV antigenic fragments is a fragment of a different HSV antigen. In some embodiments, the polypeptide comprises two or more HSV antigenic fragments, wherein at least two of the HSV antigenic fragments are fragments from the same HSV antigen. In some embodiments, the polypeptide comprises three or more HSV antigens or antigenic fragments thereof. In some embodiments, the polypeptide comprises four or more HSV antigens or antigenic fragments thereof.
[0008] In some embodiments, the polypeptide does not comprise a full-length HSV antigen.
[0009] In some embodiments, the one or more HSV antigens or antigenic fragments thereof include one or more T cell antigens or antigenic fragments thereof. In some embodiments, the one or more HSV antigens or antigenic fragments thereof include one or more B cell antigens or antigenic fragments thereof.
[0010] In some embodiments, the one or more HSV antigens or antigenic fragments thereof have at least 80% sequence identity, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity, to one or more sequences selected from SEQ ID NOs: 1-74, or antigenic fragments thereof. In some embodiments, the polypeptide comprises one or more HSV-2 antigens or antigenic fragments thereof, comprising or consisting of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 174-196.
[0011] In some embodiments, the one or more HSV antigens or antigenic fragments thereof comprise: (i) one or more HSV RS1 polypeptides or antigenic fragments thereof, (ii) one or more HSV RL2 polypeptides or antigenic fragments thereof, (iii) one or more HSV UL1 polypeptides or antigenic fragments thereof, (iv) one or more HSV UL5 polypeptides or antigenic fragments thereof, (v) one or more HSV UL9 polypeptides or antigenic fragments thereof, (vi) one or more HSV UL19 polypeptides or antigenic fragments thereof, (vii) one or more HSV UL21 polypeptides or antigenic fragments thereof, (viii) one or more HSV UL25 polypeptides or antigenic fragments thereof, (ix) one or more HSV UL27 polypeptides or antigenic fragments thereof, (x) one or more HSV UL29 polypeptides or antigenic fragments thereof, (xi) one or more HSV UL30 polypeptides or antigenic fragments thereof, (xii) one or more HSV UL39 polypeptides or antigenic fragments thereof, (xiii) one or more HSV UL40 polypeptides or antigenic fragments thereof, (xiv) one or more HSV UL46 polypeptides or antigenic fragments thereof, (xv) one or more HSV UL47 polypeptide or an antigenic fragment thereof, (xvi) one or more HSV UL48 polypeptides or antigenic fragments thereof, (xvii) one or more HSV UL49 polypeptides or antigenic fragments thereof, (xviii) one or more HSV UL52 polypeptides or antigenic fragments thereof, (xix) one or more HSV UL54 polypeptides or antigenic fragments thereof, or (xx) a combination thereof.In some embodiments, the polypeptide comprises one or more HSV antigenic fragments, and the one or more HSV antigenic fragments comprise: (i) one or more HSV RS1 polypeptide antigenic fragments, (ii) one or more HSV RL2 polypeptide antigenic fragments, (iii) one or more HSV UL1 polypeptide antigenic fragments, (iv) one or more HSV UL5 polypeptide antigenic fragments, (v) one or more HSV UL9 polypeptide antigenic fragments, (vi) one or more HSV UL19 polypeptide antigenic fragments, (vii) one or more HSV UL21 polypeptide antigenic fragments, (viii) one or more HSV UL25 polypeptide antigenic fragments, (ix) one or more HSV UL27 polypeptide antigenic fragments, (x) one or more HSV UL29 polypeptide antigenic fragments, (xi) one or more HSV UL30 polypeptide antigenic fragments, (xii) one or more HSV UL39 polypeptide antigenic fragments, (xiii) one or more HSV UL40 polypeptide antigenic fragments, (xiv) one or more HSV UL46 polypeptide antigenic fragments, (xv) one or more HSV UL47 polypeptide antigenic fragment, (xvi) one or more HSV UL48 polypeptide antigenic fragment, (xvii) one or more HSV UL49 polypeptide antigenic fragment, (xviii) one or more HSV UL52 polypeptide antigenic fragment, (xix) one or more HSV UL54 polypeptide antigenic fragment, or (xx) a combination thereof.
[0012] In some embodiments, the polypeptide comprises one or more HSV RL2 polypeptides or antigenic fragments thereof, one or more HSV RS1 polypeptides or antigenic fragments thereof, and one or more HSV UL54 polypeptides or antigenic fragments thereof. In some embodiments, the polypeptide comprises an HSV-1 gD secretion signal, one or more RL2 polypeptides or antigenic fragments thereof, one or more RS1 polypeptides or antigenic fragments thereof, one or more UL54 polypeptides or antigenic fragments thereof, and MITD.
[0013] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, a UL54 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 197.
[0014] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL54 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 201.
[0015] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-2 gD secretion signal, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, a UL54 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 205.
[0016] In some embodiments, the polypeptide comprises one or more HSV UL29 polypeptides or antigenic fragments thereof, one or more HSV UL39 polypeptides or antigenic fragments thereof, one or more HSV UL49 polypeptides or antigenic fragments thereof, and one or more HSV UL9 polypeptides or antigenic fragments thereof. In some embodiments, the polypeptide comprises an HSV-1 gD secretion signal, one or more HSV UL29 polypeptides or antigenic fragments thereof, one or more HSV UL39 polypeptides or antigenic fragments thereof, one or more HSV UL49 polypeptides or antigenic fragments thereof, one or more HSV UL9 polypeptides or antigenic fragments thereof, and MITD.
[0017] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL29 polypeptide or an antigenic fragment thereof, a linker, a UL39 polypeptide or an antigenic fragment thereof, a linker, a UL49 polypeptide or an antigenic fragment thereof, a linker, a UL9 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 198.
[0018] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL9 polypeptide or an antigenic fragment thereof, a linker, a UL49 polypeptide or an antigenic fragment thereof, a linker, a UL39 polypeptide or an antigenic fragment thereof, a linker, a UL29 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 202.
[0019] In some embodiments, the polypeptide comprises one or more HSV UL30 polypeptides or antigenic fragments thereof, one or more HSV UL40 polypeptides or antigenic fragments thereof, one or more HSV UL5 polypeptides or antigenic fragments thereof, and one or more HSV UL52 polypeptides or antigenic fragments thereof. In some embodiments, the polypeptide comprises an HSV-1 gD secretion signal, one or more HSV UL30 polypeptides or antigenic fragments thereof, one or more HSV UL40 polypeptides or antigenic fragments thereof, one or more HSV UL5 polypeptides or antigenic fragments thereof, one or more HSV UL52 polypeptides or antigenic fragments thereof, and MITD.
[0020] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL40 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL52 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 199.
[0021] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL52 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL40 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 203.
[0022] In some embodiments, the polypeptide comprises one or more HSV UL1 polypeptides or antigenic fragments thereof, one or more HSV UL19 polypeptides or antigenic fragments thereof, one or more HSV UL21 polypeptides or antigenic fragments thereof, one or more HSV UL27 polypeptides or antigenic fragments thereof, one or more HSV UL46 polypeptides or antigenic fragments thereof, one or more HSV UL47 polypeptides or antigenic fragments thereof, one or more UL48 polypeptides or antigenic fragments thereof, and one or more HSV UL25 polypeptides or antigenic fragments thereof. In some embodiments, the polypeptide comprises an HSV-1 gD secretion signal, one or more HSV UL1 polypeptides or antigenic fragments thereof, one or more HSV UL19 polypeptides or antigenic fragments thereof, one or more HSV UL21 polypeptides or antigenic fragments thereof, one or more HSV UL27 polypeptides or antigenic fragments thereof, one or more HSV UL46 polypeptides or antigenic fragments thereof, one or more HSV UL47 polypeptides or antigenic fragments thereof, one or more UL48 polypeptides or antigenic fragments thereof, and one or more HSV UL25 polypeptides or antigenic fragments thereof, and MITD.
[0023] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, an HSV UL1 polypeptide or an antigenic fragment thereof, a linker, an HSV UL19 polypeptide or an antigenic fragment thereof, a linker, an HSV UL21 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL46 polypeptide or an antigenic fragment thereof, a linker, an HSV UL47 polypeptide or an antigenic fragment thereof, a linker, an HSV UL25 polypeptide or an antigenic fragment thereof, a linker, an HSV UL48 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 200.
[0024] In some embodiments, the polypeptide comprises, from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, an HSV UL48 polypeptide or an antigenic fragment thereof, a linker, an HSV UL25 polypeptide or an antigenic fragment thereof, a linker, an HSV UL47 polypeptide or an antigenic fragment thereof, a linker, an HSV UL46 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL21 polypeptide or an antigenic fragment thereof, a linker, an HSV UL19 polypeptide or an antigenic fragment thereof, a linker, an HSV UL1 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence according to SEQ ID NO: 204.
[0025] In some embodiments, the one or more HSV antigens or antigenic fragments thereof comprise one or more HSV glycoproteins. In some embodiments, the one or more HSV glycoproteins include HSV glycoprotein B (gB), HSV glycoprotein E (gE), HSV glycoprotein G (gG), HSV glycoprotein H (gH), HSV glycoprotein I (gI), HSV glycoprotein L (gL), or a combination thereof.
[0026] In some embodiments, the polypeptide comprises a single HSV antigen. In some embodiments, the single HSV antigen is an HSV glycoprotein. In some embodiments, the HSV glycoprotein is a full-length HSV glycoprotein. In some embodiments, the HSV glycoprotein is HSV gB, HSV gE, HSV gG, HSV gH, HSV gl, and HSV gL.
[0027] In some embodiments, the HSV glycoprotein is HSV-2 gB. In some embodiments, HSV-2 gB is or comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 7, 8, 9, or 74. In some embodiments, HSV-2 gB consists of or comprises the amino acid sequence according to SEQ ID NO: 7, 8, 9, or 74.
[0028] In some embodiments, the HSV glycoprotein is HSV-2 gE. In some embodiments, the HSV-2 gE is or comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 66, 67, 68, or 69. In some embodiments, the HSV-2 gE consists of or comprises an amino acid sequence according to SEQ ID NO: 66, 67, 68, or 69. In some embodiments, the sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 80, 81, 82, 83, or 84.
[0029] In some embodiments, the HSV glycoprotein is HSV-2gH. In some embodiments, HSV-2gH is or comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 70, 71, 72, or 74. In some embodiments, HSV-2gH consists of or comprises the amino acid sequence according to SEQ ID NO: 70, 71, 72, or 74.
[0030] In some embodiments, the HSV glycoprotein is HSV-2 gI. In some embodiments, HSV-2 gI is or comprises an amino acid sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 62, 63, 64, or 65. In some embodiments, HSV-2 gI consists of or comprises an amino acid sequence according to SEQ ID NO: 62, 63, 64, or 65. In some embodiments, the sequence is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 75, 76, 77, 78, or 79.
[0031] In some embodiments, the HSV glycoprotein is HSV-2 gL. In some embodiments, HSV-2 gL is or comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 58, 59, 60, or 61. In some embodiments, HSV-2 gL consists of or comprises the amino acid sequence according to SEQ ID NO: 58, 59, 60, or 61.
[0032] In some embodiments, the polypeptide comprises a secretion signal. In some embodiments, the secretion signal comprises or consists of a viral secretion signal. In some embodiments, the viral secretion signal comprises or consists of an HSV secretion signal. In some embodiments, the secretion signal is a heterologous secretion signal. In some embodiments, the HSV secretion signal comprises or consists of an HSV-1 or HSV-2 secretion signal.
[0033] In some embodiments, the HSV secretion signal is selected from: a) a gD2 secretion signal; b) a gD1 secretion signal; c) a gB1 secretion signal; d) a gI2 secretion signal; e) a gE2 secretion signal; f) a gC2 secretion signal; g) an Eboz secretion signal; h) an IL2 secretion signal; and i) an HLA-DR secretion signal.
[0034] In some embodiments, the HSV secretion signal comprises or consists of an HSV gD secretion signal. In some embodiments, the HSV gD secretion signal comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 87. In some embodiments, the HSV gD secretion signal comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 88. In some embodiments, the HSV gD secretion signal consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 110. In some embodiments, the HSV gD secretion signal consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 111.
[0035] In some embodiments, the secretion signal is located at the N-terminus of the polypeptide.
[0036] In some embodiments, the HSV secretion signal comprises or consists of the HSV-2 glycoprotein I (gI) secretion signal.
[0037] In some embodiments, the HSV-2 gI secretion signal comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 107.
[0038] In some embodiments, the HSV-2 gI secretion signal comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 108.
[0039] In some embodiments, the polypeptide comprises a transmembrane region. In some embodiments, the transmembrane region comprises or consists of a viral transmembrane region. In some embodiments, the transmembrane region comprises or consists of an HSV transmembrane region. In some embodiments, the HSV transmembrane region comprises or consists of an HSV-1 or HSV-2 transmembrane region. In some embodiments, the HSV transmembrane region comprises or consists of an HSV gD transmembrane region. In some embodiments, the HSV gD transmembrane region consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 160.
[0040] In some embodiments, the polypeptide does not comprise a transmembrane region.
[0041] In some embodiments, the polypeptide comprises a multimerization domain.
[0042] In some embodiments, the polypeptide comprises one or more linkers. A polyribonucleotide as described in item 215, wherein the one or more linkers comprise one or more glycine (G) residues and / or one or more serine (S) residues. In some embodiments, the one or more linkers comprise an amino acid sequence according to SEQ ID NO: 163 or consist of an amino acid sequence according to SEQ ID NO: 163. In some embodiments, the one or more linkers comprise an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 165 or consist of it. In some embodiments, the one or more linkers comprise an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 168 or consist of it. In some embodiments, one or more linkers comprise or consist of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 217.
[0043] In some embodiments, the polyribonucleotide is an isolated polyribonucleotide.
[0044] In some embodiments, the polyribonucleotide is an engineered polyribonucleotide.
[0045] In some embodiments, the polyribonucleotide is a codon-optimized polyribonucleotide.
[0046] The present disclosure also provides RNA constructs.
[0047] In some embodiments, the RNA construct comprises, in 5' to 3' order: (i) a 5'UTR; (ii) any polyribonucleotide according to the present disclosure; (iv) a 3'UTR; and (v) a poly A tail sequence. In some embodiments, the RNA construct comprises (i) a 5'UTR comprising or consisting of a modified human α-globin 5'-UTR; (ii) a 3'UTR comprising or consisting of a first sequence from a split amino-terminal enhancer (AES) messenger RNA and a second sequence from a mitochondrially encoded 12S ribosomal RNA; or (iii) both.
[0048] In some embodiments, the 5'UTR comprises or consists of a ribonucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 208. In some embodiments, the 5'UTR comprises or consists of a ribonucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 209. In some embodiments, the 3'UTR comprises or consists of a ribonucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 215. In some embodiments, the 3'UTR comprises or consists of a ribonucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to SEQ ID NO: 216. In some embodiments, the poly A tail sequence is a split poly A tail sequence. In some embodiments, the split poly A tail sequence is composed of a ribonucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to a ribonucleic acid sequence selected from SEQ ID NO: 210, 212 or 213. In some embodiments, the RNA construct further comprises a 5' cap. In some embodiments, the RNA construct comprises a cap proximal sequence comprising positions +1, +2, +3, +4 and +5 of the polyribonucleotides. In some embodiments, the 5' cap comprises or consists of m7(3'OMeG)(5')ppp(5')(2'OMeA1)pG2, wherein A1 is position +1 of the polyribonucleotide and G2 is position +2 of the polyribonucleotide. In some embodiments, the cap-proximal sequence comprises A1 and G2 of the Cap1 structure and a sequence comprising A3A4U5 (SEQ ID NO: 207) at positions +3, +4, and +5 of the polyribonucleotide, respectively.
[0049] In some embodiments, the polyribonucleotide includes modified uridines instead of all uridines, optionally wherein each modified uridine is N1-methyl-pseudouridine.
[0050] The present disclosure also provides compositions.
[0051] In some embodiments, compositions comprises one or more polyribonucleotides according to the present disclosure.In some embodiments, compositions comprises one or more RNA constructs as described in any one of the 224th to 236th.In some embodiments, compositions also comprises lipid nanoparticle, polyplex (polyplex) (PLX), lipidated polyplex (LPLX) or liposome, wherein one or more polyribonucleotides are encapsulated in lipid nanoparticle, polyplex (PLX), lipidated polyplex (LPLX) or liposome wholly or in part.In some embodiments, compositions also comprises lipid nanoparticle, wherein one or more polyribonucleotides are encapsulated in lipid nanoparticle.
[0052] The present disclosure also provides pharmaceutical compositions.
[0053] In some embodiments, the pharmaceutical composition comprises a composition according to the present disclosure and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises a cryoprotectant, optionally wherein the cryoprotectant is sucrose. In some embodiments, the pharmaceutical composition comprises a buffered aqueous solution, optionally wherein the buffered aqueous solution comprises one or more of Tris base, Tris HCl, NaCl, KCl, Na2HPO4, and KH2PO4.
[0054] The present disclosure also provides combinations.
[0055] In some embodiments, the combination comprises a first polyribonucleotide according to the present disclosure; and a second polyribonucleotide according to the present disclosure, wherein the first polyribonucleotide and the second polyribonucleotide are different.
[0056] In some embodiments, the combination comprises a first pharmaceutical composition and a second pharmaceutical composition, wherein the first pharmaceutical composition comprises a first polyribonucleotide, wherein the first polyribonucleotide is a polyribonucleotide according to the present disclosure; and the second pharmaceutical composition comprises a second polyribonucleotide, wherein the second polyribonucleotide is a polyribonucleotide according to the present disclosure, wherein the first polyribonucleotide and the second polyribonucleotide are different.
[0057] In some embodiments, the combination comprises a first polyribonucleotide according to the present disclosure; and a second polyribonucleotide encoding a second polypeptide, wherein the second polypeptide comprises one or more HSV RL2 polypeptides or antigenic fragments thereof, one or more HSV RS1 polypeptides or antigenic fragments thereof, and one or more HSV UL54 polypeptides or antigenic fragments thereof. In some embodiments, the combination comprises: a first pharmaceutical composition comprising the first polyribonucleotide, wherein the first polyribonucleotide is a polyribonucleotide according to the present disclosure; and a second pharmaceutical composition comprising the second polyribonucleotide, wherein the second polyribonucleotide comprises one or more HSV RL2 polypeptides or antigenic fragments thereof, one or more HSV RS1 polypeptides or antigenic fragments thereof, and one or more HSV UL54 polypeptides or antigenic fragments thereof. In some embodiments, the second polypeptide comprises, in order from N-terminus to C-terminus, an HSV-1 gD secretion signal, an RL2 polypeptide or antigenic fragment thereof, a linker, an RL2 polypeptide or antigenic fragment thereof, a linker, an RS1 polypeptide or antigenic fragment thereof, a linker, a UL54 polypeptide or antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 197. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, a UL54 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 201. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-2 gD secretion signal, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, a UL54 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 205.
[0058] In some embodiments, the combination comprises a first polyribonucleotide according to the present disclosure; and a second polyribonucleotide encoding a second polypeptide, wherein the second polypeptide comprises one or more HSV UL29 polypeptides or antigenic fragments thereof, one or more HSV UL39 polypeptides or antigenic fragments thereof, one or more HSV UL49 polypeptides or antigenic fragments thereof, and one or more HSV UL9 polypeptides or antigenic fragments thereof. In some embodiments, the combination comprises a first pharmaceutical composition and a second pharmaceutical composition, wherein the first pharmaceutical composition comprises a first polyribonucleotide, wherein the first polyribonucleotide is a polyribonucleotide according to the present disclosure; and the second pharmaceutical composition comprises a second polyribonucleotide, wherein the second polypeptide comprises one or more HSV UL29 polypeptides or antigenic fragments thereof, one or more HSV UL39 polypeptides or antigenic fragments thereof, one or more HSV UL49 polypeptides or antigenic fragments thereof, and one or more HSV UL9 polypeptides or antigenic fragments thereof. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, a UL29 polypeptide or an antigenic fragment thereof, a linker, a UL39 polypeptide or an antigenic fragment thereof, a linker, a UL49 polypeptide or an antigenic fragment thereof, a linker, a UL9 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 198. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, a UL9 polypeptide or an antigenic fragment thereof, a linker, a UL49 polypeptide or an antigenic fragment thereof, a linker, a UL39 polypeptide or an antigenic fragment thereof, a linker, a UL29 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:202.
[0059] In some embodiments, the combination comprises a first polyribonucleotide according to the present disclosure; and a second polyribonucleotide encoding a second polypeptide, wherein the second polypeptide comprises one or more HSV UL30 polypeptides or antigenic fragments thereof, one or more HSV UL40 polypeptides or antigenic fragments thereof, one or more HSV UL5 polypeptides or antigenic fragments thereof, and one or more HSV UL52 polypeptides or antigenic fragments thereof. In some embodiments, the combination comprises a first pharmaceutical composition and a second pharmaceutical composition, wherein the first pharmaceutical composition comprises a first polyribonucleotide, wherein the first polyribonucleotide is a polyribonucleotide according to the present disclosure; and the second pharmaceutical composition comprises a second polyribonucleotide, wherein the second polypeptide comprises one or more HSV UL30 polypeptides or antigenic fragments thereof, one or more HSV UL40 polypeptides or antigenic fragments thereof, one or more HSV UL5 polypeptides or antigenic fragments thereof, and one or more HSV UL52 polypeptides or antigenic fragments thereof. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL40 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL52 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 199. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, a UL52 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL40 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 203.
[0060] In some embodiments, the combination comprises a first polyribonucleotide according to the present disclosure; and a second polyribonucleotide encoding a second polypeptide, wherein the second polypeptide comprises one or more HSV UL1 polypeptides or antigenic fragments thereof, one or more HSV UL19 polypeptides or antigenic fragments thereof, one or more HSV UL21 polypeptides or antigenic fragments thereof, one or more HSV UL27 polypeptides or antigenic fragments thereof, one or more HSV UL46 polypeptides or antigenic fragments thereof, one or more HSV UL47 polypeptides or antigenic fragments thereof, one or more UL48 polypeptides or antigenic fragments thereof, and one or more HSV UL25 polypeptides or antigenic fragments thereof. In some embodiments, the combination comprises a first pharmaceutical composition comprising a first polyribonucleotide, wherein the first polyribonucleotide is a polyribonucleotide according to the present disclosure; and a second pharmaceutical composition comprising a second polyribonucleotide, wherein the second polypeptide comprises one or more HSV UL1 polypeptides or antigenic fragments thereof, one or more HSV UL19 polypeptides or antigenic fragments thereof, one or more HSV UL21 polypeptides or antigenic fragments thereof, one or more HSV UL27 polypeptides or antigenic fragments thereof, one or more HSV UL46 polypeptides or antigenic fragments thereof, one or more HSV UL47 polypeptides or antigenic fragments thereof, one or more UL48 polypeptides or antigenic fragments thereof, and one or more HSV UL25 polypeptides or antigenic fragments thereof. In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, an HSV UL1 polypeptide or an antigenic fragment thereof, a linker, an HSV UL19 polypeptide or an antigenic fragment thereof, a linker, an HSV UL21 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL46 polypeptide or an antigenic fragment thereof, a linker, an HSV UL47 polypeptide or an antigenic fragment thereof, a linker, an HSV UL25 polypeptide or an antigenic fragment thereof, a linker, an HSV UL48 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 200.In some embodiments, the second polypeptide comprises, from N-terminus to C-terminus, an HSV-1 gD secretion signal, an HSV UL48 polypeptide or an antigenic fragment thereof, a linker, an HSV UL25 polypeptide or an antigenic fragment thereof, a linker, an HSV UL47 polypeptide or an antigenic fragment thereof, a linker, an HSV UL46 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL21 polypeptide or an antigenic fragment thereof, a linker, an HSV UL19 polypeptide or an antigenic fragment thereof, a linker, an HSV UL1 polypeptide or an antigenic fragment thereof, a linker, and a MITD. In some embodiments, the second polypeptide comprises or consists of an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 204. In some embodiments, the second polypeptide is HSV gB. In some embodiments, the second polypeptide consists of or comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO: 7, 8, 9, or 74.
[0061] The present disclosure also provides a method comprising administering the polyribonucleotide according to the present disclosure or the RNA construct according to the present disclosure to a subject.
[0062] The present disclosure also provides a method comprising administering a composition according to the present disclosure to a subject.
[0063] The present disclosure also provides a method comprising administering one or more doses of a composition according to the present disclosure or a pharmaceutical composition according to the present disclosure to a subject.
[0064] The present disclosure also provides a method comprising administering to a subject a combination according to the present disclosure.
[0065] The present disclosure also provides a pharmaceutical composition according to the present disclosure for treating HSV infection, comprising administering one or more doses of the pharmaceutical composition to a subject.
[0066] The present disclosure also provides a pharmaceutical composition according to the present disclosure for preventing HSV infection, comprising administering one or more doses of the pharmaceutical composition to a subject.
[0067] In some embodiments, the methods according to the present disclosure or the uses of the pharmaceutical compositions according to the present disclosure comprise administering two or more doses of the pharmaceutical composition to the subject.
[0068] In some embodiments, the methods according to the present disclosure or the uses of the pharmaceutical compositions according to the present disclosure comprise administering three or more doses of the pharmaceutical composition to the subject.
[0069] The present disclosure also provides a method comprising administering a combination according to the present disclosure to a subject. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are administered on the same day. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are administered on different days. In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are administered to the subject at different locations on the subject's body. In some embodiments, the method is a method for treating an HSV infection. In some embodiments, the method is a method for preventing an HSV infection. In some embodiments, the subject has an HSV infection or is at risk of developing an HSV infection.
[0070] In some embodiments, the subject is a human.
[0071] In some embodiments, administration induces an anti-HSV immune response in the subject. In some embodiments, the anti-HSV immune response in the subject includes an adaptive immune response. In some embodiments, the anti-HSV immune response in the subject includes a T cell response. In some embodiments, the T cell response is or includes a CD4+ T cell response. In some embodiments, the T cell response is or includes a CD8+ T cell response. In some embodiments, the anti-HSV immune system response includes a B cell response. In some embodiments, the anti-HSV immune system response includes the production of antibodies against one or more HSV antigens or antigenic fragments thereof, wherein the one or more HSV antigens or antigenic fragments thereof are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to one or more sequences selected from SEQ ID NO: 1-74 or antigenic fragments thereof.
[0072] The present disclosure also provides use of the pharmaceutical composition according to the present disclosure in treating herpes simplex virus infection.
[0073] The present disclosure also provides use of the pharmaceutical composition according to the present disclosure in preventing herpes simplex virus infection.
[0074] The present disclosure also provides use of the pharmaceutical composition according to the present invention for inducing an anti-herpes simplex immune response in a subject.
[0075] The present disclosure also provides polypeptides encoded by the polyribonucleotides according to the present disclosure.
[0076] The present disclosure also provides a polypeptide encoded by the RNA construct of any one of items 224 to 236.
[0077] The present disclosure also provides a host cell comprising a polyribonucleotide according to the present disclosure.
[0078] The present disclosure also provides a host cell comprising the RNA construct according to the present disclosure.
[0079] The present disclosure also provides a host cell comprising a polypeptide according to the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Figure 1 is a schematic diagram of an HSV particle.
[0081] Figure 2 This is a schematic overview of the HSV life cycle. Figure 2 Modified from Ibanez, FJ et al., “Experimental Dissection of the Lytic Replication Cycles of Herpes Simplex Virus in vitro,” Front Microbiol. 2018;9:2406, which is incorporated herein by reference in its entirety.
[0082] Figure 3 Schematic diagram of the model of HSV latent infection. Figure 3 Modified from Knipe, DM et al., “Clues to mechanisms of herpesviral latent infection and potential cures,” PNAS 2015 Sep 29 112(39) 11993-11994, which is incorporated herein by reference in its entirety.
[0083] Figure 4 This table summarizes the clinical trial results of HSV candidate vaccines. This table has been modified according to Aschner, CB and Herold, BC (2021), Alphaherpesvirus vaccines. Current Issues in Molecular Biology, 41, 469-508, which is incorporated herein by reference in its entirety.
[0084] Figure 5This table summarizes the HSV-2 vaccine candidates in preclinical development. This table has been modified from Aschner, CB and Herold, BC (2021), Alphaherpesvirus vaccines. Current Issues in Molecular Biology, 41, 469-508, which is incorporated herein by reference in its entirety.
[0085] Figure 6 This is a heatmap evaluating the phylogeny and homology of HSV-1 and HSV-2 genes. As shown, HSV-1 and HSV-2 genes are homologous, with approximately 75% sequence identity. HSV-2 exhibits the least inter-strain variability.
[0086] Figure 7 Included are line graphs depicting the times when intermediate early, early, and late genes are expressed following HSV infection.
[0087] Figure 8 is a table showing certain characteristics of the data analyzed by Hosken 2006, Jing 2012, and Long 2014, including HSV species, number of subjects, number of genes measured, experimental methods, and symptom status of the subjects.
[0088] Figure 9 is a graph showing the percentage of subjects identified in the data analyzed by Hosken 2006 who had T cells targeting products of each of the 48 analyzed HSV genes at levels above the indicated thresholds (greater than 20 SFU / 10 6 ). Data taken from Hosken 2006.
[0089] Figure 10 Graph showing the percentage of subjects identified in the Long 2014 analysis who had T cells and / or CD4 T cells targeting products of each of the 75 analyzed HSV genes. Data adapted from the Long 2014 figure.
[0090] Figure 11This is a set of three graphs showing correlations between pairs of datasets analyzed from the literature, specifically between Hosken 2006 and Jing 2012, between Hosken 2006 and Long 2014, or between Jing 2012 and Long 2014, for T cells detected targeting each of a series of individual HSV genes. The R value for each graph is shown. Despite the differences in species, a Hosken 2006 / Jing 2012 correlation was observed (Jing 2012 HSV-1, Hosken 2006 HSV-2). No correlation was observed between the Long 2014 data and either the Hosken 2006 or Jing 2012 data.
[0091] Figure 12 Graph showing expression levels for each of a series of HSV genes determined by analysis of multiple datasets from different sources, including human cells, minced meat, and DRGs from latently infected tree shrews. The horizontal dashed line shows the determined median expression.
[0092] Figure 13 The % of T cells targeting HSV gene products and the median expression of each of the various HSV genes are plotted from Hosken 2006 (see Figure 12 Threshold values indicate genes that are immunogenic and well expressed (the upper right quadrant based on the dashed line indicates the threshold value).
[0093] Figure 14 The % of T cells targeting HSV gene products and the median expression of each of the various HSV genes from Jing 2012 are plotted (see Figure 12 Threshold values indicate genes that are immunogenic and well expressed (the upper right quadrant based on the dashed line indicates the threshold value).
[0094] Figure 15 Depicted are conservation scores determined for amino acids located at positions along the RL2 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0095] Figure 16 Depicted are conservation scores determined for amino acids located at positions along the RS1 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0096] Figure 17 Depicted are conservation scores determined for amino acids located at positions along the UL19 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0097] Figure 18 Depicted are conservation scores determined for amino acids located at positions along the UL1 consensus sequence.For this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0098] Figure 19 Depicted are conservation scores determined for amino acids located at positions along the UL21 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0099] Figure 20 Depicted are conservation scores determined for amino acids located at positions along the UL25 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0100] Figure 21 Depicted are conservation scores determined for amino acids located along the UL27 consensus sequence. UL27 encodes HSV gB. For this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0101] Figure 22 Depicted are conservation scores determined for amino acids located at positions along the UL29 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0102] Figure 23Depicted are conservation scores determined for amino acids located at positions along the UL30 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0103] Figure 24 Depicted are conservation scores determined for amino acids located at positions along the UL39 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0104] Figure 25 Depicted are conservation scores determined for amino acids located at positions along the UL40 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0105] Figure 26 Depicted are conservation scores determined for amino acids located at positions along the UL46 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0106] Figure 27 Depicted are conservation scores determined for amino acids located at positions along the UL47 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0107] Figure 28 Depicted are conservation scores determined for amino acids located at positions along the UL48 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0108] Figure 29Depicted are conservation scores determined for amino acids located at positions along the UL49 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0109] Figure 30 Depicted are conservation scores determined for amino acids located at positions along the UL52 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0110] Figure 31 Depicted are conservation scores determined for amino acids located at positions along the UL54 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0111] Figure 32 Depicted are conservation scores determined for amino acids located at positions along the UL5 consensus sequence. To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0112] Figure 33 Depicted are conservation scores determined for amino acids located at positions along the UL9 consensus sequence.To perform this analysis, complete HSV-1 and HSV-2 genomes were downloaded from the VIPR database, and HSV-1 strain 17 and HSV-2 strain HG52 were used as reference strains for HSV-1 and HSV-2, respectively.
[0113] Figure 34 Depicted are HSV strain conservation scores determined for amino acids located at positions along the RL2 consensus sequence.
[0114] Figure 35 Depicted are HSV strain conservation scores determined for amino acids located at positions along the RS1 consensus sequence.
[0115] Figure 36 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL19 consensus sequence.
[0116] Figure 37 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL1 consensus sequence.
[0117] Figure 38 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL21 consensus sequence.
[0118] Figure 39 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL25 consensus sequence.
[0119] Figure 40 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL27 consensus sequence.
[0120] Figure 41 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL29 consensus sequence.
[0121] Figure 42 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL30 consensus sequence.
[0122] Figure 43 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL39 consensus sequence.
[0123] Figure 44 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL40 consensus sequence.
[0124] Figure 45 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL46 consensus sequence.
[0125] Figure 46 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL47 consensus sequence.
[0126] Figure 47 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL48 consensus sequence.
[0127] Figure 48 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL49 consensus sequence.
[0128] Figure 49 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL52 consensus sequence.
[0129] Figure 50 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL54 consensus sequence.
[0130] Figure 51Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL5 consensus sequence.
[0131] Figure 52 Depicted are HSV strain conservation scores determined for amino acids located at positions along the UL9 consensus sequence.
[0132] Figure 53 Depict four HSV antigen constructs A, B, C, and D. Construct A includes RL2, RL2, RS1, and UL54 T cell antigens. Construct B includes UL29, UL39, UL49, and UL9 T cell antigens. Construct C includes UL30, UL40, UL5, and UL52 T cell antigens. Construct D includes UL1, UL19, UL21, UL27, UL46, UL47, UL25, and UL48 T cell antigens.
[0133] Certain definitions
[0134] Generally speaking, unless otherwise explicitly indicated, the terms used herein have the same meaning as understood in the art. The following provides clear definitions of certain terms; those skilled in the art will understand the meaning of these and other terms in specific situations throughout this specification based on the context.
[0135] In order to make the present invention more easily understood, some terms are first defined below. The following terms and other terms are further defined throughout the specification.
[0136] About: The term "about" when used herein to refer to a value refers to a value that is similar to the referenced value in context. Generally, one skilled in the art familiar with the context will understand the relative degree of variation encompassed by "about" in that context. For example, in some embodiments, the term "about" can encompass a range of values that are within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of the referenced value.
[0137] Agent: As used herein, the term "agent" can refer to a physical entity or phenomenon. In some embodiments, an agent can be characterized by specific characteristics and / or effects. In some embodiments, an agent can be a compound, molecule, or entity of any chemical class, including, for example, small molecules, polypeptides, nucleic acids, sugars, lipids, metals, or combinations or complexes thereof. In some embodiments, the term "agent" can refer to a compound, molecule, or entity that comprises a polymer. In some embodiments, the term can refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term "agent" can refer to a compound, molecule, or entity that is substantially free of a particular polymer or polymeric moiety. In some embodiments, the term can refer to a compound, molecule, or entity that lacks or is substantially free of any polymer or polymeric moiety.
[0138] Amino Acid: In the broadest sense, as used herein, the term "amino acid" refers to a compound and / or substance that can be, is, or has been incorporated into a polypeptide chain, for example, by forming one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N–C(H)(R)–COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a non-natural amino acid; in some embodiments, the amino acid is a D-amino acid; in some embodiments, the amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than the standard amino acids, whether synthetically prepared or obtained from a natural source. In some embodiments, the amino acids in a polypeptide (including the carboxyl and / or amino terminal amino acids) may contain structural modifications compared to the general structure described above. For example, in some embodiments, an amino acid may be modified compared to the general structure by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., substitution of an amino group, a carboxylic acid group, one or more protons, and / or hydroxyl groups). In some embodiments, such modifications may, for example, alter the circulating half-life of a polypeptide comprising the modified amino acid, compared to a polypeptide comprising an otherwise identical unmodified amino acid. In some embodiments, such modifications do not significantly alter the relevant activity of a polypeptide comprising the modified amino acid, compared to a polypeptide comprising an otherwise identical unmodified amino acid. As will be clear from the context, in some embodiments, the term "amino acid" may be used to refer to a free amino acid; in some embodiments, it may be used to refer to an amino acid residue of a polypeptide.
[0139] Antibody agent: As used herein, the term "antibody agent" refers to an agent that specifically binds to a specific antigen. In some embodiments, the term encompasses a polypeptide or polypeptide complex comprising an immunoglobulin structural element sufficient to confer specific binding. For example, in some embodiments, the antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as complementary determining regions (CDRs); in some embodiments, the antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and / or at least one light chain CDR) that is substantially identical to a CDR found in a reference antibody. In some embodiments, the included CDR is substantially identical to the reference CDR because it is either identical in sequence or contains between 1-5 amino acid substitutions compared to the reference CDR. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that they exhibit at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that they exhibit at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity to the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that at least one amino acid is deleted, added, or substituted within the included CDRs compared to the reference CDRs, but the included CDRs have an amino acid sequence that is otherwise identical to the amino acid sequence of the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs because 1-5 amino acids are deleted, added, or substituted in the included CDRs compared to the reference CDRs, but the included CDRs have an amino acid sequence that is otherwise identical to the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs because at least one amino acid is substituted in the included CDRs compared to the reference CDRs, but the included CDRs have an amino acid sequence that is otherwise identical to the amino acid sequence of the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs because 1-5 amino acids are deleted, added, or substituted in the included CDRs compared to the reference CDRs, but the included CDRs have an amino acid sequence that is otherwise identical to the amino acid sequence of the reference CDRs. In some embodiments, the antibody agent is or comprises a polypeptide whose amino acid sequence comprises structural elements recognized by those skilled in the art as immunoglobulin variable domains.In some embodiments, the antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements that are recognized by those skilled in the art as corresponding to CDRs 1, 2, and 3 of an antibody variable domain; in some such embodiments, the antibody agent is or comprises a polypeptide or polypeptide group whose amino acid sequence together includes structural elements that are recognized by those skilled in the art as corresponding to heavy and light chain variable region CDRs (e.g., heavy chain CDRs 1, 2, and / or 3 and light chain CDRs 1, 2, and / or 3). In some embodiments, the antibody agent is a polypeptide protein having a binding domain that is homologous or substantially homologous to an immunoglobulin binding domain. In some embodiments, the antibody agent may be or comprise a polyclonal antibody preparation. In some embodiments, the antibody agent may be or comprise a monoclonal antibody preparation. In some embodiments, the antibody agent may include one or more constant region sequences that are unique to a specific organism such as camel, human, mouse, primate, rabbit, or rat; in many embodiments, the antibody agent may include one or more constant region sequences that are unique to humans. In some embodiments, the antibody agent may include one or more sequence elements that those skilled in the art will recognize as humanized sequences, primatized sequences, chimeric sequences, and the like. In some embodiments, the antibody agent can be a canonical antibody (e.g., can comprise two heavy chains and two light chains). In some embodiments, the antibody agent can be in a form selected from, but not limited to, complete IgA, IgG, IgE, or IgM antibodies; bispecific or multispecific antibodies (e.g., etc.); Antibody fragments, such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd' fragments, Fd fragments and isolated CDRs or collections thereof; Single chain Fv; Polypeptide-Fc fusions; Single domain antibodies (e.g., shark single domain antibodies, such as IgNAR or fragments thereof); Cameloid antibodies; Masked antibodies (e.g., ); Small type mold Block waived Epidemic medicine Object("SMIP TM” ); single-chain or tandem diabodies VHH; miniantibodies; Ankyrin repeat protein or DARTs; TCR-like antibodies; MicroProteins; and In some embodiments, the antibodies may lack covalent modifications (e.g., attachment of glycans) that they would have if they were produced in nature. In some embodiments, the antibodies may contain covalent modifications (e.g., attachment of glycans, payloads (e.g., detectable moieties, therapeutic moieties, catalytic moieties, etc.) or other side groups (e.g., polyethylene glycol, etc.).
[0140] Antigen: It will be understood by those skilled in the art who read this specification that the term "antigen" refers to a molecule that is recognized by the immune system (e.g., in certain embodiments, the adaptive immune system) so that it triggers an antigen-specific immune response. In some embodiments, an antigen-specific immune response can be or include the production of antibodies and / or antigen-specific T cells. In some embodiments, an antigen is a peptide or polypeptide comprising at least one epitope against which an immune response can be generated. In one embodiment, the antigen is presented by a cell of the immune system, such as an antigen-presenting cell, such as a dendritic cell or a macrophage. In one embodiment, the antigen or its processed product, such as a T cell antigen, is bound by a T or B cell receptor or by an immunoglobulin molecule, such as an antibody. Thus, the antigen or its processed product can react specifically with an antibody or a T lymphocyte (T cell). In one embodiment, the antigen is a parasite antigen. According to the present disclosure, in some embodiments, the antigen can be delivered by the RNA molecules described herein. In some embodiments, peptide or polypeptide antigen length can be 2-100 amino acid, including for example 5 amino acids, 10 amino acids, 15 amino acids, 20 amino acids, 25 amino acids, 30 amino acids, 35 amino acids, 40 amino acids, 45 amino acids or 50 amino acids. In some embodiments, peptide or polypeptide antigen can be more than 50 amino acids. In some embodiments, peptide or polypeptide antigen can be more than 100 amino acids. In some embodiments, antigen is recognized by immune effector cells. In some embodiments, if antigen is recognized by immune effector cells, then it can induce the stimulation, initiation and / or amplification of immune effector cells carrying antigen receptors that recognize the antigen in the presence of appropriate costimulatory signals. In the context of embodiments of the present disclosure, in some embodiments, antigen can be presented or exist on the surface of cell (for example, antigen presenting cell). In one embodiment, antigen is presented by diseased cells such as virus-infected cells. In one embodiment, antigen receptor is a TCR combined with the epitope of the antigen presented in the context of MHC. In one embodiment, when a TCR is expressed by a T cell and / or presented on a T cell, its binding to an antigen presented by a cell (such as an antigen presenting cell) results in stimulation, priming, and / or expansion of the T cell. In one embodiment, when a TCR is expressed by a T cell and / or presented on a T cell, its binding to an antigen presented on a diseased cell results in cytolysis and / or apoptosis of the diseased cell, wherein the T cell preferably releases cytotoxic factors, such as perforin and granzymes.
[0141] Associated: As the term is used herein, two events or entities are "associated" with each other if the presence, level, extent, type, and / or form of one event or entity is correlated with the presence, level, extent, type, and / or form of another event or entity. For example, a particular entity (e.g., a polypeptide, genetic marker, metabolite, microorganism, etc.) is considered to be associated with a particular disease, disorder, or condition if its presence, level, and / or form is correlated with the incidence, susceptibility, severity, stage, etc. of the disease, disorder, or condition (e.g., among related populations). In some embodiments, two or more entities are physically "associated" with each other if they interact, directly or indirectly, so that they are in physical proximity and / or remain in physical proximity to each other. In some embodiments, two or more entities that are physically associated with each other are covalently linked to each other; in some embodiments, two or more entities that are physically associated with each other are not covalently linked to each other, but are non-covalently associated, for example, by means of hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetic forces, and combinations thereof.
[0142] Binding: Those skilled in the art who read this specification will appreciate that the term "binding" generally refers to a non-covalent association between or among entities or moieties. In some embodiments, binding data are expressed as "IC50." As understood in the art, the IC50 is the concentration of the agent being evaluated in a binding assay at which 50% inhibition of binding of a reference agent known to bind to the relevant binding partner is observed. In some embodiments, under the conditions under which the assay is performed (e.g., limiting binding to the target and reference concentrations), these values are close to the K D Values. Assays for determining binding are well known in the art and are described in detail, for example, in PCT publications WO 94 / 20127 and WO 94 / 03205 and other publications, such as Sidney et al., Current Protocols in Immunology 18.3.1 (1998); Sidney et al., J. Immunol. 154:247 (1995); and Sette et al., Mol. Immunol. 31:813 (1994). Alternatively, binding can be expressed relative to binding of a reference standard peptide. For example, the binding can be expressed based on its IC relative to a reference standard peptide. 50 IC 50Binding can also be determined using other assay systems, including those using living cells (e.g., Ceppellini et al., Nature 339:392 (1989); Christnick et al., Nature 352:67 (1991); Busch et al., Int. Immunol. 2:443 (1990); Hill et al., J. Immunol. 147:189 (1991); del Guercio et al., J. Immunol. 154:685 (1995)), cell-free systems using detergent lysates (e.g., Cerundolo et al., J. Immunol. 154:685 (1995)), and immunoprecipitation systems (e.g., ELISA ... 21:2069 (1991)), immobilized purified MHC (e.g., Hill et al., J. Immunol. 152, 2890 (1994); Marshall et al., J. Immunol. 152:4946 (1994)), ELISA systems (e.g., Reay et al., EMBO J. 11:2829 (1992)), surface plasmon resonance (e.g., Khilko et al., J. Biol. Chem. 268:15425 (1993)); high-throughput soluble phase assays (Hammer et al., J. Exp. Med. 180:2353 (1994)), and measurements of class I MHC stabilization or assembly (e.g., Ljunggren et al., Nature 346:476 (1990); Schumacher et al., Cell 62:563 (1990); Townsend et al., Cell 62:285 (1990); Parker et al., J. Immunol. 149:1896 (1992).
[0143] Cap: As used herein, the term "cap" refers to a structure comprising or consisting essentially of a nucleoside-5'-triphosphate, which is typically attached to the 5' end of an uncapped RNA (e.g., an uncapped RNA with a 5'-diphosphate). In some embodiments, the cap is or comprises a guanine nucleotide. In some embodiments, the cap is or comprises a naturally occurring RNA 5' cap, including, for example, but not limited to, a 7-methylguanosine cap having a structure designated as "m7G". In some embodiments, the cap is or comprises a synthetic cap analog that is similar to the RNA cap structure and has the ability to stabilize RNA if attached thereto, including, for example, but not limited to, anti-reverse cap analogs (ARCAs) known in the art. It will be appreciated by those skilled in the art that methods of attaching a cap to the 5' end of an RNA are known in the art. For example, in some embodiments, capped RNA can be obtained by in vitro capping of RNA having a 5' triphosphate group or RNA having a 5' diphosphate group using a capping enzyme system (including, for example, but not limited to, a vaccinia capping enzyme system or a Saccharomyces cerevisiae capping enzyme system). Alternatively, capped RNA can be obtained by in vitro transcription (IVT) of a single-stranded DNA template in the presence of a dinucleotide or trinucleotide cap analog.
[0144] Cell-mediated immunity: "Cell-mediated immunity," "cellular immunity," "cellular immune response," or similar terms are intended to include cellular responses directed against cells characterized by the expression of antigens, particularly by presentation of antigens with class I or class II MHC. The cellular response involves immune effector cells, particularly T cells or T lymphocytes that act as "helpers" or "killers." Helper T cells (also known as CD4 + T cells or CD4 T cells) play a central role by regulating the immune response, and killer cells (also known as cytotoxic T cells, cytolytic T cells, CD8 + T cells, CD8 T cells or CTLs) kill diseased cells, such as virus-infected cells, thereby preventing the production of more diseased cells.
[0145] Co-administration: As used herein, the term "co-administration" refers to the use of a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) described herein and an additional therapeutic agent. The combined use of a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) described herein and an additional therapeutic agent can be performed simultaneously or separately (e.g., sequentially in any order). In some embodiments, the pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) described herein and the additional therapeutic agent can be combined in a pharmaceutically acceptable carrier, or they can be placed in separate carriers and delivered to target cells or administered to a subject at different times. As long as the pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) described herein and the additional therapeutic agent are delivered or administered close enough in time so that there is at least some temporal overlap in the biological effects produced by each on the target cell or the subject being treated, each of these situations is considered to be within the meaning of "co-administration" or "combination."
[0146] Codon optimized: As used herein, the term "codon optimized" refers to changing the codons in the coding region of a nucleic acid molecule to reflect the typical codon usage of the host organism, without preferably changing the amino acid sequence encoded by the nucleic acid molecule. Within the context of the present disclosure, in some embodiments, the coding region is codon optimized for optimal expression in a subject to be treated with the RNA molecules described herein. In some embodiments, codon optimization can be performed so that frequently occurring tRNA-available codons are inserted in place of "rare codons." In some embodiments, codon optimization can include increasing the G / C content of the coding region of the RNA described herein compared to the guanosine / cytosine (G / C) content of the corresponding coding sequence of the wild-type RNA, wherein the amino acid sequence encoded by the RNA is preferably not modified compared to the amino acid sequence.
[0147] Combination therapy: As used herein, the term "combination therapy" refers to those situations in which a subject is exposed to two or more treatment regimens (e.g., two or more therapeutic agents) simultaneously. In some embodiments, two or more regimens can be administered simultaneously; in some embodiments, such regimens can be administered sequentially (e.g., all "doses" of the first regimen are administered, followed by any doses of the second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, "administration" of a combination therapy may involve administering one or more agents or modalities in combination to a subject receiving other agents or modalities. For clarity, combination therapy does not require that the individual agents be administered together in a single composition (or not even necessarily simultaneously), but in some embodiments, two or more agents, or active portions thereof, can be combined in a composition and administered together.
[0148] Comparable: As used herein, the term "comparable" refers to two or more sets of agents, entities, situations, conditions, etc. that may not be identical to one another but are sufficiently similar to allow comparisons to be made therebetween so that one skilled in the art would understand that conclusions can be reasonably drawn based on the observed differences or similarities. In some embodiments, comparable sets of conditions, situations, individuals, or populations are characterized by a plurality of substantially identical features and one or a few different features. One of ordinary skill in the art would understand, in context, what degree of consistency is required for two or more such sets of agents, entities, situations, conditions, etc. to be considered comparable in any given case. For example, one of ordinary skill in the art would understand that sets of conditions, individuals, or populations are comparable to one another when they are characterized by a sufficient number and type of substantially identical features to ensure that the conclusion is reasonable that differences in the results obtained under different sets of conditions, individuals, or populations or in the phenomena observed with different sets of conditions, individuals, or populations are caused by or indicate changes in those features that have changed.
[0149] Corresponding to: As used herein, the term "corresponding to" refers to a relationship between two or more entities. For example, the term "corresponding to" can be used to indicate the position / characteristic of a structural element in a compound or composition relative to another compound or composition (e.g., relative to an appropriate reference compound or composition). For example, in some embodiments, monomer residues in a polymer (e.g., amino acid residues in a polypeptide or nucleic acid residues in a polynucleotide) can be identified as "corresponding to" residues in an appropriate reference polymer. For example, one of ordinary skill in the art will appreciate that, for simplicity, residues in polypeptides are often named using a canonical numbering system based on a reference to a related polypeptide, so that, for example, an amino acid that "corresponds to" a residue at position 190 need not actually be the 190th amino acid in a particular amino acid chain, but rather corresponds to the residue found at 190 in a reference polypeptide; one of ordinary skill in the art will readily understand how to identify a "corresponding" amino acid. For example, those skilled in the art will be aware of various sequence alignment strategies, including software programs such as BLAST, CS-BLAST, CUSASW++, DIAMOND, FASTA, GGSEARCH / GLSEARCH, Genoogle, HMMER, HHpred / HHsearch, IDF, Infernal, KLAST, USEARCH, parasail, PSI-BLAST, PSI-Search, ScalaBLAST, Sequilab, SAM, SSEARCH, SWAPHI, SWAPHI-LS, SWIMM, or SWIPE, which can be used, for example, to identify "corresponding" residues in polypeptides and / or nucleic acids according to the present disclosure. Those skilled in the art will also appreciate that, in some cases, the term "corresponding to" can be used to describe an event or entity that shares a relevant similarity with another event or entity (e.g., an appropriate reference event or entity). As just one example, a gene or protein in one organism may be described as "corresponding to" a gene or protein from another organism to indicate that, in some embodiments, they play a similar role or perform a similar function and / or that they exhibit a particular degree of sequence identity or homology, or share particular characteristic sequence elements.
[0150] Derived: In the context of an amino acid sequence (peptide or polypeptide) that is "derived from" a specified amino acid sequence (peptide or polypeptide), it refers to a structural analog of the specified amino acid sequence. In some embodiments, an amino acid sequence derived from a specific amino acid sequence has an amino acid sequence that is identical, substantially identical, or homologous to that specific sequence or a fragment thereof. An amino acid sequence derived from a specific amino acid sequence may be a variant of that specific sequence or a fragment thereof. For example, one of ordinary skill in the art will appreciate that the antigens useful herein may be altered such that they differ in sequence from the naturally occurring or native sequences from which they are derived while retaining the desired activity of the native sequence.
[0151] Designed: As used herein, the term "designed" refers to an agent that (i) has a structure that is or was selected by the hand of man; (ii) is produced by methods requiring human effort; and / or (iii) is different from naturally occurring substances and other known agents.
[0152] Dosing regimen: Those skilled in the art will appreciate that the term "dosing regimen" can be used to refer to a group of unit doses (usually more than one) that are administered individually to a subject, typically at intervals of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, the dosing regimen comprises multiple doses, each dose separated in time from the other doses. In some embodiments, each dose is separated from each other by a time period of the same length; in some embodiments, the dosing regimen comprises multiple doses, each dose separated by at least two different time periods. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen have different amounts. In some embodiments, a dosing regimen comprises a first dose of the amount of the first dose, followed by one or more additional doses of the amount of the second dose that is different from the amount of the first dose. In some embodiments, a dosing regimen comprises a first dose of the amount of the first dose, followed by one or more additional doses of the amount of the second dose that is the same as the amount of the first dose. In some embodiments, a dosing regimen is associated with a desired or beneficial outcome when administered to a relevant population (i.e., it is a therapeutic dosing regimen).
[0153] Encoding: As used herein, the term "encode / encoding" refers to the sequence information of a first molecule, which guides the production of a second molecule having a determined nucleotide sequence (e.g., mRNA) or a determined amino acid sequence. For example, a DNA molecule can encode an RNA molecule (e.g., by a transcription process comprising a DNA-dependent RNA polymerase). An RNA molecule can encode a polypeptide (e.g., by a translation process). Therefore, if the transcription and translation of the mRNA corresponding to a gene produces a polypeptide in a cell or other biological system, the gene, cDNA or RNA molecule (e.g., mRNA) encodes the polypeptide. In some embodiments, the coding region of an RNA molecule encoding a target antigen refers to a coding strand whose nucleotide sequence is identical to the mRNA sequence of such a target antigen. In some embodiments, the coding region of an RNA molecule encoding a target antigen refers to a non-coding strand of such a target antigen, which can be used as a template for transcription of a gene or cDNA.
[0154] Engineered: Generally, the term "engineered" refers to aspects that have been manipulated by the hand of man. For example, a polynucleotide is considered "engineered" when two or more sequences that are not linked together in an order found in nature are directly linked to one another in an engineered polynucleotide by human manipulation and / or when specific residues in a polynucleotide are non-naturally occurring and / or are caused by the action of man to be linked to entities or moieties to which they are not naturally linked.
[0155] Epitope: As used herein, the term "epitope" refers to a portion that is specifically recognized by an immunoglobulin (e.g., an antibody or receptor) binding component. For example, an epitope can be recognized by a T cell, a B cell, or an antibody. In some embodiments, an epitope is composed of multiple chemical atoms or groups on an antigen. In some embodiments, when the antigen adopts a related three-dimensional conformation, such chemical atoms or groups are surface exposed. In some embodiments, when the antigen adopts such a conformation, such chemical atoms or groups are physically close to each other in space. In some embodiments, when the antigen adopts an alternative conformation (e.g., linearized), at least some of such chemical atoms and groups are physically separated from each other. Therefore, in some embodiments, the epitope of an antigen may include continuous or discontinuous fragments of the antigen. In some embodiments, an epitope is or comprises a T cell epitope. In some embodiments, an epitope may have a length of about 5 to about 30 amino acids, or about 10 to about 25 amino acids, or about 5 to about 15 amino acids, or about 5 to 12 amino acids, or about 6 to about 9 amino acids.
[0156] Expression: As used herein, the term "expression" of a nucleic acid sequence refers to the production of a gene product from the nucleic acid sequence. In some embodiments, the gene product may be a transcript. In some embodiments, the gene product may be a polypeptide. In some embodiments, expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from the DNA sequence (e.g., by transcription); (2) processing of the RNA transcript (e.g., by splicing, editing, etc.); (3) translation of the RNA into a polypeptide or protein; and / or (4) post-translational modification of the polypeptide or protein.
[0157] Five terminal untranslated region: As used herein, the term "five terminal untranslated region" or "5'UTR" refers to the sequence of an mRNA molecule between the transcription start site and the start codon of the coding region of the RNA. In some embodiments, "5'UTR" refers to the sequence of an mRNA molecule, e.g., in its native context, which starts at the transcription start site and ends one nucleotide (nt) before the start codon (usually AUG) of the coding region of the RNA molecule.
[0158] Fragment: As used herein in the context of a nucleic acid sequence (e.g., an RNA sequence) or an amino acid sequence, the term "fragment" generally refers to a fragment of a reference sequence. In some embodiments, the reference sequence is, for example, the full-length sequence of a nucleic acid sequence or an amino acid sequence. Thus, a fragment generally refers to a sequence that is identical to a corresponding segment within a reference sequence. In some embodiments, a fragment comprises a continuous stretch of nucleotides or amino acid residues that corresponds to at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the total length of the reference sequence from which the fragment is derived. In some embodiments, the term "fragment" with respect to an amino acid sequence (peptide or polypeptide) refers to a portion of an amino acid sequence, for example, a sequence representing an amino acid sequence that is shortened at the N-terminus and / or C-terminus. In some embodiments, a fragment of an amino acid sequence comprises at least 6, particularly at least 8, at least 12, at least 15, at least 20, at least 30, at least 50, or at least 100 consecutive amino acids from an amino acid sequence.
[0159] Homology: As used herein, the terms "homology" or "homologs" refer to the overall relatedness between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are considered to be "homologous" to each other if their sequences are at least 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, if the sequences of polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% similar (e.g., containing residues of related chemical properties at corresponding positions), they are considered to be "homologous" to each other. For example, as is well known to those of ordinary skill in the art, certain amino acids are generally classified as "hydrophobic" or "hydrophilic" amino acids that are similar to each other, and / or have "polar" or "non-polar" side chains. The substitution of an amino acid by another amino acid of the same type is generally considered to be a "homologous" substitution.
[0160] Humoral immunity: As used herein, the term "humoral immunity" or "humoral immune response" refers to antibody production and the accompanying ancillary processes, including: Th2 activation and cytokine production, germinal center formation and isotype switching, affinity maturation, and memory cell production. It also refers to the effector functions of antibodies, which include pathogen neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.
[0161] Identity: As used herein, the term "identity" refers to the overall correlation between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules. In some embodiments, if the sequence between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or polypeptide molecules is at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical, then they are considered to be "substantially identical" to each other. The calculation of the identity percentage of two nucleic acid or polypeptide sequences can be performed, for example, by comparing two sequences for the purpose of optimal comparison (e.g., gaps can be introduced in one or both of the first and second sequences for optimal comparison, and for the purpose of comparison, non-identical sequences can be ignored). In certain embodiments, the length of the sequence compared for the purpose of comparison is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or substantially 100% of the length of the reference sequence. The nucleotides at the corresponding positions are then compared. When the position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, the molecules are identical at that position. Taking into account the number of gaps and the length of each gap, the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, which gaps need to be introduced for the optimal comparison of the two sequences. A mathematical algorithm can be used to complete the comparison of the sequences between the two sequences and the determination of the percent identity. For example, the algorithm of Meyers and Miller, 1989, which has been incorporated into the ALIGN program (version 2.0), can be used to determine the percent identity between two nucleotide sequences. In some exemplary embodiments, nucleic acid sequence comparisons performed with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Alternatively, the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package using the NWSgapdna.CMP matrix.
[0162] Immunologically equivalent: The term "immunologically equivalent" means that immunologically equivalent molecules, such as immunologically equivalent amino acid sequences, exhibit the same or substantially the same immunological properties and / or exert the same or substantially the same immunological effect, for example, in terms of the type of immunological effect. In the context of the present disclosure, in some embodiments, the term "immunologically equivalent" is used with respect to the immunological effect or properties of the antigen or antigen variant used for immunization. For example, an amino acid sequence is immunologically equivalent if, when exposed to the immune system of a subject, it induces an immune response having a specificity that reacts with a reference amino acid sequence.
[0163] In one embodiment, the antigen receptor is an antibody or B cell receptor that binds to an epitope of the antigen. In one embodiment, the antibody or B cell receptor binds to a native epitope of the antigen.
[0164] Increased, induced or decreased: As used herein, these terms or grammatically comparable comparative terms indicate values measured relative to a comparable reference. For example, in some embodiments, an evaluation value obtained with a provided pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) may be "increased" relative to an evaluation value obtained with a comparable reference pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine). Alternatively or additionally, in some embodiments, an evaluation value obtained in a subject may be "increased" relative to an evaluation value obtained in the same subject under different conditions (e.g., before or after an event; or in the presence or absence of an event, such as administration of a pharmaceutical composition as described herein (e.g., an immunogenic composition, such as a vaccine)) or in different comparable subjects (e.g., in a comparable subject different from a subject of interest previously exposed to, for example, the absence of administration of a pharmaceutical composition as described herein (e.g., an immunogenic composition, such as a vaccine)). In some embodiments, a comparative term refers to a statistically relevant difference (e.g., prevalence and / or magnitude sufficient to achieve statistical relevance). Those skilled in the art will recognize or will be able to readily determine the degree of difference and / or prevalence required or sufficient to achieve such statistical significance in a given context. In some embodiments, the term "reduced" or equivalent terms refer to a decrease in the level of an assessment value by at least 5%, at least 10%, at least 20%, at least 50%, at least 75% or more compared to a comparable reference. In some embodiments, the term "reduced" or equivalent terms refer to complete or substantially complete inhibition, i.e., reduction to zero or substantially to zero. In some embodiments, the term "increased" or "induced" refers to an increase in the level of an assessment value by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 80%, at least 100%, at least 200%, at least 500% or more compared to a comparable reference.
[0165] Ionizable: The term "ionizable" refers to a compound, group, or atom that is charged at a certain pH. In the context of an ionizable amino lipid, such lipid or its functional group or atom is positively charged at a certain pH. In some embodiments, the ionizable amino lipid is positively charged at acidic pH. In some embodiments, the ionizable amino lipid is primarily neutral at physiological pH, such as, in some embodiments, about 7.0-7.4, but becomes positively charged at lower pH values. In some embodiments, the ionizable amino lipid may have a pKa ranging from about 5 to about 7.
[0166] Isolated: The term "isolated" means altered or removed from its native state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials in its native state is "isolated." An isolated nucleic acid or protein can exist in a substantially purified form or can exist in a non-native environment, such as a host cell.
[0167] Lipid: As used herein, the terms "lipid" and "lipid-like substance" are broadly defined as a molecule comprising one or more hydrophobic portions or groups and optionally also comprising one or more hydrophilic portions or groups. Molecules comprising a hydrophobic portion and a hydrophilic portion are also commonly referred to as amphiphilic molecules.
[0168] RNA lipid nanoparticles: As used herein, the term "RNA lipid nanoparticle" refers to a nanoparticle comprising at least one lipid and an RNA molecule. In some embodiments, the RNA lipid nanoparticle comprises at least one ionizable amino lipid. In some embodiments, the RNA lipid nanoparticle comprises at least one ionizable amino lipid, at least one helper lipid, and at least one polymer-conjugated lipid (e.g., PEG-conjugated lipid). In various embodiments, the RNA lipid nanoparticles as described herein may have an average size (e.g., Z-average) of about 100 nm to 1000 nm, or about 200 nm to 900 nm, or about 200 nm to 800 nm, or about 250 nm to about 700 nm. In some embodiments of the present disclosure, the RNA lipid nanoparticle can have a granularity (e.g., Z-average) of about 30nm to about 200nm or about 30nm to about 150nm, about 40nm to about 150nm, about 50nm to about 150nm, about 60nm to about 130nm, about 70nm to about 110nm, about 70nm to about 100nm, about 80nm to about 100nm, about 90nm to about 100nm, about 70nm to about 90nm, about 80nm to about 90nm, or about 70nm to about 80nm. In some embodiments, the average size of the lipid nanoparticle is determined by measuring the particle diameter. In some embodiments, the RNA lipid nanoparticle can be prepared by mixing lipid with RNA molecules as described herein.
[0169] Lipidoid: As used herein, "lipidoid" refers to a lipid-like molecule. In some embodiments, a lipid is an amphiphilic molecule having one or more lipid-like physical properties. In the context of the present disclosure, the term lipid is considered to encompass lipidoids.
[0170] Nanoparticles: As used herein, the term "nanoparticles" refers to particles of an average size suitable for parenteral administration. In some embodiments, the longest dimension (e.g., diameter) of the nanoparticles is less than 1,000 nanometers (nm). In some embodiments, the nanoparticles may be characterized by a longest dimension (e.g., diameter) of less than 300 nm. In some embodiments, the nanoparticles may be characterized by a longest dimension (e.g., diameter) of less than 100 nm. In many embodiments, the nanoparticles may be characterized by a longest dimension between about 1 nm and about 100 nm, or between about 1 μm and about 500 nm, or between about 1 nm and 1,000 nm. In many embodiments, the nanoparticle population is characterized by an average size (e.g., longest dimension) of about 1,000 nm, about 500 nm, about 100 nm, about 50 nm, about 40 nm, about 30 nm, about 20 nm, or about 10 nm or less, and typically above about 1 nm. In many embodiments, the nanoparticles may be substantially spherical such that their longest dimension may be their diameter. In some embodiments, the nanoparticles have a diameter of less than 100 nm as defined by the National Institutes of Health.
[0171] Naturally occurring: As used herein, the term "naturally occurring" refers to an entity that can be found in nature. For example, a peptide or nucleic acid that is present in an organism (including viruses) and can be isolated from a source in nature and has not been intentionally modified by man in the laboratory is naturally occurring.
[0172] Neutralization: As used herein, the term "neutralization" refers to an event in which a binding agent (e.g., an antibody) binds to a biologically active site (e.g., a receptor binding protein) of a virus, thereby inhibiting parasitic infection of a cell. In some embodiments, the term "neutralization" refers to an event in which a binding agent eliminates or significantly reduces the ability of a binding agent to infect a cell.
[0173] Nucleic Acid Particles: "Nucleic acid particles" can be used to deliver nucleic acids to a target site of interest (e.g., a cell, tissue, organ, etc.). Nucleic acid particles can comprise at least one cationic or cationically ionizable lipid or lipid-like substance, at least one cationic polymer such as protamine, or a mixture thereof, and a nucleic acid. In some embodiments, the nucleic acid particle is a lipid nanoparticle. In some embodiments, the nucleic acid particle is a lipoplex particle.
[0174] Nucleic acid / polynucleotide: As used herein, the term "nucleic acid" refers to a polymer of at least 10 or more nucleotides. In some embodiments, the nucleic acid is or comprises DNA. In some embodiments, the nucleic acid is or comprises RNA. In some embodiments, the nucleic acid is or comprises peptide nucleic acid (PNA). In some embodiments, the nucleic acid is or comprises single-stranded nucleic acid. In some embodiments, the nucleic acid is or comprises double-stranded nucleic acid. In some embodiments, the nucleic acid comprises both single-stranded and double-stranded fragments. In some embodiments, the nucleic acid comprises a backbone comprising one or more phosphodiester linkages. In some embodiments, the nucleic acid comprises a backbone comprising both phosphodiester and non-phosphodiester linkages. For example, in some embodiments, the nucleic acid may comprise a backbone comprising one or more phosphorothioate or 5'-N-phosphoramidite linkages and / or one or more peptide bonds, such as in "peptide nucleic acids." In some embodiments, the nucleic acid comprises one or more or all natural residues (e.g., adenine, cytosine, deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). In some embodiments, the nucleic acid comprises one or more or all non-natural residues. In some embodiments, the non-natural residues include nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 6-O-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, the non-natural residues comprise one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to the sugars in the natural residues. In some embodiments, nucleic acid has a nucleotide sequence encoding a functional gene product such as an RNA or polypeptide. In some embodiments, nucleic acid has a nucleotide sequence comprising one or more introns. In some embodiments, nucleic acid can be prepared by separation from a natural source, enzymatic synthesis (e.g., by polymerization based on a complementary template, such as in vivo or in vitro), replication in a recombinant cell or system, or chemical synthesis.In some embodiments, the nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, or 20,000 residues or nucleotides in length.
[0175] Nucleotide: As used herein, the term "nucleotide" has its art-recognized meaning. When the number of nucleotides is used as an indicator of the size of, for example, a polynucleotide, a certain number of nucleotides refers to the number of nucleotides on, for example, a single strand of the polynucleotide.
[0176] Patient: As used herein, the term "patient" refers to any organism that has a disease, condition, or illness or is at risk of developing a disease, condition, or illness. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is a human. In some embodiments, the patient has or is susceptible to one or more diseases, conditions, or illnesses. In some embodiments, the patient exhibits one or more symptoms of the disease, condition, or illness. In some embodiments, the patient has been diagnosed with one or more diseases, conditions, or illnesses. In some embodiments, the disease, condition, or illness suitable for the provided technology is or includes an HSV infection. In some embodiments, the patient is receiving or has received a therapy to diagnose and / or treat the disease, condition, or illness. In some embodiments, the patient is a patient who has or is susceptible to an HSV infection.
[0177] PEG-conjugated lipid: The term "PEG-conjugated lipid" refers to a molecule comprising a lipid portion and a polyethylene glycol portion.
[0178] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, the active agent is present in an amount suitable for administration in a unit dose in a treatment regimen that, when administered to a relevant population, demonstrates a statistically significant probability of achieving a predetermined therapeutic effect. In some embodiments, the pharmaceutical composition can be specifically formulated for parenteral administration, such as by subcutaneous, intramuscular, or intravenous injection, for example, as a sterile solution or suspension formulation.
[0179] Pharmaceutically effective amount: The term "pharmaceutically effective amount" or "therapeutically effective amount" refers to an amount that, alone or in combination with further doses, achieves a desired response or desired effect. In the case of treating a particular disease, the desired response, in some embodiments, involves inhibiting the course of the disease. In some embodiments, such inhibition may include slowing the progression of the disease and / or interrupting or reversing the progression of the disease. In some embodiments, the desired response in the treatment of a disease may be or include delaying or preventing the onset of the disease or disorder. The effective amount of a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) described herein will depend, for example, on the disease or disorder to be treated, the severity of the disease or disorder, the patient's individual parameters (including, for example, age, physiological condition, body shape and weight), the duration of treatment, the type of concomitant therapy (if any), the specific route of administration, and similar factors. Therefore, the dosage of a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) described herein may depend on a variety of such parameters. In the event that a patient's response to an initial dose is insufficient, a higher dose (or an effectively higher dose obtained by a different, more localized route of administration) may be used.
[0180] Poly(A) sequence: As used herein, the term "poly(A) sequence" or "poly(A) tail" refers to an uninterrupted or interrupted sequence of adenosine residues typically located at the 3' end of an RNA molecule. Poly(A) sequences are known to those skilled in the art and may follow the 3'-UTR in the RNAs described herein. An uninterrupted poly(A) sequence is characterized by consecutive adenosine residues. In nature, uninterrupted poly(A) sequences are typical. The RNAs disclosed herein may have a poly(A) sequence that is attached to the free 3' end of the RNA by a template-independent RNA polymerase after transcription or a poly(A) sequence that is encoded by DNA and transcribed by a template-dependent RNA polymerase.
[0181] Polypeptide: As used herein, the term "polypeptide" refers to a polymeric chain of amino acids. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an engineered amino acid sequence, meaning that it is designed and / or produced by the hand of man. In some embodiments, a polypeptide may comprise or consist of natural amino acids, non-natural amino acids, or both. In some embodiments, a polypeptide may comprise or consist exclusively of natural amino acids, or consist exclusively of non-natural amino acids. In some embodiments, a polypeptide may comprise D-amino acids, L-amino acids, or both. In some embodiments, a polypeptide may comprise exclusively D-amino acids. In some embodiments, a polypeptide may comprise exclusively L-amino acids. In some embodiments, a polypeptide may include one or more side groups or other modifications, such as modifications at the N-terminus of the polypeptide, at the C-terminus of the polypeptide, or any combination thereof, or attached to one or more amino acid side chains. In some embodiments, such side groups or modifications include acetylation, amidation, lipidation, methylation, pegylation, and the like, including combinations thereof. In some embodiments, the polypeptide may be cyclic and / or may contain a cyclic portion. In some embodiments, the polypeptide is not cyclic and / or does not contain any cyclic portion. In some embodiments, the polypeptide is linear. In some embodiments, the polypeptide may be or include a stapled polypeptide. In some embodiments, the term "polypeptide" may be appended to the name, activity, or structure of a reference polypeptide; in such cases, it is used herein to refer to polypeptides that share a related activity or structure and are therefore considered members of the same class or family of polypeptides. For each such class, this specification provides and / or those skilled in the art will be aware of exemplary polypeptides whose amino acid sequences and / or functions within that class are known; in some embodiments, such exemplary polypeptides are reference polypeptides for that class or family of polypeptides. In some embodiments, members of a class or family of polypeptides exhibit significant sequence homology or identity with a reference polypeptide of that class, share common sequence motifs (e.g., characteristic sequence elements) with a reference polypeptide of that class, and / or share a common activity (in some embodiments at a comparable level or within a specified range; in some embodiments, compared to all polypeptides within that class).For example, in some embodiments, the member polypeptides exhibit an overall sequence homology or identity to the reference polypeptide of at least about 30-40%, and typically greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, and / or include at least one region (e.g., a conserved region that may be or contain characteristic sequence elements in some embodiments) that exhibits very high sequence identity, typically greater than 90% or even 95%, 96%, 97%, 98% or 99%. Such conserved regions typically encompass at least 3-4, and typically up to 20 or more amino acids; in some embodiments, conserved regions encompass at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more consecutive amino acids. In some embodiments, the related polypeptides may comprise or consist of fragments of the parent polypeptide.
[0182] Prevent: As used herein, the terms "prevent" and "prevention" when used in conjunction with the occurrence of a disease, condition, and / or disorder refer to reducing the risk of developing the disease, condition, and / or disorder and / or delaying the onset of one or more characteristics or symptoms of the disease, condition, or disorder. Prevention can be considered complete when the onset of the disease, condition, or disorder has been delayed for a predefined period of time.
[0183] Recombinant: The term “recombinant” in the context of this disclosure means “made by genetic engineering.” In some embodiments, a “recombinant” entity (eg, a recombinant nucleic acid) in the context of this disclosure does not occur in nature.
[0184] Reference: As used herein, the term "reference" describes a standard or control relative to which a comparison is made. For example, in some embodiments, an agent, animal, individual, population, sample, sequence, or value of interest is compared to a reference or control agent, animal, individual, population, sample, sequence, or value. In some embodiments, the test and / or determination of the reference or control is substantially contemporaneous with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as will be understood by those skilled in the art, a reference or control is determined or characterized under conditions or circumstances comparable to those under assessment. Those skilled in the art will understand when there is sufficient similarity to justify reliance on and / or comparison to a particular possible reference or control.
[0185] Ribonucleic acid (RNA): As used herein, the term "RNA" refers to a polymer of ribonucleotides. In some embodiments, RNA is single-stranded. In some embodiments, RNA is double-stranded. In some embodiments, RNA comprises both single-stranded and double-stranded fragments. In some embodiments, RNA may comprise a backbone structure as described in the definition of "nucleic acid / polynucleotide" above. RNA may be a regulatory RNA (e.g., siRNA, microRNA, etc.) or a messenger RNA (mRNA). In some embodiments, wherein RNA is mRNA. In some embodiments wherein RNA is mRNA, RNA typically comprises a poly (A) region at its 3' end. In some embodiments wherein RNA is mRNA, RNA typically comprises a cap structure recognized in the art at its 5' end, for example, for identifying mRNA and attaching it to ribosomes to initiate translation. In some embodiments, RNA is synthetic RNA. Synthetic RNA includes RNA synthesized in vitro (e.g., by enzymatic synthesis methods and / or by chemical synthesis methods).
[0186] Ribonucleotide: As used herein, the term "ribonucleotide" encompasses unmodified ribonucleotides and modified ribonucleotides. For example, unmodified ribonucleotides include the purine bases adenine (A) and guanine (G) and the pyrimidine bases cytosine (C) and uracil (U). Modified ribonucleotides may include one or more modifications, including but not limited to, for example (a) end modifications, such as 5' end modifications (e.g., phosphorylation, dephosphorylation, conjugation, reverse linkage, etc.), (b) base modifications, such as replacement with modified bases, stabilized bases, destabilized bases, or bases that pair with an expanded repertoire of partners or conjugated bases, (c) sugar modifications (e.g., at the 2' position or the 4' position) or replacement of sugars, and (d) internucleoside linkage modifications, including modification or replacement of phosphodiester linkages. The term "ribonucleotide" also encompasses ribonucleotide triphosphates, including modified and unmodified ribonucleotide triphosphates.
[0187] Risk: As will be understood from the context, the "risk" of a disease, condition, and / or illness refers to the likelihood that a particular individual will develop the disease, condition, and / or illness. In some embodiments, risk is expressed as a percentage. In some embodiments, the risk is 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, up to 100%. In some embodiments, risk is expressed as a risk relative to the risk associated with a reference sample or reference sample group. In some embodiments, a reference sample or reference sample group has a known risk of a disease, condition, illness, and / or event. In some embodiments, a reference sample or reference sample group is from an individual comparable to a particular individual. In some embodiments, the relative risk is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or higher. In some embodiments, risk can reflect one or more genetic attributes, e.g., that may predispose an individual to developing (or not developing) a particular disease, condition, and / or disorder. In some embodiments, risk can reflect one or more epigenetic events or attributes and / or one or more lifestyle or environmental events or attributes.
[0188] RNA liposome complex particles: As used herein, the term "RNA liposome complex particle" refers to a complex comprising a liposome (particularly a cationic liposome) and an RNA molecule. Without wishing to be bound by a particular theory, electrostatic interactions between the positively charged liposomes and the negatively charged RNA lead to complexation and spontaneous formation of the RNA liposome complex particles. In some embodiments, the positively charged liposomes may comprise a cationic lipid, such as DOTMA in some embodiments, and an additional lipid, such as DOPE in some embodiments. In one embodiment, the RNA liposome complex particle is a nanoparticle.
[0189] Selectivity or specificity: The terms "selectivity" or "specificity" when used herein to refer to an agent having activity are understood by those skilled in the art to mean that the agent will discriminate between potential target entities, states, or cells. For example, in some embodiments, an agent is considered to "specifically" bind to its target if it preferentially binds to its target in the presence of one or more competing alternative targets. In many embodiments, specific interactions depend on the presence of specific structural features (e.g., epitopes, clefts, binding sites) of the target entity. It is to be understood that specificity is not necessarily absolute. In some embodiments, specificity can be assessed relative to the specificity of the target binding portion of one or more other potential target entities (e.g., competitors). In some embodiments, specificity is assessed relative to the specificity of a reference specific binding portion. In some embodiments, specificity is assessed relative to the specificity of a reference non-specific binding portion.
[0190] Stable: As used herein, the term "stable" in the context of the present disclosure refers to a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) as a whole and / or its components meeting or exceeding predetermined acceptance criteria. For example, in some embodiments, a stable pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) exhibits no unacceptable levels of microbial growth and substantially no or no decomposition or degradation of active biomolecule components. In some embodiments, a stable pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) refers to an RNA molecule whose integrity is maintained at at least 90% or higher. In some embodiments, a stable pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) refers to an RNA molecule that is at least 90% or more (including, for example, at least 95%, at least 96%, at least 97% or more) and is retained within the lipid nanoparticle. In some embodiments, a stable pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) refers to a formulation that is still capable of eliciting a desired immunological response when administered to a subject. In some embodiments, a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) remains stable for a specified period of time under certain conditions.
[0191] Subject: As used herein, the term "subject" refers to an organism to which a composition described herein is administered, for example, for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, domestic pets, etc.) and humans. In some embodiments, the subject is a human subject. In some embodiments, the subject suffers from a disease, disorder, or condition (e.g., HSV infection). In some embodiments, the subject is susceptible to a disease, disorder, or condition (e.g., HSV infection). In some embodiments, the subject exhibits one or more symptoms or characteristics of a disease, disorder, or condition (e.g., HSV infection). In some embodiments, the subject exhibits one or more nonspecific symptoms of a disease, disorder, or condition (e.g., HSV infection). In some embodiments, the subject does not exhibit any symptoms or characteristics of a disease, disorder, or condition (e.g., HSV infection). In some embodiments, the subject is a person who is susceptible to a disease, disorder, or condition (e.g., HSV infection) or has one or more characteristics specific to the above-mentioned risks. In some embodiments, the subject is a patient. In some embodiments, the subject is an individual who is receiving and / or has received diagnosis and / or treatment.
[0192] Suffering from: An individual suffering from a disease, condition, and / or disorder has been diagnosed with and / or exhibits one or more symptoms of the disease, condition, and / or disorder.
[0193] Susceptible to: An individual who is "susceptible" to a disease, condition, and / or disorder is an individual who is at a higher risk of developing the disease, condition, and / or disorder than members of the general public. In some embodiments, an individual who is susceptible to a disease, condition, and / or disorder may not have been diagnosed with the disease, condition, and / or disorder. In some embodiments, an individual who is susceptible to a disease, condition, and / or disorder may exhibit symptoms of the disease, condition, and / or disorder. In some embodiments, an individual who is susceptible to a disease, condition, and / or disorder may not exhibit symptoms of the disease, condition, and / or disorder. In some embodiments, an individual who is susceptible to a disease, condition, and / or disorder will develop the disease, condition, and / or disorder. In some embodiments, an individual who is susceptible to a disease, condition, and / or disorder will not develop the disease, condition, and / or disorder.
[0194] Synthetic: As used herein, the term "synthetic" refers to an entity that is made by man or human intervention or that is produced synthetically rather than occurring in nature. For example, in some embodiments, a synthetic nucleic acid or polynucleotide refers to a nucleic acid molecule that is chemically synthesized, such as by solid-phase synthesis in some embodiments. In some embodiments, the term "synthetic" refers to an entity that is made outside of a biological cell. For example, in some embodiments, a synthetic nucleic acid or polynucleotide refers to a nucleic acid molecule (e.g., RNA) that is produced by in vitro transcription using a template.
[0195] Therapy: The term "therapy" refers to the administration or delivery of an agent or intervention that has a therapeutic effect and / or induces a desired biological and / or pharmacological effect (e.g., has been shown to be statistically likely to have such an effect when administered to a relevant population). In some embodiments, a therapeutic agent or therapy is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a disease, disorder, and / or condition. In some embodiments, a therapeutic agent or therapy is a medical intervention (e.g., surgery, radiation, phototherapy) that can be performed to alleviate, relieve, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a disease, disorder, and / or condition.
[0196] 3'UTR: As used herein, the term "3'UTR" or "3'UTR" refers to the sequence of an mRNA molecule that begins after the stop codon of the coding region of the open reading frame sequence. In some embodiments, the 3'UTR begins immediately after the stop codon of the coding region of the open reading frame sequence, such as in its natural context. In other embodiments, the 3'UTR does not begin immediately after the stop codon of the coding region of the open reading frame sequence, such as in its natural context.
[0197] Threshold level (e.g., acceptance criteria): As used herein, the term "threshold level" refers to a level used as a reference to obtain information about the results of a measurement and / or to classify the results of a measurement, such as the results of a measurement obtained in an assay. For example, in some embodiments, a threshold level means a value measured in an assay that defines a dividing line between two subsets of a population (e.g., a batch that meets a quality control standard and a batch that does not meet a quality control standard). Thus, a value equal to or higher than the threshold level defines a subset of the population, and a value below the threshold level defines another subset of the population. The threshold level can be determined based on one or more control samples or among a population of control samples. The threshold level can be determined before, simultaneously with, or after the measurement of interest is performed. In some embodiments, the threshold level can be a range of values.
[0198] Treatment: As used herein, the terms "treat / treatment / treating" refer to any method for partially or completely alleviating, ameliorating, alleviating, inhibiting, preventing, delaying the onset of, reducing the severity of, and / or reducing the incidence of one or more symptoms or features of a disease, disorder, and / or condition. Treatment can be performed on subjects who do not show signs of the disease, disorder, and / or condition. In some embodiments, treatment can be performed on subjects who only show early signs of the disease, disorder, and / or condition, for example, for the purpose of reducing the risk of developing pathology associated with the disease, disorder, and / or condition. In some embodiments, treatment can be performed on subjects who are in the late stages of the disease, disorder, and / or condition.
[0199] Vaccination: As used herein, the term "vaccination" refers to the administration of a composition intended to generate an immune response, for example, to a disease-associated (e.g., pathogenic) agent. In some embodiments, vaccination can be performed before, during, and / or after exposure to a disease-associated agent, and in certain embodiments, vaccination can be performed shortly before, during, and / or after exposure to the agent. In some embodiments, vaccination comprises multiple administrations of a vaccine composition appropriately spaced in time. In some embodiments, vaccination generates an immune response to an infectious agent.
[0200] Vaccine: As used herein, the term "vaccine" refers to a composition that induces an immune response upon administration to a subject. In some embodiments, the induced immune response provides protective immunity.
[0201] Variant: As used herein in the context of molecules (e.g., nucleic acids, proteins, or small molecules), the term "variant" refers to a molecule that exhibits significant structural identity with a reference molecule but is structurally different from the reference molecule, for example, one or more chemical moieties are present, absent, or at different levels compared to the reference entity. In some embodiments, a variant is also functionally different from its reference molecule. Generally, whether a particular molecule is properly considered a "variant" of a reference molecule is based on the degree of its structural identity with the reference molecule. As will be appreciated by those skilled in the art, any biological or chemical reference molecule has certain characteristic structural elements. A variant is defined as a different molecule that shares one or more such characteristic structural elements with the reference molecule but is different in at least one aspect. In some embodiments, a variant polypeptide or nucleic acid may differ from a reference polypeptide or nucleic acid due to one or more differences in amino acid or nucleotide sequence and / or one or more differences in chemical moieties (e.g., carbohydrates, lipids, phosphate groups) that are covalent components of the polypeptide or nucleic acid (e.g., attached to the polypeptide or nucleic acid backbone). In some embodiments, the variant polypeptide or nucleic acid exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 99% overall sequence identity to the reference polypeptide or nucleic acid. In some embodiments, the variant polypeptide or nucleic acid does not share at least one characteristic sequence element with the reference polypeptide or nucleic acid. In some embodiments, the reference polypeptide or nucleic acid has one or more biological activities. In some embodiments, the variant polypeptide or nucleic acid shares one or more biological activities of the reference polypeptide or nucleic acid. In some embodiments, the variant polypeptide or nucleic acid lacks one or more biological activities of the reference polypeptide or nucleic acid. In some embodiments, the variant polypeptide or nucleic acid exhibits a reduced level of one or more biological activities compared to the reference polypeptide or nucleic acid. In some embodiments, a polypeptide or nucleic acid of interest is considered a "variant" of a reference polypeptide or nucleic acid if it has an amino acid or nucleotide sequence identical to the reference except for minor sequence changes at specific positions. Typically, less than about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3% or about 2% of the residues in the variant are substituted, inserted or deleted compared to the reference. In some embodiments, the variant polypeptide or nucleic acid comprises about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2 or about 1 substituted residues compared to the reference. Typically, the variant polypeptide or nucleic acid comprises a very small amount (e.g., less than about 5, about 4, about 3, about 2 or about 1) of substituted, inserted or deleted functional residues (i.e., residues involved in a specific biological activity) relative to the reference. In some embodiments, the variant polypeptide or nucleic acid comprises no more than about 5, about 4, about 3, about 2 or about 1 additions or deletions compared to the reference, and in some embodiments does not comprise additions or deletions.In some embodiments, a variant polypeptide or nucleic acid comprises fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and typically fewer than about 5, about 4, about 3, or about 2 additions or deletions compared to a reference. In some embodiments, a reference polypeptide or nucleic acid is one found in nature.
[0202] Vector: As used herein, it refers to a nucleic acid molecule that is capable of transporting another nucleic acid to which it is connected. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop to which additional DNA segments can be connected. Another type of vector is a viral vector, in which additional DNA segments can be connected to the viral genome. Certain vectors are capable of autonomous replication in the host cell into which they are introduced (e.g., bacterial vectors and episomal mammalian vectors having a bacterial origin of replication). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of the host cell after being introduced into the host cell, thereby being replicated together with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operably connected. Such vectors are referred to herein as "expression vectors." In some embodiments, known techniques can be used, for example, to produce or manipulate recombinant DNA, for oligonucleotide synthesis, and for tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to the manufacturer's instructions, or as commonly performed in the art, or as described herein. The foregoing techniques and procedures can generally be performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout the present specification. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)), which is incorporated herein by reference for any purpose.
[0203] All documents and similar materials cited in this application, including but not limited to patents, patent applications, articles, books, papers and web pages, regardless of the format of such documents and similar materials, are expressly incorporated by reference in their entirety. In the event that one or more of the incorporated documents and similar materials differs from or conflicts with this application (including but not limited to defined terms, term usage, described technology, etc.), this application shall prevail. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described in any way.
[0204] Detailed Description of Certain Embodiments
[0205] As discussed above, the present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) and related technologies (e.g., methods) for delivering specific herpes simplex virus (HSV) antigenic constructs (e.g., HSV-1 antigenic constructs, HSV-2 antigenic constructs, or a combination thereof) to a subject (e.g., a patient). In particular, the present disclosure provides HSV (e.g., HSV-1, HSV-2, or both) vaccine compositions and related technologies (e.g., methods).
[0206] The present disclosure provides polyribonucleotides such as those encoding one or more HSV antigens. In some embodiments, such polyribonucleotides can be a part of an RNA construct. In some embodiments, polyribonucleotides or RNA constructs as described herein can be a part of a composition (e.g., a pharmaceutical composition, such as an immunogenic composition, such as a vaccine).
[0207] In some embodiments, the technology provided herein is directed to HSV. Below is a description of HSV and certain exemplary features.
[0208] I. Herpes simplex virus (HSV)
[0209] Herpes simplex virus (HSV) belongs to the α subfamily of the human herpesvirus family and includes HSV-1 and HSV-2. The structure of HSV-1 and HSV-2 mainly includes (from the inside out) a DNA core, a capsid, a tunica, and an envelope. Both HSV-1 and HSV-2 have a double-stranded DNA genome of approximately 153 kb, encoding at least 80 genes. The DNA core is surrounded by an icosapentahedral capsid composed of 162 capsid particles, 150 hexons, and 12 pentons, which is composed of six different viral proteins. The DNA is surrounded by at least 20 different viral envelope proteins, which have structural and regulatory effects. Some of them are involved in the transport of the capsid to the nucleus and other organelles, the entry of viral DNA into the nucleus, the activation of early gene transcription, the inhibition of cellular protein biosynthesis, and the degradation of mRNA. The viral envelope surrounding the tunica has at least 12 different glycoproteins (BN) on their surface. The glycoprotein can exist as heterodimers (H / L and E / I), but most exist as monomers.
[0210] HSV-1 and HSV-2 are responsible for a number of mild, moderate and severe pathologies, including oral and genital ulcers, virus-induced blindness, viral encephalitis and disseminated infection of newborns. HSV-1 and HSV-2 are typically transmitted by different routes and affect different parts of the body, but the signs and symptoms they cause may overlap. Infections caused by HSV-1 are one of the more common infections of the orofacial area and typically cause cold sores, herpetic stomatitis and keratitis. HSV-2 typically causes genital herpes and is primarily transmitted through direct sexual contact with lesions. Most genital HSV infections are caused by HSV-2, however, an increasing number of genital HSV infections have been attributed to HSV-1. Genital HSV-1 infections are generally less severe than genital HSV-2 infections and are less likely to occur.
[0211] HSV infects and is spread by contact with herpes lesions, mucosal surfaces, genital secretions or oral secretions. The average incubation period after exposure is generally 4 days, but the scope can be between 2 days and 12 days. HSV particles can infect neuronal extensions, thereby weakening peripheral tissues, and establish a latent period in these cells, namely in the trigeminal ganglia and dorsal root ganglia in the sacral area where they can therefrom occasionally reactivate. In addition, similar to other herpes viruses, HSV infection is lifelong and usually asymptomatic. Without wishing to be bound by any particular theory, it is understood that the HSV particle can come off from infected individuals, and has nothing to do with the appearance of clinical manifestations.
[0212] HSV infection is rarely fatal but is characterized by painful blisters that may rupture. Clinical presentation varies slightly depending on the type of infecting virus. However, as discussed above, HSV-1 infection tends to be less severe than HSV-2 infection, and patients infected with HSV-2 typically experience more flare-ups.
[0213] A. Life cycle
[0214] As described herein, to initiate infection, HSV (HSV-1 or HSV-2) particles bind to the cell surface using viral glycoproteins and fuse their envelope with the plasma membrane (see, e.g., Figure 2 , step 1). After membrane fusion, the viral capsid and envelope proteins are internalized in the cytoplasm (see, e.g. Figure 2 , step 2). Once in the cytoplasm, viral capsids accumulate in the nucleus and release viral DNA into the nucleus (see e.g. Figure 2, step 3). HSV replicates through three rounds of transcription, producing: α (immediate early) proteins, which primarily regulate viral replication; β (early) proteins, which synthesize and package DNA; and γ (late) proteins, the majority of which are virion proteins (see Whitley et al., Lancet 2001 May 12;357(9267); Taylor et al., Front Biosci. 2002 Mar 1;7:d752-64; and et al., Front Microbiol. 2018 Oct 11;9:2406; each of which is incorporated herein by reference in its entirety) (see e.g. Figure 2 , steps 4-6).
[0215] HSV capsids assemble within the nucleus of infected cells (see e.g. Figure 2 , step 7). Once the viral capsids have been assembled in the nucleus, the particles continue their maturation process in the same compartment by acquiring envelope proteins. After leaving the nucleus, additional envelope proteins are added to the capsids. Concurrently, glycoproteins are translated and glycosylated in the endoplasmic reticulum and processed in the trans-Golgi network (TGN) before being directed to multivesicular bodies (see, e.g., Figure 2 , step 8). They are then transported to plasma membrane glycoproteins within early endosomes (see e.g. Figure 2 , step 9). The viral capsid in the cytoplasm will then fuse with the endosome containing the HSV-glycoprotein to form infectious virions within the vesicle (see, e.g. Figure 2 , steps 10-12).
[0216] HSV (HSV-1 or HSV-2) can establish latent infection. After the initial infection, HSV either replicates in large quantities in epithelial cells or enters the axons of sensory neurons and moves to the nucleus of neurons. There, viral DNA is still circular extrachromosomal DNA and does not have any solubility gene expression; However, the transcripts related to the incubation period are expressed and then spliced to produce mRNA. This general transcriptional silencing allows the virus to remain hidden in the cell by avoiding immune surveillance. In some aspects, provided herein are techniques (e.g., compositions and methods) for strengthening, inducing, promoting, enhancing and / or improving the immune response to HSV (e.g., HSV-1 and / or HSV-2) or its components (e.g., proteins or fragments thereof). In some embodiments, provided herein are techniques for strengthening, inducing, promoting, enhancing and / or improving the immune memory to HSV or its components (e.g., proteins or fragments thereof). In some embodiments, the technology described herein is intended to be used as an immunopotentiator for primary vaccines, such as vaccines for antigens and / or epitopes of HSV (e.g., HSV-1 and / or HSV-2).
[0217] The virus remains in this state for the lifetime of the host, or until appropriate signals reactivate the virus and produce new progeny. The progeny viruses then traverse the neuronal axis to the site of primary infection to restart the lytic replication cycle.
[0218] B. HSV genome
[0219] The genome of HSV-1 and HSV-2 is a double-stranded DNA of approximately 150 kb in length, with slight differences between subtypes and strains. The genome encodes more than 80 genes and has a high GC content: 67% for HSV-1 and 69% for HSV-2 (see Whitley et al., Lancet 2001 May 12; 357(9267); Taylor et al., Front Biosci. 2002 Mar 1; 7: d752-64; and Jiao et al., Microbiol Resour Announc. 2019 Sep; 8(39): e00993-19, which are incorporated herein by reference in their entirety).
[0220] Genome is organized into unique long region (UL) and unique short region (US). UL is usually bounded by terminal long (TRL) repeat sequence and internal long (IRL) repeat sequence. US is usually bounded by terminal short (IRS) repeat sequence and internal short (TRS) repeat sequence. The gene found in the unique region is present in the genome as a single copy, but the gene encoded in the repeat sequence region is present in the genome with two copies (see Whitley et al., Lancet 2001 May 12; 357 (9267); Taylor et al., Front Biosci. 2002 March 1; 7: d752-64; and Jiao et al., Microbiol Resour Announc. 2019 September; 8 (39): e00993-19, the above-mentioned documents are incorporated herein by reference in their entirety).
[0221] HSV contains three replication origins within the genome, named according to their location in the long (oriL) or short (oriS) region of the genome. OriL is found as a single copy in the UL segment, but oriS is located in the repeat sequence region of the short segment; therefore, it is present in the genome in two copies. Both oriL and oriS are palindromic sequences, consisting of an AT-rich central region flanked by inverted repeats that contain multiple binding sites with different affinities for a virus-derived binding polypeptide (UL9). One of the oriL or oriS sequences is sufficient for viral replication (see Whitley et al., Lancet 2001 May 12; 357(9267); Taylor et al., Front Biosci. 2002 Mar 1; 7: d752-64; and Jiao et al., Microbiol Resour Announc. 2019 Sep; 8(39): e00993-19, incorporated herein by reference in their entirety).
[0222] The viral genome also contains a signal that coordinates the newly synthesized genome to be properly processed to be packaged into a preformed capsid. The daughter genome is produced in a long concatemer that needs to be cut into unit length monomers. For this purpose, the viral genome contains two DNA sequence elements, pac1 and pac2, which ensure the correct cutting and packaging of the daughter genome of unit length. These elements are located in the same direction repeat sequence (DR) seen in the inverted repeat sequence region at the end of the viral genome (see Whitley et al., Lancet May 12, 2001; 357 (9267); Taylor et al., Front Biosci. March 1, 2002; 7: d752-64; and Jiao et al., Microbiol Resour Announc. September 2019; 8 (39): e00993-19, the above-mentioned document is incorporated herein by reference in its entirety).
[0223] C. Certain HSV proteins
[0224] ICP0
[0225] The infectious cell protein 0 (ICP0) of herpes simplex virus 1 (HSV-1) is the alpha (immediate early) protein of herpes simplex virus 1 and is able to activate HSV-1 gene expression, disrupt the nuclear domain (ND) 10 structure, mediate the degradation of cellular proteins, and evade the intrinsic and innate antiviral defenses of the host cell (see Smith et al., Future Virol. 2011 Apr;6(4):421–429).
[0226] ICP22
[0227] Infected cell protein 22 (ICP22) is expressed by immediate early (IE) genes during the replication cycle of HSV-1 and HSV-2. ICP22 can usually regulate viral and host gene transcription by changing the phosphorylation state of host RNA polymerase II (RNA pol II), and can also promote the accurate positioning of the nuclear export complex (NEC) to the nuclear membrane to promote nuclear budding (see Wu et al., Front Microbiol. 2021 June 7; 12: 668461).
[0228] VP16
[0229] The UL48 gene encodes VP16, or α-transactivator factor (α-TIF). VP16 is an important transactivator that activates transcription of viral immediate-early genes and the late stages of viral replication. In addition, VP16 participates in viral assembly as a membrane envelope (see Fan et al., Front Microbiol. 2020; 11: 1910).
[0230] In the early stages of viral infection, VP16 released by invading virions binds to the immediate early (IE) gene promoter to stimulate transcription of IE genes, acting as a transactivator specifically for IE genes (see Fan et al., Front Microbiol. 2020; 11: 1910). In the late stages, VP16 is assembled into the envelope to participate in the assembly of virions and promote their maturation (see Fan et al., Front Microbiol. 2020; 11: 1910).
[0231] glycoprotein
[0232] In order to replicate, enveloped HSV must be able to fuse with the membranes of living cells and deliver their genetic material into their cytoplasm. The HSV viral envelope that surrounds the membrane has at least 12 different glycoproteins (gB-gN) on their surface. Glycoproteins can exist as heterodimers (gH / gL and gE / gI), and most exist as monomers. HSV gC, gB, gD, gH and gL are involved in the process of viral cell entry. Initial attachment is mediated by gC, followed by gD. Then gH / gL pulls the virus and cell membrane together, and then gB triggers membrane fusion. (Reske et al., Rev Med Virol. May-June 2007; and Arii et al., Adv Exp Med Biol. 2018; 1045: 3-21).
[0233] The present disclosure provides HSV glycoprotein (e.g., gB, gC, gD, gE, gG, gH, gI and / or gL) antigens and antigenic fragments thereof, which can be used to prevent or treat HSV, for example, in HSV antigen constructs and / or HSV compositions (e.g., immunogenic compositions, e.g., vaccines) as further disclosed herein.
[0234] Glycoprotein C (gC)
[0235] Mature HSV glycoprotein C (gC) is a 56kDa protein that plays a role in initial cell attachment. Glycoprotein C is a type I membrane glycoprotein and is considered to be an important attachment protein and the main viral ligand for binding heparan sulfate proteoglycans (HSPGs) on the cell surface. This binding can occur through the interaction of gC with the HSPG-rich regions seen on F-actin-rich membrane protrusions known as filopodia.
[0236] Glycoprotein C has also been shown to participate in regulating cell entry and infection by increasing the pH threshold for acid-induced conformational changes in gB. Low pH induces reversible conformational changes in gB domains I and V, which contain hydrophobic loops important in cell fusion. By positively regulating low-pH-induced conformational changes in gB, gC may enhance the ability of HSV to enter cell types that require a low-pH entry mechanism, such as epithelial cells.
[0237] In addition to its role in attachment, glycoprotein C has also been shown to play a role in immune evasion. Glycoprotein C is a target of lymphocyte cytotoxicity in certain cell types and can bind complement component C3b to inhibit complement activation. Furthermore, neutralizing epitopes present on other HSV glycoproteins, such as gB, can be protected by gC, thereby preventing immune responses from blocking fusion.
[0238] Glycoprotein D (gD)
[0239] HSV glycoprotein D (gD) is a 46kDA type I membrane glycoprotein. The N-terminal extracellular domain consists of 316 amino acids. Glycoprotein D promotes invasion by interacting with several cell surface receptors, including herpes virus entry mediator (HVEM), connexin-1 or connexin-2, and heparin sulfate containing specific modifications. These cell receptors do not function as co-receptors because each glycoprotein interacts with the receptor of the cell independently of each other. The binding of gD to one of these cell receptors causes a conformational change that converts the self-inhibited closed state of gD into an active state that transmits one of the two signals required for the activation of the gH / gL complex. The first gD receptor confirmed, HVEM, belongs to the tumor necrosis factor receptor family and is commonly found on T cells, B cells, dendritic cells, natural killer cells, macrophages, and non-immune cell types such as neurons and epithelial cells. Within the N-terminus of gD, there is a 37-residue hairpin structure that forms the entire site that is bound to HVEM. Specifically, residues 1-32 of the N-terminal domain of gD bind to HVEM's cysteine-rich domain 1. When not in contact with HVEM, this N-terminal extension adopts an extended and flexible conformation.
[0240] Clinical strains of HSV use connexin-1 for cell entry; however, several mutant strains of HSV utilize connexin-2. Furthermore, heparan sulfate is utilized by HSV-1 but not HSV-2. The interaction of glycoprotein D with net-1 has been shown to be essential in some cell types, such as neurons, even when other receptors are present on the cell surface.
[0241] Glycoprotein H (gH) / glycoprotein L (gL) complex
[0242] Glycoprotein H (gH) is an essential 56kD protein that exists as a heterodimer complex with 25kDa glycoprotein L (gL) (complex is referred to as gH / gL in this article). The gH / gL complex is required for cell fusion and entry. The fusion protein of gH / gL and the literature record does not have any structural similarity and may not function as a fusion-promoting protein (cofusogen) with gB. Instead, gH / gL can serve as a regulatory factor for fusion and an important component in the contact between stabilizing HSV and cells. Glycoprotein H receives the signal from gD through its H1 domain and transmits this signal to the membrane proximal H3 domain, which in turn propagates this signal to the cytoplasmic tail of gH. Once the cytoplasmic tail of gH receives this signal, it releases the strain on the pre-fusion conformation of gB, which helps the fusion loop of gB to be connected to the cell surface, thereby promoting the membrane fusion of gB mediation. The sudden change in the C-terminal tail of gH has been shown to reduce fusion activity. Furthermore, it has been shown that antibody responses against gH can inhibit the fusion process mediated by gB-gH-gL. In addition to this fundamental role, gH also contains an arginylglycyl aspartate (RGD) motif that can bind to integrin receptors found on cells. It is believed that the interaction of gH with integrins triggers intracellular signals that promote capsid transport.
[0243] Glycoprotein B (gB)
[0244] Glycoprotein B is a protein with an apparent molecular weight of approximately 95-100 kDa and consists of an extended rod or spike-like extracellular domain, a hydrophobic membrane proximal region (MPR), a transmembrane region (TMR) and a C-terminal domain (CTD). The extracellular domain is well characterized as actively involved in fusion, and MPR, TMR and CTD can play a role in regulating fusion. Glycoprotein B is a Class III fusion protein (fusogen). The glycoprotein B extracellular domain architecture shares conformational similarity with fusion proteins from viruses that do not belong to the Herpesviridae family. Glycoprotein B is activated by its interaction with gH / gL, but HSV cannot fuse with target cells by activating gB alone, and requires gB to interact with specific receptors to complete fusion. A well-known receptor target of gB is cell-surface heparan sulfate, which is an interaction not necessary for HSV fusion, but is known to promote viral adhesion to the cell surface. Glycoprotein B can also interact with paired immunoglobulin-like type 2 receptors that are most common on monocytes, macrophages and dendritic cells.
[0245] HSV gB exists in two forms, i.e., pre-fusion form and post-fusion form. Several variations of the pre-fusion form of gB are believed to have led to its active and post-fusion state. The first variation occurs in domain V or MPR, which causes the fusion loop to point to the cell membrane and away from the viral membrane. This variation can produce a compact intermediate conformation 1 that has not yet attached to the cell membrane surface. The next variation occurs in domain III and involves gB adopting an extended intermediate conformation 2, which allows its fusion loop to attach to the cell membrane surface. Finally, the variation in domain V converts gB into its post-fusion conformation, which is conducive to membrane fusion.
[0246] The post-fusion form of HSV-1 gB has an extracellular domain that exists as three protomers that interact to produce a rod-like trimeric structure. Each promoter is composed of five different domains, with the linker region forming a hairpin shape. Each domain of a single protomer interacts with the same domain of an adjacent protomer to form the described trimeric structure. Domain I houses the important fusion loop and is commonly referred to as the fusion domain. Domain II facilitates interaction with gH / gL and is referred to as the gH / gL domain. Domain III is composed of alpha helices that help form the trimeric coil-coil central core of this protein. Domain IV is called the crown domain and sits at the top of the post-fusion form; it is believed to bind to cellular receptors. Antibodies that bind to the crown domain can disrupt gB binding to cellular receptors. Domain V consists of long extensions and connects the protomers together.
[0247] Glycoprotein E and glycoprotein I (gE / gI)
[0248] Glycoprotein E is about 53kDa, and glycoprotein I is about 141kDa. These two proteins interact to form a heterodimer complex (referred to as the complex of gE / gI in this article) that plays a role in intercellular diffusion and virus-induced fusion. Different from gB, gD and gH / gL, the gE / gI complex is not necessary for fusion and entry into cells, but is very important for intercellular diffusion. The destruction that gE / gI forms has an impact on HSV proliferation, because the dissolving cycle of this virus depends on intercellular diffusion. The mechanism that gE / gI promotes intercellular diffusion is considered to depend on several envelope polypeptides. The synergistic effect of envelope polypeptides UL11, UL16 and UL21 may play a role in processing, transshipment and the biological activity of gE.
[0249] Glycoprotein G
[0250] Glycoprotein G (gG) from HSV-1 (gG1) and HSV-1 (gG2) is the first viral chemokine binding protein shown to enhance the chemokine function of cells. The size of glycoprotein G varies greatly between HSV-1 and HSV-2, with sizes of 76kDa and 43kDa, respectively. Glycoprotein G is unique in that its soluble form (sgG2) can have immunomodulatory capabilities through its extracellular activity. Once outside the cell, sgG2 binds chemokines through their glycosaminoglycan (GAG) binding domain without interfering with the chemokine's G protein-coupled receptor (GPCR) binding site. The interaction of sgG2 with GAG-containing proteins allows the initiation of lipid raft formation and accumulation, which results in the aggregation of chemokine receptors into this microdomain. The aggregation of chemokine receptors, in turn, increases the local concentration of chemokines on the extracellular surface of the host cell and allows these chemokines to interact with GPCRs. This interaction has the potential to lead to increased immune signaling responses and chemokine stimulation. This combination of receptor relocalization and presentation of the chemokine complex to SgG2 provides a molecular mechanism for the enhancement of chemokine function during HSV infection. This immune modulation contrasts with other viruses that inhibit chemokine function because, in this case, chemokine function is enhanced by SgG. Without being bound by any particular theory, it is believed that overall manipulation of endogenous immune signaling may be beneficial to HSV overall.
[0251] ICP47
[0252] Infected cell protein 47 (ICP47), encoded by the gene US12, is a polymorphic protein that blocks RNA splicing early in infection and then shuttles viral mRNA from the nucleus to the cytoplasm in late infection. ICP47 directly binds to the antigen-dependent transporter (TAP), thereby restricting antigen transport and leading to the appearance of empty MHC-I (Cheng et al., Virol J. 2020 Jul 10;17(1):101). Binding of ICP47 to TAP stabilizes the inward-facing conformation, thereby blocking the translocation pathway toward the endoplasmic reticulum (ER) lumen. By blocking viral antigen entry into the ER, HSV is able to avoid attack by cytotoxic T lymphocytes, which can lead to immune escape of HSV and establish a lifelong infection in the host cell (Cheng et al., Virol J. 2020 Jul 10;17(1):101).
[0253] VHS
[0254] The virion-host shutoff (VHS) protein is a viral protein synthesized with late kinetics and packaged into mature virion particles. Functionally, VHS is a viral RNase that preferentially degrades both host and viral mRNA species. VHS has been reported to interfere with dendritic cell (DC) activation during both productive and non-productive HSV infection (Cotter et al., J Virol. 2011 Dec;85(23):12662–12672.).
[0255] US3
[0256] All members of the alphaherpesvirinae subfamily encode a serine / threonine kinase designated US3. US3 is an important virulence factor of herpes simplex virus type 1 (HSV-1) and a multifunctional polypeptide that plays various roles in the viral life cycle by phosphorylating many viral and cellular substrates (Kato et al., Adv Exp Med Biol. 2018; 1045: 45-62.).
[0257] D.HSV vaccine
[0258] Several HSV vaccines, primarily targeting HSV-2 and primarily focused on generating neutralizing antibodies (nAbs) targeting viral envelope glycoprotein D as a correlate of immune protection, have been developed and evaluated in human clinical trials, see Table 1 below. Although these vaccines have demonstrated protection against HSV in preclinical studies and, in some cases, in Phase 2 studies, none of these vaccines has demonstrated sufficient efficacy for further development or commercialization.
[0259] The present disclosure provides insight into the fact that many existing strategies for developing pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) for treating and / or preventing HSV infection focus primarily or even almost exclusively on developing neutralizing antibodies that target surface glycoproteins. The present disclosure identifies problems with such strategies, including, for example, that they may fail to appreciate the value or even criticality of ensuring that the induced immune response includes significant T cell activity (in some embodiments, CD4 T cell activity, in some embodiments, CD8 T cell activity, and in some embodiments, both). In some embodiments, pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) that comprise or deliver CD4 and CD8 epitopes of one or more HSV antigens (e.g., HSV-1 antigens, HSV-2 antigens, or a combination thereof), for example, in addition to one or more B cell antigens and / or epitopes, can be used to treat and / or prevent HSV infection.
[0260] Table 1: Some HSV vaccines in clinical development
[0261]
[0262]
[0263] E. Antiviral treatment of HSV
[0264] The present disclosure provides the recognition that the constructs and / or compositions described herein can be administered as part of a regimen with other therapeutic agents. The present disclosure also recognizes that a subject to whom a construct and / or composition described herein is administered may have previously been administered other therapeutic agents.
[0265] In some embodiments, for example, the subject may be receiving or have previously received an antiviral agent for HSV. In some embodiments, the antiviral agent may be administered to treat HSV-1 or HSV-2 infection or recurring episodes. In some embodiments, the antiviral agent is or includes acyclovir, valacyclovir, famciclovir, or a combination thereof. Table 2 below provides some information regarding the selection of an antiviral agent.
[0266] Table 2: Antiviral drugs used to treat HSV
[0267]
[0268]
[0269] II. Constructs
[0270] A. HSV antigen
[0271] The present disclosure provides HSV (e.g., HSV-1, HSV-2, or both) antigens and antigenic fragments thereof, which can be used to prevent or treat HSV, for example, in HSV antigen constructs and / or HSV compositions (e.g., immunogenic compositions, such as vaccines) as further disclosed herein.
[0272] In some embodiments, HSV antigenic fragments can be used in HSV T cell antigen constructs. In some embodiments, HSV antigens (e.g., full-length HSV antigens) can be used in HSV glycoprotein constructs.
[0273] In some embodiments, the polyribonucleotide encodes one or more HSV antigens or antigenic fragments thereof.In some embodiments, the polyribonucleotide encodes an HSV glycoprotein construct.
[0274] A variety of HSV antigens are known. The present disclosure provides polyribonucleotides encoding HSV antigens or antigenic fragments thereof as described herein. Tables 3-5 below provide an overview of exemplary amino acid sequences of certain HSV (HSV-1, HSV-2, or both) proteins. Table 6 below provides exemplary amino acid sequences of certain HSV (HSV-1, HSV-2, or both) proteins.
[0275] Table 3: Exemplary antigens of HSV
[0276]
[0277]
[0278] Table 4: Exemplary antigens selected from systematic analysis of source data
[0279]
[0280]
[0281] Table 5: Exemplary Antigens
[0282]
[0283] Table 6: Exemplary amino acid antigen sequences
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325]
[0326]
[0327]
[0328]
[0329] In some embodiments, the present disclosure provides certain HSV antigen constructs (eg, HSV-1 antigen constructs, HSV-2 antigen constructs, or a combination thereof) that are particularly useful in effective vaccination.
[0330] In various embodiments, the HSV antigen construct includes and / or encodes a plurality of HSV antigens (e.g., a plurality of HSV antigens that are or include one or more T cell and / or B cell antigens of HSV). As disclosed herein, T cell antigens include, for example, CD4 T cell antigens and / or CD8 T cells. In some embodiments, the HSV antigen is a T cell antigen. In some embodiments, the HSV antigen is a B cell antigen.
[0331] In certain embodiments, the HSV antigen construct may include and / or encode at least one of UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22 and / or UL54, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode at least one of UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48 and / or UL49, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode at least one of RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22 and / or UL54, or a fragment thereof.
[0332] In certain embodiments, the HSV antigen construct may include and / or encode multiple (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) of UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22, and / or UL54, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode multiple (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, and / or UL49, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode multiple (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) of RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22, and / or UL54, or fragments thereof.
[0333] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL1 polypeptide or a fragment thereof. In various embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL1 polypeptides known in the art include UL1 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 1, 2 and / or 3, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0334] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL21 polypeptide or a fragment thereof. In various embodiments, the UL21 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL21 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL21 polypeptides known in the art include UL21 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL21 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO:4, 5 and / or 6, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0335] The UL27 open reading frame encodes HSV gB (also referred to herein as the UL27 polypeptide). In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL27 polypeptide or a fragment thereof. In various embodiments, the UL27 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL27 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL27 polypeptides known in the art include UL27 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL27 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:7, 8, 9 and / or 74, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0336] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL29 polypeptide or a fragment thereof. In various embodiments, the UL29 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL29 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL29 polypeptides known in the art include UL29 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL29 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 10, 11 and / or 12, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0337] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL39 polypeptide or a fragment thereof. In various embodiments, the UL39 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL39 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL39 polypeptides known in the art include UL39 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL39 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 13, 14 and / or 15, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0338] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL40 polypeptide or a fragment thereof. In various embodiments, the UL40 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL40 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL40 polypeptides known in the art include UL40 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL40 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 16, 17 and / or 18, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0339] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL46 polypeptide or a fragment thereof. In various embodiments, the UL46 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL46 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL46 polypeptides known in the art include UL46 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL46 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 19, 20 and / or 21, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0340] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL47 polypeptide or a fragment thereof. In various embodiments, the UL47 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL47 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL47 polypeptides known in the art include UL47 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL47 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 22, 23 and / or 24, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0341] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL48 polypeptide or a fragment thereof. In various embodiments, the UL48 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL48 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL48 polypeptides known in the art include UL48 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL48 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 25, 26 and / or 27, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0342] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL49 polypeptide or a fragment thereof. In various embodiments, the UL49 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL49 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL49 polypeptides known in the art include UL49 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL49 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, 29 and / or 30, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0343] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes an RS1 polypeptide or a fragment thereof. In various embodiments, the RS1 polypeptide or its fragment has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to an RS1 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment. Examples of RS1 polypeptides known in the art include RS1 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the RS1 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:31, 32 and / or 33, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0344] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes an RL2 polypeptide or a fragment thereof. In various embodiments, the RL2 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to an RL2 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of RL2 polypeptides known in the art include RL2 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the RL2 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO:34, 35 and / or 36, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0345] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL5 polypeptide or a fragment thereof. In various embodiments, the UL5 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL5 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL5 polypeptides known in the art include UL5 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL5 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO:37, 38 and / or 39, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0346] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL9 polypeptide or a fragment thereof. In various embodiments, the UL9 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL9 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL9 polypeptides known in the art include UL9 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL9 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:40, 41 and / or 42, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0347] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL19 polypeptide or a fragment thereof. In various embodiments, the UL19 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL19 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL19 polypeptides known in the art include UL19 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL19 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:43, 44 and / or 45, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0348] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL25 polypeptide or a fragment thereof. In various embodiments, the UL25 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL25 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL25 polypeptides known in the art include UL25 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL25 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:46, 47 and / or 48, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0349] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL30 polypeptide or a fragment thereof. In various embodiments, the UL30 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL30 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL30 polypeptides known in the art include UL30 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL30 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 49, 50 and / or 51, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0350] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL52 polypeptide or a fragment thereof. In various embodiments, the UL52 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a UL52 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL52 polypeptides known in the art include UL52 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL52 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:52, 53 and / or 54, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0351] The US1 open reading frame encodes HSV gL (also referred to herein as the US1 polypeptide). In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a US1 polypeptide or a fragment thereof. In various embodiments, the US1 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a US1 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment. Examples of US1 polypeptides known in the art include US1 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the US1 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:58, 59, 60 and / or 61, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0352] The US7 open reading frame encodes HSV gI (also referred to herein as the US7 polypeptide). In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a US7 polypeptide or a fragment thereof. In various embodiments, the US7 polypeptide or a fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a US7 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment. Examples of US7 polypeptides known in the art include US7 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the US7 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:62, 63, 64 and / or 65, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0353] The US8 open reading frame encodes HSV gE (also referred to herein as the US8 polypeptide). In some embodiments, the HSV antigen is (e.g., a T cell or B cell antigen of HSV) or includes a US8 polypeptide or a fragment thereof. In various embodiments, the US8 polypeptide or a fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity) to a US8 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment. Examples of US8 polypeptides known in the art include US8 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the US8 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:66, 67, 68 and / or 69, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0354] The UL22 open reading frame encodes HSV gH (also referred to herein as the UL22 polypeptide). In some embodiments, the HSV antigen is (e.g., a T cell or B cell antigen of HSV) or includes a UL22 polypeptide or a fragment thereof. In various embodiments, the UL22 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL22 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL22 polypeptides known in the art include UL22 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL22 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:70, 71, 72 and / or 73, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0355] In some embodiments, the HSV antigen (e.g., a T cell or B cell antigen of HSV) is or includes a UL54 polypeptide or a fragment thereof. In various embodiments, the UL54 polypeptide or fragment thereof has at least 80% sequence identity (e.g., at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity) to a UL54 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL54 polypeptides known in the art include UL54 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL54 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:55, 56 and / or 57, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0356] In certain embodiments, the HSV antigen construct may include and / or encode one or more HSV antigens, including one or more T cell antigens of the HSV disclosed herein (e.g., CD4 and / or CD8 T cell antigens) and one or more HSV antigens that are not T cell antigens of the disclosure. In certain embodiments, the HSV antigen construct may include and / or encode one or more HSV antigens, including one or more B cell antigens of the HSV disclosed herein and one or more HSV antigens that are not B cell antigens of the disclosure. In certain embodiments, the HSV antigen construct may include and / or encode one or more HSV antigens, including one or more T cell antigens of the HSV disclosed herein and one or more HSV antigens that are B cell antigens of HSV (e.g., antigens that are or include B cell epitopes disclosed herein or otherwise known in the art). In certain embodiments, the HSV antigen construct may include and / or encode one or more HSV antigens, including one or more T cell antigens of the HSV disclosed herein and one or more HSV antigens selected from HSV glycoproteins or fragments thereof. In certain embodiments, the HSV antigen construct may include and / or encode one or more HSV antigens, including one or more T cell antigens of the HSV disclosed herein and one or more HSV antigens selected from HSV gD protein or an antigenic fragment thereof, HSV gB protein or an antigenic fragment thereof, HSV gE protein or an antigenic fragment thereof, HSV gG protein or an antigenic fragment thereof, HSV gI protein or an antigenic fragment thereof, HSV gH protein or an antigenic fragment thereof, HSV gL protein or an antigenic fragment thereof, HSV ICP4 protein or an antigenic fragment thereof, or ICP8 protein or an antigenic fragment thereof.
[0357] In various embodiments, the HSV antigenic construct can be present in a composition for delivering the HSV antigenic construct to a subject. In various embodiments, the HSV antigenic construct can be present in a composition for delivering one or more HSV antigens and / or epitopes to a subject. In various embodiments, the HSV antigenic construct can be or include an RNA molecule encoding one or more antigens and / or epitopes.
[0358] Compositions for delivering HSV antigenic constructs and / or HSV antigenic constructs may advantageously include, for example, one or more B cell antigens of HSV and one or more T cell antigens of HSV (e.g., CD4 and / or CD8 T cell antigens) in certain embodiments. Without wishing to be bound by any particular scientific theory and without suggesting that other embodiments are also advantageous, the combination of B cell antigens and T cell antigens may be advantageous in promoting immune system defense against HSV at multiple points in the life cycle, including but not limited to before and after cell entry.
[0359] Among other things, the present disclosure provides insight into the fact that many existing strategies for developing pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) for treating and / or protecting against viral infections have focused primarily, or even almost exclusively, on developing neutralizing antibodies targeting surface glycoproteins. The present disclosure identifies problems with such strategies, including, for example, that they may fail to appreciate the value or even criticality of ensuring that the induced immune response includes significant T cell activity (in some embodiments, CD4 T cell activity, in some embodiments, CD8 T cell activity, and in some embodiments, both).
[0360] Alternatively or additionally, the present disclosure provides insight that considering the expression of HSV proteins (e.g., at specific stages of the HSV life cycle and / or in specific tissues or compartments of infected subjects) can improve vaccine effectiveness.
[0361] In some embodiments, the present disclosure provides techniques for identifying, selecting, and / or characterizing HSV protein sequences (e.g., HSV-1 protein sequences, HSV-2 protein sequences, or combinations thereof) and combinations thereof that are particularly suitable for inclusion in pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) as described herein.
[0362] In some embodiments, pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) comprise or deliver, for example, CD4 and CD8 antigens of one or more HSV proteins (e.g., HSV-1 proteins, HSV-2 proteins, or a combination thereof) in addition to one or more B cell antigens. Among other aspects, the present disclosure provides HSV antigen constructs (e.g., HSV-1 antigen constructs, HSV-2 antigen constructs, or a combination thereof) and compositions (e.g., pharmaceutical compositions, such as immunogenic compositions, such as vaccines) comprising and / or delivering antigen constructs that induce both neutralizing antibodies and T cells (e.g., CD4 and / or CD8 T cells). Such neutralizing antibodies and T cells (e.g., CD4 and / or CD8 T cells) can target, for example, HSV glycoproteins, and in some embodiments, one or more additional HSV proteins. In some embodiments, the present disclosure provides such constructs and compositions that induce particularly strong neutralizing antibody responses and / or particularly diverse T cell responses (e.g., targeting multiple T cell antigens).
[0363] In some embodiments, the present disclosure provides such constructs and compositions that induce robust B cell responses.In some embodiments, the B cell response includes the production of a diverse repertoire of specific antibodies.
[0364] In some embodiments, the present disclosure provides such constructs and compositions that induce T cell and B cell responses to HSV antigens and / or epitopes.
[0365] The present disclosure provides the recognition that, for example, constructs and compositions comprising RNA molecules as described herein (e.g., encoding one or more HSV (e.g., HSV-1 and / or HSV-2) antigens and / or epitopes) provide a higher degree of antigen presentation to various immune system components and / or pathways. In some embodiments, administration of such constructs or compositions can induce T cell and / or B cell responses. The present disclosure provides the insight that, for example, in some embodiments in which T cell and B cell responses are induced in a subject, the subject can have a more sustained, long-term immune response. Such an immune response can be beneficial, for example, for preventing HSV (e.g., HSV-1 and / or HSV-2) reactivation with a single administration, which can increase vaccination rates and subject compliance compared to currently available vaccines that require administration every few years. In some embodiments, constructs and compositions comprising RNA molecules as described herein (e.g., encoding one or more HSV (e.g., HSV-1, HSV-2, or a combination thereof) antigens and / or epitopes) can provide more diverse protection (e.g., protection against HSV (e.g., HSV-1 and / or HSV-2) variants) because, without wishing to be bound by any particular theory, the constructs and compositions can induce a variety of immune system responses.
[0366] The present disclosure also provides the recognition that by administering constructs and compositions encoding HSV (e.g., HSV-1 and / or HSV-2) antigens and / or epitopes, the constructs and compositions described herein avoid the administration of HSV (e.g., HSV-1 and / or HSV-2) virions, which could infect a subject, enter latency, and reactivate to cause disease.
[0367] Still further, the present disclosure provides insight (and also identifies a source of problems in certain prior art HSV vaccination strategies) that, in some embodiments, particularly effective pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) alter one or more characteristics of the innate immune system. The present disclosure provides certain such compositions, including, for example, compositions comprising RNA constructs encoding HSV (e.g., HSV-1 and / or HSV-2) proteins (e.g., HSV antigens or HSV epitopes) as described herein.
[0368] Separately, in some embodiments, the present disclosure provides specific pharmaceutical composition (e.g., immunogenic composition, such as a vaccine) forms, including, for example, RNA pharmaceutical compositions (e.g., immunogenic composition, such as a vaccine) comprising specific elements and / or sequences that can be used for vaccination.
[0369] The present disclosure provides various insights and technologies related to such HSV (e.g., HSV-1 and / or HSV-2) antigenic constructs and vaccine (e.g., RNA vaccine) compositions.
[0370] As described herein, in many embodiments, provided compositions (e.g., pharmaceutical compositions, e.g., immunogenic compositions, e.g., vaccines) include RNA actives encoding one or more HSV (e.g., HSV-1 and / or HSV-2) polypeptides or antigenic fragments thereof; in some embodiments, such RNA actives are in the form of modified RNA in that their uridine residues are substituted with uridine analogs such as pseudouridine; alternatively or additionally, in some embodiments, such RNA actives include specific elements (e.g., cap, 5'UTR, 3'UTR, poly A tail, etc.) and / or features (e.g., codon optimization) that have been identified, selected, characterized, and / or demonstrated to achieve significant (e.g., improved) translatability (e.g., in vitro) and / or expression (i.e., in a subject to which it has been administered) of the encoded protein. Further alternatively or additionally, in some embodiments, the RNA active comprises specific elements and / or features that are identified, selected, characterized, and / or demonstrated to achieve significant RNA stability and / or efficient manufacturing, particularly for efficient production on a large scale (e.g., 0.1-10 g, 10-500 g, 500 g-1 kg, 750 g-1.5 kg; one skilled in the art will appreciate that different products can be manufactured at different scales, e.g., depending on the size of the patient population). In some embodiments, the RNA manufacturing scale can be in the range of about 0.01 g / hr RNA to about 1 g / hr RNA, 1 g / hr RNA to about 100 g / hr RNA, about 1 g RNA / hr to about 20 g RNA / hr, or about 100 g RNA / hr to about 10,000 g RNA / hr. In some embodiments, the RNA manufacturing scale can be tens or hundreds of milligrams to tens or hundreds of grams (or more) of RNA per batch. In some embodiments, this scale of RNA manufacturing can allow for batch sizes ranging from about 0.01 g to about 500 g RNA, about 0.01 g to about 10 g RNA, about 1 g to about 10 g RNA, about 10 g to about 500 g RNA, about 10 g to about 300 g RNA, about 10 g to about 200 g RNA, or about 30 g to about 60 g RNA.
[0371] Still further, in many embodiments, provided compositions (e.g., pharmaceutical compositions, e.g., immunogenic compositions, such as vaccines) comprising RNA actives are prepared, formulated, and / or utilized in specific LNP compositions as described herein.
[0372] Among other things, the present disclosure provides techniques for rapidly developing pharmaceutical compositions (eg, immunogenic compositions, such as HSV vaccines) for delivering specific HSV (eg, HSV-1 and / or HSV-2) antigenic constructs to a subject.
[0373] In addition, the present disclosure provides, for example, nucleic acid constructs encoding HSV (e.g., HSV-1 and / or HSV-2) antigens as described herein, expressed HSV (e.g., HSV-1 and / or HSV-2) proteins, and various methods of production and / or use related thereto, as well as compositions developed using the same and methods related thereto.
[0374] For example, the present disclosure provides technologies for preventing, characterizing, treating and / or monitoring HSV (e.g., HSV-1 and / or HSV-2) outbreaks and / or infections, including various nucleic acid constructs and encoded proteins as described above, as well as agents (e.g., antibodies) that bind to such proteins and compositions containing and / or delivering the same.
[0375] In some aspects, provided herein are techniques (e.g., compositions and methods) for strengthening, inducing, promoting, enhancing and / or improving immune responses to HSV (e.g., HSV-1 and / or HSV-2) or components thereof (e.g., proteins or fragments thereof). In some embodiments, provided herein are techniques for strengthening, inducing, promoting, enhancing and / or improving immune memory to HSV (e.g., HSV-1 and / or HSV-2) or components thereof (e.g., proteins or fragments thereof). In some embodiments, the techniques described herein are intended to be used as immunoboosting agents for primary vaccines, such as vaccines for antigens and / or epitopes of HSV (e.g., HSV-1 and / or HSV-2). In some embodiments, the compositions of the present disclosure comprise one or more polynucleotide constructs (e.g., one or more string constructs) encoding one or more antigens from HSV (e.g., HSV-1 and / or HSV-2). In some embodiments, the present disclosure provides vaccines or other compositions comprising nucleic acids encoding such HSV (e.g., HSV-1 and / or HSV-2) antigens; those skilled in the art will understand from the context that when reference is made to a particular polynucleotide (e.g., DNA or RNA) "encoding" such an antigen, this actually refers to the coding strand or its complement.
[0376] The present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) and related technologies (e.g., methods) for delivering specific HSV antigen constructs to subjects (e.g., patients). In some embodiments, the present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) and related technologies (e.g., methods) for delivering specific HSV-1 antigen constructs to subjects (e.g., patients). In some embodiments, the present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) and related technologies (e.g., methods) for delivering specific HSV-2 antigen constructs to subjects (e.g., patients). In some embodiments, the present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) and related technologies (e.g., methods) for delivering specific HSV-1 and HSV-2 antigen constructs to subjects (e.g., patients).
[0377] The present disclosure further provides the recognition that some HSV antigens are common to both HSV-1 and HSV-2. The present disclosure also provides the recognition that some HSV antigens include sequences that are conserved between HSV-1 and HSV-2. In addition, the present disclosure recognizes that some HSV-1 antigens have, for example, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with comparable HSV-2 antigens.
[0378] In some embodiments, the present disclosure provides certain HSV antigenic constructs that are particularly suitable for effective vaccination. In some embodiments, the HSV antigenic construct is an HSV-1 antigenic construct, an HSV-2 antigenic construct, or a combination thereof.
[0379] Antigens utilized in accordance with the present disclosure are or include HSV (e.g., HSV-1 and / or HSV-2) components (e.g., antigenic fragments thereof, including epitopes that may include non-amino acids, such as carbohydrate moieties) that induce an immune response when administered to humans (or other animals susceptible to HSV (e.g., HSV-1 and / or HSV-2) infection, such as rodents and non-human primates).
[0380] In many embodiments, as described herein, the antigens utilized in the provided pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) include B cell and T cell antigens and / or epitopes. In some specific embodiments, the delivered antigens include B cell and T cell (e.g., CD4 and / or CD8 T cell) antigens and / or epitopes, optionally together in a single antigenic polypeptide. In some embodiments, the antigens utilized in the provided pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) include T cell antigens and / or epitopes. In some embodiments, the antigens utilized in the provided pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) include B cell, CD4 T cell, and CD8 T cell epitopes together. Indeed, in some embodiments, the present disclosure defines epitopes that are particularly useful for inclusion in HSV (e.g., HSV-1 and / or HSV-2) vaccines, and / or provides antigens that include them.
[0381] Exemplary antigens and / or epitopes for use in the compositions described herein include, for example, those provided in Tables 3-5 herein and antigenic fragments thereof. In some embodiments, the exemplary antigens and / or fragments thereof and / or epitopes disclosed in Tables 3-5 may be used in the compositions described herein.
[0382] In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, such as HSV (e.g., HSV-1 and / or HSV-2) vaccines) contain or deliver (e.g., cause expression in a recipient organism, such as by administering a nucleic acid construct encoding the same as described herein, such as an RNA construct) an antigen that is or contains one or more epitopes (e.g., one or more B cell and / or one or more T cell antigens and / or epitopes) of an HSV (e.g., HSV-1 and / or HSV-2) protein. In some embodiments, the pharmaceutical compositions described herein induce an effective immune response related to HSV (e.g., by targeting an HSV-1 protein, an HSV-2 protein, or a combination thereof).
[0383] In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, e.g., HSV (e.g., HSV-1 and / or HSV-2) vaccines) comprise or deliver an antigen that is or comprises a full-length HSV (e.g., HSV-1 and / or HSV-2) protein. In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, e.g., HSV (e.g., HSV-1 and / or HSV-2) vaccines) comprise or deliver an antigen that is or comprises a fragment of an HSV (e.g., HSV-1 and / or HSV-2) protein that is smaller than the full-length HSV (e.g., HSV-1 and / or HSV-2) protein. In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, e.g., HSV (e.g., HSV-1 and / or HSV-2) vaccines) comprise or deliver a chimeric polypeptide that is or comprises a portion or all of an HSV (e.g., HSV-1 and / or HSV-2) protein and one or more heterologous polypeptide elements.
[0384] In some embodiments, the antigen included in and / or delivered by a provided pharmaceutical composition (e.g., an immunogenic composition, such as an HSV (e.g., HSV-1 and / or HSV-2) vaccine) is or comprises one or more peptide fragments of an HSV (e.g., HSV-1 and / or HSV-2) antigen; in some such embodiments, each of the one or more peptide fragments comprises at least one epitope (e.g., one or more B cell epitopes and / or one or more T cell epitopes), e.g., that can be predicted, selected, evaluated, and / or characterized as described herein.
[0385] In some embodiments, the antigens included in and / or delivered by provided pharmaceutical compositions (e.g., immunogenic compositions, such as HSV (e.g., HSV-1 and / or HSV-2) vaccines) are or comprise multiple peptide fragments of one or more HSV (e.g., HSV-1 and / or HSV-2) antigens. In some embodiments, a single polypeptide antigen can include multiple such fragments, e.g., present as a series of antigens or fragments thereof as described herein (e.g., because a single polypeptide includes multiple amino acid sequences derived from different HSV antigens or fragments thereof, optionally separated by or otherwise associated with amino acid linkers or other intervening or terminal amino acid sequences). In some embodiments, a single RNA antigen construct can include multiple sequences encoding HSV antigens, e.g., present as a series of antigens encoding sequences as described herein (e.g., because a single RNA molecule includes multiple nucleic acid sequences encoding different HSV antigens or fragments thereof, optionally separated by or otherwise associated with nucleic acid linkers or other intervening or terminal nucleic acid sequences).
[0386] In some embodiments, one or more HSV (e.g., HSV-1 and / or HSV-2) antigens or antigenic fragments thereof may be linked to one or more sequences to which they are linked in nature. In some such embodiments, such sequences may be or comprise one or more heterologous elements (e.g., one or more elements not naturally found in the relevant HSV (e.g., HSV-1 and / or HSV-2), such as a polypeptide or antigenic fragment thereof that is not naturally found directly linked to a relevant HSV (e.g., HSV-1 and / or HSV-2) antigen). For example, in some embodiments, the antigenic peptides provided and / or utilized in accordance with the present disclosure may include one or more linker elements and / or one or more membrane-associated elements and / or one or more secretory elements, etc. In some embodiments, the antigenic polypeptide may comprise multiple HSV (e.g., HSV-1 and / or HSV-2) protein fragments or epitopes separated from each other by linkers.
[0387] In some embodiments, the HSV (e.g., HSV-1 and / or HSV-2) polypeptides or fragments thereof or epitopes utilized in constructs as described herein (or encoded by polyribonucleotides described herein) may include one or more sequence changes relative to a specific reference HSV (e.g., HSV-1 and / or HSV-2) polypeptide or fragment thereof or epitope. For example, in some embodiments, the antigen utilized may include one or more sequence variations seen or predicted to occur in circulating strains, for example, based on an assessment of sequence conservation and / or evolution of HSV (e.g., HSV-1 and / or HSV-2) polypeptides over time and / or across strains. Alternatively or additionally, in some embodiments, the antigen utilized may include one or more sequence variations selected, for example, to affect the stability, folding, processing, and / or display of the antigen or any epitope thereof.
[0388] In some embodiments, the HSV (e.g., HSV-1 and / or HSV-2) polypeptides or fragments or epitopes thereof utilized in the antigens as described herein exhibit at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to a related corresponding reference (e.g., wild-type) polypeptide, fragment or epitope. In some embodiments, the HSV (e.g., HSV-1 and / or HSV-2) polypeptides or fragments or epitopes thereof utilized in the antigens as described herein exhibit at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence homology (i.e., identity or conservative substitution as understood in the art), amino acid sequence identity with a related corresponding reference (e.g., wild-type) protein, fragment or epitope. In addition, in some embodiments, the HSV (e.g., HSV-1 and / or HSV-2) polypeptides or fragments or epitopes thereof utilized in the antigens as described herein share conserved amino acid residues (e.g., at corresponding positions) with a related corresponding reference (e.g., wild-type) polypeptide, fragment or epitope. It will be appreciated by those skilled in the art that, in general, lower percentage identities or homologous sequences can be tolerated for shorter peptides because, by definition, a single change will have a greater effect on the percentage identity or homology when considered relative to a smaller number of residues. For example, it will be appreciated by those skilled in the art that for sequences longer than about 20 amino acids, the percentage identity or homology will typically be greater than about 80%; and for sequences longer than about 50 amino acids, the percentage identity or homology will typically be greater than about 90%.
[0389] In some embodiments, the assessment of conservation can take into account the physicochemical differences between the two amino acids, as described in, for example, WO2014 / 180569, which is incorporated herein by reference in its entirety. It is well known in molecular evolution that frequently exchanged amino acids are likely to have chemical and physical similarities, while rarely exchanged amino acids are likely to have different physicochemical properties. The likelihood of such a substitution occurring in nature can be measured by a logarithmic probability matrix compared to the likelihood of a given substitution occurring by chance. The pattern observed in the logarithmic probability matrix imposed by natural selection "reflects the similarity of the functions of amino acid residues in their weak interactions with each other in the three-dimensional conformation of the protein" (see Dayhoff et al., Atlas of protein sequence and structure 5:345, 1978180569, which is incorporated herein by reference in its entirety). In some embodiments, an evolution-based logarithmic probability matrix (which may be referred to as a "T score") can be used to reflect the extent to which sequence variation may affect T cell recognition. Substitutions with positive T scores (i.e., log odds) are likely to occur in nature and therefore correspond to two amino acids with similar physicochemical properties. Substitutions with positive T scores are less likely to alter immunogenicity. Conversely, substitutions with negative T scores reflect substitutions that are unlikely to occur in nature and therefore correspond to two amino acids with significantly different physicochemical properties. Such substitutions are more likely to alter immunogenicity. In some embodiments, the presence of a substitution with a negative T score within a sequence, even if it is otherwise highly conserved, may also indicate that it is relatively less useful in a vaccine antigen as described herein.
[0390] In some embodiments, the antigens utilized induce an immune response targeting the HSV envelope glycoprotein. In some embodiments, one or more antigens induce an immune response targeting the HSV envelope glycoprotein. In some embodiments, one or more antigens comprise one or more HSV protein sequences of antigens or epitopes of the HSV envelope glycoprotein (e.g., conserved sequences and / or sequences comprising one or more B cell epitopes and / or one or more CD4 epitopes and / or one or more CD8 epitopes). In some embodiments, one or more antigens are or comprise HSV gD protein or a fragment or epitope thereof. In some embodiments, one or more antigens are or comprise HSV gB protein or a fragment or epitope thereof. In some embodiments, one or more antigens are or comprise HSV gE protein or a fragment or epitope thereof. In some embodiments, one or more antigens are or comprise HSV gG protein or a fragment or epitope thereof. In some embodiments, one or more antigens are or comprise HSV gI protein or a fragment or epitope thereof. In some embodiments, one or more antigens are or comprise HSV gE protein or a fragment or epitope thereof. In some embodiments, one or more antigens are or comprise HSV gH protein or a fragment or epitope thereof. In some embodiments, the one or more antigens are or comprise HSV gL protein, or a fragment or epitope thereof. In some embodiments, the one or more antigens are or comprise HSV ICP4 protein, or a fragment or epitope thereof. In some embodiments, the one or more antigens are or comprise ICP8 polypeptide, a fragment or epitope thereof.
[0391] In various embodiments, the HSV antigen constructs include and / or encode a plurality of HSV antigens (e.g., a plurality of HSV antigens that are or include one or more T cell antigens of HSV) or fragments thereof provided in Table 3. In certain embodiments, the HSV antigen constructs may include and / or encode at least one HSV antigen or fragment thereof provided in Table 3. In certain embodiments, the HSV antigen constructs may include and / or encode at least one HSV antigen or fragment thereof provided in Table 4. In certain embodiments, the HSV antigen constructs may include and / or encode at least one HSV antigen or fragment thereof provided in Table 5.
[0392] In certain embodiments, the HSV antigenic construct may include and / or encode at least one T cell antigen or fragment thereof of the HSV provided in Table 3. In certain embodiments, the HSV antigenic construct may include and / or encode at least one T cell antigen or fragment thereof of the HSV provided in Table 4. In certain embodiments, the HSV antigenic construct may include and / or encode at least one T cell antigen or fragment thereof of the HSV provided in Table 5.
[0393] In certain embodiments, the HSV antigen constructs may include and / or encode a plurality (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) of HSV antigens or fragments thereof provided in Table 3. In certain embodiments, the HSV antigen constructs may include and / or encode a plurality (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of HSV antigens or fragments thereof provided in Table 4. In certain embodiments, the HSV antigen constructs may include and / or encode a plurality (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of HSV antigens or fragments thereof provided in Table 5.
[0394] In certain embodiments, the HSV antigen construct may include and / or encode a plurality (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) of HSV T cell antigens or fragments thereof selected from the HSV antigens provided in Table 3. In certain embodiments, the HSV antigen construct may include and / or encode a plurality (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of HSV T cell antigens or fragments thereof selected from the antigens provided in Table 4. In certain embodiments, the HSV antigen construct may include and / or encode a plurality (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of HSV T cell antigens or fragments thereof selected from the antigens provided in Table 5.
[0395] In some embodiments, antigens utilized in accordance with the present disclosure include HSV (e.g., HSV-1 and / or HSV-2) protein sequences identified and / or characterized by one or more of the following:
[0396] 1) HLA-I or HLA-II binding (e.g., to HLA alleles present in the relevant population)
[0397] 2) HLA ligandome data, optionally confirmed by mass spectrometry
[0398] 3) Relatively high expression
[0399] 4) Sequence conservation
[0400] 5) Surface exposure
[0401] 6) Serological reactivity
[0402] 7) Immunogenicity (e.g., presence of one or more B-cell and / or T-cell antigens and / or epitopes; evidence of ability to induce sterile protection in model systems including, e.g., humans, non-human primates, and / or mice).
[0403] 8) There is no sequence overlap with the human proteome
[0404] In some embodiments, such characteristics are assessed experimentally or computationally. In some embodiments, such characteristics are assessed by reviewing published reports.
[0405] For example, in some embodiments, HLA-I and / or HLA-II binding is assessed experimentally; in some embodiments, it is predicted.
[0406] In some embodiments, predicted HLA-I or HLA-II binding is assessed using algorithms such as neonmhc1 and / or neonmhc2, which predict and / or characterize the likelihood of MHC class I and MHC class II binding, respectively. Alternatively or additionally, in some embodiments, the MHC-peptide presentation prediction algorithm or MHC-peptide presentation predictor is or includes NetMHCpan or NetMHCIIpan. In some embodiments, MHC-peptide presentation prediction and / or characterization can be performed using a hidden Markov model approach. In some embodiments, the peptide prediction model MARIA can be utilized. In some embodiments, NetMHCpan is not utilized to predict or characterize the MHC binding likelihood of peptides as described herein. In some embodiments, the peptide prediction model MARIA can be utilized. In some embodiments, NetMHCIIpan is not utilized to predict or characterize the MHC binding likelihood of peptides as described herein. In some embodiments, neither NetMHCpan nor NetMHCIIpan is utilized to predict or characterize the MHC binding likelihood of peptides as described herein. In some embodiments, the MHC-peptide presentation prediction algorithm or MHC-peptide presentation predictor is or includes (Real-time epitope computation for oncology), which provides high-quality MHC-peptide presentation predictions based on expression, processing, and binding capacity. See, e.g., Abelin et al., Immunity 21:315, 2017; Abelin et al., Immunity 15:766, 2019.
[0407] In some embodiments, HLA binding and / or ligandomics assessment will take into account the geographic region of the subject to be immunized. For example, in some embodiments, HLA allele diversity will be considered. In some embodiments, the antigen included in the provided pharmaceutical composition (e.g., immunogenic composition, such as a vaccine) will be or include a peptide (e.g., epitope) that is expected or determined to be present in a significant percentage (e.g., at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more) of the HLA alleles expected or known to be present in the relevant region or population when considered together. In some embodiments, the antigen included in the provided pharmaceutical composition (e.g., immunogenic composition, such as a vaccine) will be or include a peptide that is expected or determined to be present in the most common (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 most common, or at least 1, 2, 3, 4 or 5 of the 10 most common, etc.) HLA alleles expected or known to be present in the relevant region or population when considered together.
[0408] In some embodiments, expression levels are determined experimentally (e.g., in a model system or in infected humans). In some embodiments, expression levels are reported levels (e.g., in a published or submitted report). In some embodiments, expression levels are assessed using RNA (e.g., via RNASeq). In some embodiments (and generally preferably), expression levels are assessed using protein.
[0409] In some embodiments, sequence conservation is assessed, for example, using publicly available sequence evaluation software (e.g., multiple sequence alignment programs MAFFT, Clustal Omega, etc.). In some embodiments, sequence conservation is determined by consulting published resources (e.g., sequences). In some embodiments, sequence conservation includes consideration of current or recently detected strains (e.g., in active outbreaks).
[0410] In some embodiments, surface exposure is assessed by reference to publicly available databases and / or software.
[0411] In some embodiments, serum reactivity is assessed by contacting a serum sample from an infected individual with a polypeptide comprising a sequence of interest (e.g., display via, for example, phage display or peptide arrays; see, e.g., Whittemore et al., "A General Method to Discover Epitopes from Sera," Plos One, 2016; https: / / doi.org / 10.1371 / journal.pone.0157462). In some embodiments, serum reactivity is assessed by consulting literature reports and / or database data indicating serum recognition sequences.
[0412] In some embodiments, assessment of immunoreactivity and / or the presence of an epitope can be or include consulting the Immune Epitope Database (IEDB), which, as will be known to those skilled in the art, is a freely available resource funded by NIAID that catalogs experimental data on antibody and T cell epitopes (see iedb.org).
[0413] In some embodiments, antigens utilized in accordance with the present disclosure are characterized by dendritic cell presentation, which in turn may be indicative of HLA binding and / or immunogenicity.
[0414] In some embodiments, the antigens utilized in accordance with the present disclosure are or comprise sequences of HSV proteins found in the HSV envelope (e.g., epitopes, fragments, complete proteins). In some embodiments, the antigens utilized in accordance with the present disclosure are or comprise sequences of HSV proteins found in the HSV envelope (e.g., epitopes, fragments, complete proteins).
[0415] Among other things, the present disclosure provides the insight that, in some embodiments, it may be desirable to include two or more different epitopes, optionally from two or more different HSV (e.g., HSV-1 and / or HSV-2) proteins, in the composition of a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) that can be used to treat HSV.
[0416] Table 7: Exemplary Antigenic Fragments
[0417]
[0418]
[0419] 1. Exemplary Antigen Formats
[0420] In some embodiments, the antigens utilized as described herein are or comprise full-length viral proteins. In some embodiments, the antigens utilized as described herein are or comprise fragments or domains of viral polypeptides or antigenic fragments thereof. In some embodiments, the antigens utilized as described herein are membrane-bound antigens (e.g., antigenic fragments thereof are fused to membrane-associated portions, such as transmembrane portions). In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) comprise or deliver antigenic sequences that are or comprise one or more antibody epitopes and / or one or more CD4 T cell and / or CD8 T cell epitopes.
[0421] In some embodiments, the antigens utilized as described herein include one or more variant sequences relative to a related reference antigen. For example, in some embodiments, a protease cleavage site is removed or blocked; alternatively or additionally, in some embodiments, a terminally truncated antigen is utilized.
[0422] In some embodiments, an antigen utilized as described herein includes a multimerization element (eg, a heteromultimerization element).
[0423] In some embodiments, an antigen utilized as described herein includes a membrane-associated element (eg, a heterologous membrane-associated element), such as a transmembrane domain.
[0424] In some embodiments, an antigen utilized as described herein includes a secretion signal (eg, a heterologous secretion signal).
[0425] In some embodiments, the sequences utilized can be longer (and, for example, thus can include more epitopes) than viral proteins found in nature.
[0426] In some embodiments, the sequences utilized can be from a different strain or strains (e.g., that may be circulating and / or otherwise related to a population to which a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) is administered).
[0427] In some embodiments, antigens utilized as described herein may include multiple epitopes (e.g., B cell and / or T cell antigens and / or epitopes) arranged in a non-natural configuration (e.g., in a string construct as described herein). In some embodiments, antigens utilized as described herein may include multiple epitopes predicted or demonstrated to bind to HLA alleles that reflect the population of components of a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) to be administered as described herein.
[0428] In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) may comprise or deliver multiple antigens. One or more antigens comprising B cell epitopes and one or more antigens comprising T cell epitopes. In some embodiments, provided pharmaceutical compositions (e.g., immunogenic compositions, such as vaccines) may comprise or deliver an antigen comprising both B cell and CD4 epitopes and a separate antigen comprising a CD8 epitope.
[0429] As described herein, in some embodiments, the provided technology involves administering multiple antigens to the same subject. In some embodiments, multiple antigens are administered simultaneously (e.g., in a single dose). In some embodiments, different antigens can be administered at different times (e.g., in different doses—e.g., a primary dose versus a booster dose). In some embodiments, multiple antigens are administered via the same composition.
[0430] For clarity, a single "antigenic" polypeptide may include multiple "epitopes," which may or may not be linked to each other in nature. For example, a single-chain construct antigen may include multiple epitopes, which may be from different parts of the same HSV (e.g., HSV-1 and / or HSV-2) protein, and / or from different HSV (e.g., HSV-1 and / or HSV-2) proteins linked together in a single polypeptide as described herein.
[0431] Thus, a single pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) as described herein may contain or deliver (e.g., because the pharmaceutical composition includes a nucleic acid, such as RNA, that encodes the antigen and is expressed upon administration) a single antigen that itself may contain multiple epitopes (in its native arrangement relative to each other or in an engineered or constructed arrangement as described herein), or may contain or deliver multiple antigens, each of which may similarly be or contain a single epitope or multiple epitopes (in its native arrangement relative to each other or in an engineered or constructed arrangement as described herein). Still further, a single pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) may, for example, include multiple different nucleic acids (e.g., RNA) that each encode a different antigen, or, in some embodiments, may include a single nucleic acid that encodes (and expresses) multiple antigens. Still further, in some embodiments, a single pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) that includes multiple different nucleic acids (e.g., RNA) encoding an antigen may be prepared by mixing the RNAs and then incorporating the mixture into LNPs, or by formulating separate RNAs into LNPs and then mixing the LNPs. In some embodiments, the mixture (whether of pre-LNP preparation RNA or LNP) can include the relevant RNA in a 1:1 ratio in the subject to which the composition is administered, or in other ratios that may be preferred (e.g., to achieve a desired relative presentation of the antigen or epitope).
[0432] In some specific embodiments, a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) may comprise or deliver a combination comprising polypeptides encoded by all or part of UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22 and / or UL54, or fragments thereof.
[0433] In some embodiments, provided compositions include or deliver an HSV (e.g., HSV-1 and / or HSV-2) envelope glycoprotein antigen (e.g., a full-length HSV (e.g., HSV-1 and / or HSV-2) envelope glycoprotein, a fragment thereof, or one or more epitopes thereof, e.g., in a string construct). In some embodiments, provided compositions include or deliver such an HSV (e.g., HSV-1 and / or HSV-2) envelope glycoprotein antigen and one or more B cell targets (e.g., epitopes), which can, for example, be or comprise one or more other HSV (e.g., HSV-1 and / or HSV-2) proteins (or fragments or epitopes thereof). In some embodiments, such a B cell target is or comprises an HSV (e.g., HSV-1 and / or HSV-2) protein (or fragment or epitope thereof) that is predicted or known to induce a B cell response in infected humans. For example, in some embodiments, the B cell target is or comprises an HSV (e.g., HSV-1 and / or HSV-2) protein (or a fragment or B cell epitope thereof) against which serum from an infected individual is reactive. In some specific embodiments, the B cell target is or comprises an HSV (e.g., HSV-1 and / or HSV-2) envelope glycoprotein or other related HSV (e.g., HSV-1 and / or HSV-2) protein or a fragment or epitope thereof.
[0434] In some embodiments, provided compositions comprise or deliver string construct antigens comprising multiple T cell epitopes, optionally from more than one HSV (e.g., HSV-1 and / or HSV-2) protein. In some such embodiments, provided compositions further comprise or deliver one or more B cell targets. Alternatively or additionally, in some embodiments, the string construct antigens so utilized comprise HSV (e.g., HSV-1 and / or HSV-2) sequences (e.g., one or more fragments or epitopes, such as T cell epitopes and / or B cell epitopes, but in some embodiments specifically T cell epitopes).
[0435] In some embodiments, the string construct antigen includes both B cell epitopes and T cell epitopes (optionally from the same HSV (e.g., HSV-1 and / or HSV-2) protein or from different HSV (e.g., HSV-1 and / or HSV-2) proteins).
[0436] In some embodiments, different antigens can be delivered by administering different compositions, which in turn can be administered simultaneously in some embodiments (e.g., as a mixture, or otherwise administered substantially simultaneously), and in some embodiments, can be administered at different times. As just one example, in some embodiments, a particular antigen or antigens can be delivered via an initial pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) dose, and one or more additional antigens can be delivered via one or more booster doses.
[0437] 2. Exemplary Multi-epitope Antigens
[0438] In some embodiments, the antigens utilized by (i.e., included in and / or otherwise delivered by) the pharmaceutical compositions described herein (e.g., immunogenic compositions, such as vaccines) comprise, for example, multiple epitopes of a single HSV (e.g., HSV-1 and / or HSV-2) protein or multiple proteins.
[0439] In some embodiments, the antigen may comprise two or more epitopes from the same HSV (e.g., HSV-1 and / or HSV-2) protein and in their native configuration relative to each other (e.g., in a fragment if they are related proteins). However, in some embodiments, the antigen may comprise at least two epitopes configured in a non-natural relationship relative to each other (e.g., included in a string construct as described herein).
[0440] Among other things, the present disclosure provides insight that string construct antigens may be particularly useful or effective for vaccination against HSV (e.g., HSV-1 and / or HSV-2) infection. Without wishing to be bound by any particular theory, the present disclosure proposes that the ability to link predicted or determined single epitopes with specific properties—e.g., binding to relevant HLA alleles, expression at relevant times of infection, representing particularly conserved sequences, potentially spanning multiple different HSV (e.g., HSV-1 and / or HSV-2) proteins—may prove uniquely beneficial or indeed critical for effective vaccination against HSV (e.g., HSV-1 and / or HSV-2), where more traditional vaccination approaches have thus far provided only limited protection.
[0441] In some embodiments, polyepitope antigens (e.g., string construct antigens or multi-epitope antigens) can be administered as polypeptides and / or as a collection of peptides. Alternatively or additionally, polyepitope antigens can be administered as a preparation of cells comprising (e.g., expressing) the antigen. However, the disclosure further provides such insights, i.e., in some embodiments, it may be particularly useful and / or effective to deliver by administering nucleic acids (and particularly RNA) encoding polyepitope antigens.
[0442] As noted elsewhere herein, experience with SARS-CoV-2 has demonstrated that RNA administration may be a particularly effective way to deliver infectious disease antigens. Furthermore, the present disclosure provides the insight that various features of nucleic acid forms, including, for example, their flexibility and adaptability to rapid design and modification, including the integration of various insights (e.g., bioinformatics input, etc.), make them particularly attractive for use in HSV (e.g., HSV-1 and / or HSV-2) vaccines. Among other things, the present disclosure provides the insight that, in some embodiments, administration of RNA encoding the string construct antigens as described herein may be a particularly desirable and / or effective method for immunizing against HSV (e.g., HSV-1 and / or HSV-2) infection.
[0443] In some embodiments, a "string" polynucleotide sequence encodes multiple antigens and / or epitopes in series. In some embodiments, the string encodes about 2 to about 100, about 2 to about 75, about 2 to about 50, about 2 to about 25, about 2 to about 20, about 2 to about 15, about 2 to about 10, or about 2 to about 5 antigens and / or epitopes. In some embodiments, the string encodes about 5 to about 100, about 5 to about 75, about 5 to about 50, about 5 to about 25, about 5 to about 20, about 5 to about 15, or about 5 to about 10 antigens and / or epitopes. In some embodiments, a "string" polynucleotide sequence encodes multiple epitopes in series. In some embodiments, the string encodes about 2 to about 1000 or about 2 to about 10,000 antigens and / or epitopes. In some embodiments, about 2-5,000 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 2-4,000 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 2-3,000 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 2-2,000 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 2-1,000 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 10-500 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 10-200 antigens and / or epitopes are encoded in one polynucleotide string. In some embodiments, about 20-100 antigens and / or epitopes are encoded in one polynucleotide string.
[0444] In some embodiments, the epitopes encoded by the string constructs include epitopes predicted by HLA binding and presentation prediction software to be highly likely to be presented by HLA-encoded proteins to T cells to elicit an immune response. In some embodiments, the epitopes predicted to be highly likely to be presented by HLA-encoded proteins are selected from any of the proteins or peptides described in Tables 3-5. In some embodiments, the epitopes in the string constructs include membrane-associated or otherwise accessible epitopes, such as at relevant times during the life cycle of HSV (e.g., HSV-1 and / or HSV-2).
[0445] In some embodiments, the antigens utilized in accordance with the present disclosure are or comprise UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22 and / or UL54 or fragments thereof and variants thereof and / or fragments or epitopes of any of the foregoing and combinations of any of the foregoing. In some embodiments, the antigens utilized in accordance with the present disclosure are or comprise HSV proteins, are or comprise HSV envelope proteins, HSV envelope proteins, HSV membrane proteins and variants thereof and / or fragments or epitopes of any of the foregoing and combinations of any of the foregoing. In some embodiments, the string construct may comprise many epitopes from 2, 3, 4 or more HSV proteins. In some embodiments, the string construct comprises one or more features described herein (including the Examples and Tables). In some embodiments, the string construct comprises a sequence as described in Tables 3-5 or is encoded by said sequence.
[0446] Alternatively or additionally, in some embodiments, one or more string constructs may include one or more other epitopes (e.g., as can be predicted or demonstrated, for example, in the literature). In some embodiments, the string constructs may include sequences encoding features such as linkers and cleavage sites (e.g., autocleavage sites, such as T2A or P2A sequences). In some embodiments, linkers rich in G and S residues may be used. In some embodiments, exemplary linkers may have the sequence GGGGSGGGGS (SEQ ID NO: 167) or GGSGGGGS GG (SEQ ID NO: 165).
[0447] In some embodiments, the string construct comprises two or more overlapping epitope sequences.
[0448] In some embodiments, the string construct comprises or is encoded by a sequence having 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the sequences in Tables 3-5. As noted above, where the compared sequences are longer than about 20 amino acids, the percent identity or homology is typically greater than about 80%; for sequences longer than about 50 amino acids, the percent identity or homology is typically greater than about 90%.
[0449] In some embodiments, epitopes are arranged on a string to maximize the immunogenicity of the string, for example, by maximizing recognition by the subject's HLA allele repertoire. In some embodiments, the same string encodes epitopes that can bind to different HLA alleles and / or are predicted to bind to different HLA alleles. For example, as fully exemplified in the sequence listing, for example, at least in Tables 3-5, a string can encode epitopes comprising: (a) a first epitope that binds or is predicted to bind to a first MHC peptide encoded by a first HLA allele; (b) a second epitope that binds or is predicted to bind to a second MHC peptide encoded by a second HLA allele; (c) a third epitope that binds or is predicted to bind to a third MHC peptide encoded by a third HLA allele - and more such epitopes can be added, for example, in a string sequence as provided herein; wherein the first, second, and third epitopes are epitopes from the same HSV (e.g., HSV-1 and / or HSV-2) protein or from different HSV (e.g., HSV-1 and / or HSV-2) proteins. In this way, the distribution of epitopes encoded by a single string is maximized to hit different MHC-based presentations to T cells, thereby maximizing the likelihood of generating the desired immune response from a wider range of patients in a given population and the robustness of each patient's response.
[0450] In some embodiments, epitopes included in the string construct are selected based on high-scoring predictions for binding to HLA by a reliable prediction algorithm or system (such as the RECON prediction algorithm). In some embodiments, the present disclosure provides insights into providing particularly successful strings by selecting epitopes based on highly reliable and effective prediction algorithms in the layout of epitopes encoded by strings, with or without non-epitope sequences or sequences flanking epitopes, and enabling the immunogenicity of the strings to be validated in ex vivo cell culture models or in animal models, particularly by showing epitope-specific T cell responses in T cell induction after vaccination with string constructs or polypeptides encoded by string constructs. In some embodiments, validation can come from use in human patients, and it was found that T cells obtained from patients after vaccination showed epitope-specific, effective, and durable T cell responses. In some embodiments, the efficiency of the strings as vaccines is affected by their design, which in part depends on the strength of the bioinformatics information used in the careful execution of the design, the reliability of the MHC presentation prediction model, the efficiency of epitope processing when the string vaccine is expressed in cells, and the like.
[0451] In some embodiments, the multi-epitope RNA (e.g., mRNA) construct as described above comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more antigens and / or epitopes. In some embodiments, the pharmaceutical composition comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more strings. In some embodiments, the pharmaceutical composition comprises 6 strings. In some embodiments, the pharmaceutical composition comprises 7 strings. In some embodiments, the pharmaceutical composition comprises 8 strings. In some embodiments, the pharmaceutical composition comprises 9 strings. In some embodiments, the pharmaceutical composition comprises 10 strings.
[0452] In some embodiments, the epitope encoding sequence in the string construct is flanked by one or more sequences selected to achieve higher immunogenicity, better cleavage of the peptide for presentation to MHC, better expression, and / or improved translation in the cells of the subject. In some embodiments, the flanking sequence comprises a linker with a specific cleavable sequence. In some embodiments, the epitope encoding sequence in the string construct is flanked by a secreted protein sequence.
[0453] In some embodiments, the epitope encoded by the string sequence may comprise or otherwise be linked to a signal sequence such as those listed in Table 7, or a sequence having at least 1, 2, 3, 4, or 5 amino acid differences therefrom. In some embodiments, the epitope encoded by the string sequence may comprise or otherwise be linked to a signal sequence such as MFVFLVLLPLVSSQCVNL T (SEQ ID NO: 90), or a sequence having at least 1, 2, 3, 4, or at most 5 amino acid differences therefrom. In some embodiments, the epitope encoded by the string sequence may be linked at the N-terminus via a sequence rich in G and S residues, or a sequence having 1, 2, 3, 4, or at most 5 amino acid differences therefrom. In some embodiments, an exemplary linker useful for linking an epitope has the sequence GGSGGGGSGG (SEQ ID NO: 165).
[0454] In some embodiments, the linked sequences can comprise a linker having a cleavage sequence, for example, having a specific cleavable sequence.
[0455] In some embodiments, the string construct is connected to a transmembrane domain (TM) or other membrane-associated elements. In some embodiments, the length of the joint can be 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids. In some embodiments, a joint of no more than about 30, 25, 20, 15, 10 or less amino acids is used. In some embodiments, the joint sequence is not limited to comprising any specific amino acid; In some embodiments, the joint sequence comprises any amino acid. In some embodiments, the joint or cleavage sequence comprises glycine (G). In some embodiments, the joint or cleavage sequence comprises serine (S). In some embodiments, the joint is designed to comprise an amino acid based on a cutting predictor to produce a highly cleavable sequence peptide sequence, and is a novel and effective way to deliver immunogenic T cell epitopes in a T cell vaccine environment.
[0456] In some embodiments, the distribution of epitopes encoded in the string constructs and their juxtaposition are designed to favor the cleavage sequence contributed by the amino acid sequence and / or flanking or connecting residues of the epitope, thereby using minimal linker sequence. Some exemplary cleavage sequences can be, but are not limited to, one or more of FRAC, KRCF, KKRY, ARMA, RRSG, MRAC, KMCG, ARCA, KKQG, YRSY, SFMN, FKAA, KRNG, YNSF, KKNG, RRRG, KRYS, and ARYA (SEQ ID NOs: 62-79, respectively).
[0457] In some embodiments, the string construct is RNA (e.g., mRNA). In some embodiments, the pharmaceutical composition comprises one or more RNA (e.g., mRNA) string constructs, each construct comprising a sequence encoding multiple epitopes as described herein. In some embodiments, one or more RNA (e.g., mRNA) comprises multiple epitopes, wherein each of the multiple epitopes is predicted by an HLA binding and presentation prediction algorithm to be highly likely to be presented to T cells by a protein encoded by an HLA to elicit an immune response.
[0458] In some embodiments, one or more RNAs (e.g., mRNAs) utilized in a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) as described herein encode a plurality of epitopes (e.g., including one or more or two or more antigens or fragments thereof provided in Table 4, Table 5, or Table 6), optionally wherein each of the plurality is predicted by an HLA binding and presentation prediction algorithm to be highly likely to be presented to T cells by a protein encoded by an HLA to elicit an immune response. In some embodiments, the plurality of epitopes comprises epitopes from a single HSV (e.g., HSV-1 and / or HSV-2) protein. In some embodiments, the plurality of epitopes comprises epitopes from multiple HSV (e.g., HSV-1 and / or HSV-2) proteins.
[0459] In some embodiments, one or more RNAs (e.g., mRNAs) utilized in pharmaceutical compositions as described herein (e.g., immunogenic compositions, such as vaccines) include a first RNA encoding an HSV (e.g., HSV-1, HSV-2, or both) antigen that is expressed prior to cell infiltration or infection, and includes one or more fragments that are expected or known to interface with the host cytoplasm. In some embodiments, the HSV antigen encoded by the first RNA is or comprises an HSV antigen, fragment, or epitope, such as UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22, and / or UL54, or a fragment thereof, an epitope thereof, and / or a combination thereof. In some embodiments, one or more RNAs (e.g., mRNAs) utilized in pharmaceutical compositions as described herein (e.g., immunogenic compositions, e.g., vaccines) include a second antigen RNA encoding a polyepitope (e.g., multiple epitope) antigen. In some embodiments, the polyepitope antigen comprises two or more antigens or fragments thereof or epitopes thereof as seen in Tables 3-5 herein. In some embodiments, the polyepitope antigen comprises two or more antigens and / or fragments thereof and / or epitopes listed in Tables 3-5.
[0460] In some embodiments, one or more RNAs (e.g., mRNAs) utilized in a pharmaceutical composition (e.g., an immunogenic composition, such as a vaccine) as described herein include multiple epitopes that are predicted by an HLA binding and presentation prediction algorithm to be highly likely to be presented to T cells by a protein encoded by an HLA to elicit an immune response. In some embodiments, the multiple epitopes include epitopes from a single HSV (e.g., HSV-1, HSV-2, or both) protein. In some embodiments, the multiple epitopes include epitopes from multiple HSV (e.g., HSV-1 and / or HSV-2) proteins.
[0461] In some embodiments, the RNA (e.g., mRNA) comprises a 5'UTR and a 3'UTR. In some embodiments, the UTR comprises a poly A sequence. In some embodiments, the poly A sequence comprises between 50-200 nucleotides.
[0462] In some embodiments, the epitope encoded in the string construct can be flanked by a signal peptide sequence, such as the SP1 sequence (HSV-1 gD signal peptide / secretion domain).
[0463] In some embodiments, the polynucleotide comprises a dEarI-hAg sequence.
[0464] In some embodiments, the poly A tail of the string construct may comprise about 150 A residues. In some embodiments, the poly A tail may comprise 120 or less residues. In some embodiments, the poly A tail of the string construct may comprise about 120 A residues. In some embodiments, the poly A tail of the string construct may comprise about 100 residues. In some embodiments, the poly A tail of the string comprises a "split" or "interrupted" poly A tail (e.g., as described in WO2016 / 005324).
[0465] In some embodiments, the polyepitopic antigen encodes a polypeptide with a supermotif or motif and an auxiliary epitope (e.g., a heterologous auxiliary epitope) and an endoplasmic reticulum translocation signal sequence. See, e.g., An and Whitton J. Virol. 71:2292, 1997; Thomson et al., J. Immunol. 157:822, 1996; Whitton et al., J. Virol 67:348, 1993; Hanke et al., Vaccine 16:426, 1998.
[0466] 3. T cell antigens and related constructs
[0467] In certain embodiments, the HSV antigen construct may include and / or encode at least one T cell antigen of HSV (e.g., at least one CD4 and / or CD8 T cell antigen) selected from UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22 and / or UL54, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode at least one T cell antigen of HSV selected from UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48 and / or UL49, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode at least one T cell antigen of HSV selected from RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22 and / or UL54 or a fragment thereof.
[0468] In certain embodiments, the HSV antigen construct may include and / or encode multiple (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19) HSV T cell antigens (e.g., CD4 and / or CD8 T cell antigens) selected from UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, UL49, RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22, and / or UL54, or fragments thereof. In certain embodiments, the HSV antigen construct may include and / or encode a plurality of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) T cell antigens of HSV selected from UL1, UL21, UL27, UL29, UL39, UL40, UL46, UL47, UL48, and / or UL49, or a fragment thereof. In certain embodiments, the HSV antigen construct may include and / or encode a plurality of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) T cell antigens of HSV selected from RS1, RL2, UL5, UL9, UL19, UL25, UL30, UL52, US1, US7, US8, UL22, and / or UL54, or a fragment thereof.
[0469] In some embodiments, the polyribonucleotides according to the present disclosure encode polypeptides comprising two or more HSV antigens or antigenic fragments. In some embodiments, the two or more HSV antigenic fragments are each fragments of different HSV antigens. In some embodiments, at least two HSV antigenic fragments are fragments from the same HSV antigen.
[0470] In some embodiments, the polyribonucleotide encoding a polypeptide comprises three or more HSV antigens or antigenic fragments thereof. In some embodiments, the three or more HSV antigenic fragments are each a fragment of a different HSV antigen. In some embodiments, at least two of the three HSV antigenic fragments are fragments from the same HSV antigen.
[0471] In some embodiments, the polyribonucleotide encoding a polypeptide comprises four or more HSV antigens or antigenic fragments thereof. In some embodiments, the four or more HSV antigenic fragments are each a fragment of a different HSV antigen. In some embodiments, at least two of the four HSV antigenic fragments are fragments from the same HSV antigen.
[0472] In some embodiments, the polyribonucleotide encoding a polypeptide comprises five or more HSV antigens or antigenic fragments thereof. In some embodiments, the five or more HSV antigenic fragments are each a fragment of a different HSV antigen. In some embodiments, at least two of the five HSV antigenic fragments are fragments from the same HSV antigen.
[0473] In some embodiments, the polyribonucleotide encoding a polypeptide comprises six or more HSV antigens or antigenic fragments thereof. In some embodiments, each of the six or more HSV antigenic fragments is a fragment of a different HSV antigen. In some embodiments, at least two of the six HSV antigenic fragments are fragments from the same HSV antigen.
[0474] In some embodiments, a polypeptide according to the present disclosure does not comprise a full-length HSV antigen.
[0475] In some embodiments, polypeptides according to the present disclosure comprise one or more HSV antigens or antigenic fragments thereof comprising one or more T cell antigens.
[0476] In some embodiments, one or more HSV antigens or antigenic fragments thereof have at least 80% sequence identity with one or more sequences selected from SEQ ID NOs: 1-74 or corresponding fragments thereof.
[0477] In some embodiments, the HSV T cell antigen is or includes a UL1 polypeptide or a fragment thereof. In various embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL1 polypeptides known in the art include UL1 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 1, 2 and / or 3, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0478] In some embodiments, the HSV T cell antigen is or includes a UL21 polypeptide or a fragment thereof. In various embodiments, the UL21 polypeptide or a fragment thereof has at least 80% sequence identity with a UL21 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL21 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL21 polypeptides known in the art include UL21 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL21 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO:4, 5 and / or 6, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0479] The UL27 open reading frame encodes HSV gB (also referred to herein as the UL27 polypeptide). In some embodiments, the HSV T cell antigen is or includes a UL27 polypeptide or a fragment thereof. In various embodiments, the UL27 polypeptide or fragment thereof has at least 80% sequence identity with a UL27 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL27 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL27 polypeptides known in the art include UL27 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL27 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:7, 8, 9 and / or 74, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0480] In some embodiments, the HSV T cell antigen is or includes a UL29 polypeptide or a fragment thereof. In various embodiments, the UL29 polypeptide or a fragment thereof has at least 80% sequence identity with a UL29 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL29 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL29 polypeptides known in the art include UL29 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL29 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 10, 11 and / or 12, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0481] In some embodiments, the HSV T cell antigen is or includes a UL39 polypeptide or a fragment thereof. In various embodiments, the UL39 polypeptide or fragment thereof has at least 80% sequence identity with a UL39 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL39 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL39 polypeptides known in the art include UL39 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL39 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 13, 14 and / or 15, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0482] In some embodiments, the HSV T cell antigen is or includes a UL40 polypeptide or a fragment thereof. In various embodiments, the UL40 polypeptide or fragment thereof has at least 80% sequence identity with a UL40 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, with a UL40 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL40 polypeptides known in the art include UL40 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL40 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 16, 17 and / or 18, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0483] In some embodiments, the HSV T cell antigen is or includes a UL46 polypeptide or a fragment thereof. In various embodiments, the UL46 polypeptide or fragment thereof has at least 80% sequence identity with a UL46 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL46 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL46 polypeptides known in the art include UL46 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL46 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 19, 20 and / or 21, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0484] In some embodiments, the HSV T cell antigen is or includes a UL47 polypeptide or a fragment thereof. In various embodiments, the UL47 polypeptide or fragment thereof has at least 80% sequence identity with a UL47 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL47 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL47 polypeptides known in the art include UL47 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL47 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 22, 23 and / or 24, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0485] In some embodiments, the HSV T cell antigen is or includes a UL48 polypeptide or a fragment thereof. In various embodiments, the UL48 polypeptide or fragment thereof has at least 80% sequence identity with a UL48 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL48 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL48 polypeptides known in the art include UL48 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL48 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO: 25, 26 and / or 27, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0486] In some embodiments, the HSV T cell antigen is or includes a UL49 polypeptide or a fragment thereof. In various embodiments, the UL49 polypeptide or a fragment thereof has at least 80% sequence identity with a UL49 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL49 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL49 polypeptides known in the art include UL49 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL49 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 28, 29 and / or 30, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0487] In some embodiments, the HSV T cell antigen is or includes an RS1 polypeptide or a fragment thereof. In various embodiments, the RS1 polypeptide or its fragment has at least 80% sequence identity to a RS1 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment. In some embodiments, the UL1 polypeptide or its fragment has at least 80% sequence identity to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity. Examples of RS1 polypeptides known in the art include RS1 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the RS1 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:31, 32 and / or 33, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0488] In some embodiments, the HSV T cell antigen is or includes an RL2 polypeptide or a fragment thereof. In various embodiments, the RL2 polypeptide or fragment thereof has at least 80% sequence identity with a RL2 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the RL2 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99%, or 100% sequence identity, with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of RL2 polypeptides known in the art include RL2 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the RL2 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO:34, 35 and / or 36, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0489] In some embodiments, the HSV T cell antigen is or includes a UL5 polypeptide or a fragment thereof. In various embodiments, the UL5 polypeptide or a fragment thereof has at least 80% sequence identity with a UL5 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL5 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL5 polypeptides known in the art include UL5 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL5 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence as shown in SEQ ID NO:37, 38 and / or 39, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0490] In some embodiments, the HSV T cell antigen is or includes a UL9 polypeptide or a fragment thereof. In various embodiments, the UL9 polypeptide or a fragment thereof has at least 80% sequence identity with a UL9 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL9 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL9 polypeptides known in the art include UL9 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL9 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:40, 41 and / or 42, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0491] In some embodiments, the HSV T cell antigen is or includes a UL19 polypeptide or a fragment thereof. In various embodiments, the UL19 polypeptide or a fragment thereof has at least 80% sequence identity with a UL19 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL19 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL19 polypeptides known in the art include UL19 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL19 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:43, 44 and / or 45, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0492] In some embodiments, the HSV T cell antigen is or includes a UL25 polypeptide or a fragment thereof. In various embodiments, the UL25 polypeptide or fragment thereof has at least 80% sequence identity with a UL25 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL25 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL25 polypeptides known in the art include UL25 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL25 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:46, 47 and / or 48, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0493] In some embodiments, the HSV T cell antigen is or includes a UL30 polypeptide or a fragment thereof. In various embodiments, the UL30 polypeptide or fragment thereof has at least 80% sequence identity with a UL30 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL30 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL30 polypeptides known in the art include UL30 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL30 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO: 49, 50 and / or 51, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0494] In some embodiments, the HSV T cell antigen is or includes a UL52 polypeptide or a fragment thereof. In various embodiments, the UL52 polypeptide or a fragment thereof has at least 80% sequence identity with a UL52 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment. In some embodiments, the UL52 polypeptide or a fragment thereof has at least 80% sequence identity with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or its corresponding fragment, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity. Examples of UL52 polypeptides known in the art include UL52 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL52 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:52, 53 and / or 54, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0495] The US1 open reading frame encodes HSV gL (also referred to herein as the UL1 polypeptide). In some embodiments, the HSVT cellular antigen is or includes a US1 polypeptide or a fragment thereof. In various embodiments, the US1 polypeptide or a fragment thereof has at least 80% sequence identity with a US1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the Us1 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of US1 polypeptides known in the art include US1 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the US1 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:58, 59, 60 and / or 61, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0496] The US7 open reading frame encodes HSV gI (also referred to herein as the US7 polypeptide). In some embodiments, the HSVT cellular antigen is or includes a US7 polypeptide or a fragment thereof. In various embodiments, the US7 polypeptide or a fragment thereof has at least 80% sequence identity with a US7 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL1 polypeptide or a fragment thereof has at least 80% sequence identity, such as at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 99% or 100% sequence identity, with a US7 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of US7 polypeptides known in the art include US7 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the US7 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:62, 63, 64 and / or 65, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0497] The US8 open reading frame encodes HSV gE (also referred to herein as the US8 polypeptide). In some embodiments, the HSVT cellular antigen is or includes a US8 polypeptide or a fragment thereof. In various embodiments, the US8 polypeptide or fragment thereof has at least 80% sequence identity with a US8 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity, with a US8 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of US8 polypeptides known in the art include US8 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the US8 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:66, 67, 68 and / or 69, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0498] The UL22 open reading frame encodes HSV gH (also referred to herein as the UL22 polypeptide). In some embodiments, the HSV T cell antigen is or includes a UL22 polypeptide or a fragment thereof. In various embodiments, the UL22 polypeptide or fragment thereof has at least 80% sequence identity with a UL22 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL22 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity, to a UL1 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL22 polypeptides known in the art include UL22 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL22 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:70, 71, 72 and / or 73, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0499] In some embodiments, the HSV T cell antigen is or includes a UL54 polypeptide or a fragment thereof. In various embodiments, the UL54 polypeptide or fragment thereof has at least 80% sequence identity with a UL54 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. In some embodiments, the UL1 polypeptide or fragment thereof has at least 80% sequence identity, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity, to a UL54 amino acid sequence shown in Table 3 or otherwise known in the art, or a corresponding fragment thereof. Examples of UL54 polypeptides known in the art include UL54 polypeptides encoded by known HSV strains, such as, but not limited to, HG52, G, 333, and MS strains. In some embodiments, the UL54 polypeptide or fragment thereof has at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:55, 56 and / or 57, such as at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity.
[0500] In some embodiments, the HSV antigens used in accordance with the present disclosure comprise an RL2 polypeptide or an antigenic fragment thereof, an RS1 polypeptide or an antigenic fragment thereof, a UL54 polypeptide or an antigenic fragment thereof, a UL29 polypeptide or an antigenic fragment thereof, a UL39 polypeptide or an antigenic fragment thereof, a UL49 polypeptide or an antigenic fragment thereof, a UL9 polypeptide or an antigenic fragment thereof, a UL30 polypeptide or an antigenic fragment thereof, a UL40 polypeptide or an antigenic fragment thereof, a UL5 polypeptide or an antigenic fragment thereof, a UL52 polypeptide or an antigenic fragment thereof, a UL1 polypeptide or an antigenic fragment thereof, a UL19 polypeptide or an antigenic fragment thereof, a UL21 polypeptide or an antigenic fragment thereof, a UL27 polypeptide or an antigenic fragment thereof, a UL46 polypeptide or an antigenic fragment thereof, a UL47 polypeptide or an antigenic fragment thereof, a UL48 polypeptide or an antigenic fragment thereof, a UL25 polypeptide or an antigenic fragment thereof, or a combination thereof.
[0501] In some embodiments, the polyribonucleotides provided herein encode one or more of an RL2 polypeptide or antigenic fragment thereof, an RS1 polypeptide or antigenic fragment thereof, a UL54 polypeptide or antigenic fragment thereof, a UL29 polypeptide or antigenic fragment thereof, a UL39 polypeptide or antigenic fragment thereof, a UL49 polypeptide or antigenic fragment thereof, a UL9 polypeptide or antigenic fragment thereof, a UL30 polypeptide or antigenic fragment thereof, a UL40 polypeptide or antigenic fragment thereof, a UL5 polypeptide or antigenic fragment thereof, a UL52 polypeptide or antigenic fragment thereof, a UL1 polypeptide or antigenic fragment thereof, a UL19 polypeptide or antigenic fragment thereof, a UL21 polypeptide or antigenic fragment thereof, a UL27 polypeptide or antigenic fragment thereof, a UL46 polypeptide or antigenic fragment thereof, a UL47 polypeptide or antigenic fragment thereof, a UL48 polypeptide or antigenic fragment thereof, a UL25 polypeptide or antigenic fragment thereof, a US1 polypeptide or antigenic fragment thereof, a US7 polypeptide or antigenic fragment thereof, a US8 polypeptide or antigenic fragment thereof, and a UL22 polypeptide or antigenic fragment thereof.
[0502] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is an RL2 polypeptide or an antigenic fragment thereof. In some embodiments, the RL2 polypeptide or an antigenic fragment thereof comprises or consists of the following amino acid sequence: CTDEIAPPLRCQSFPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDP RTRVEAEAAVRAGTAVDFIWTGNPRTAPRSLS (SEQ ID NO: 174). In some embodiments, the RL2 polypeptide or an antigenic fragment thereof comprises or consists of the following amino acid sequence: LPIAGVSSVVALAPYVNKTVTGDCLP VLDMETGHIGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHA RNCVRPPDYPTPPASEWNSLWMTPVGNMLFDQGTLVG (SEQ ID NO: 175).
[0503] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is an RS1 polypeptide or an antigenic fragment thereof. In some embodiments, the RS1 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: RAAAWMRQVPDPEDVRVVILYSPLPGEDLAAGRAGGGPPPEWSAERGGLSCLLAALGNRLCGPATAAWAGNWTGAPDVSALGAQGVLLLSTRDLAFAGAVEFLGLLAGACDRRLIVVNAVRAADWPADGPVVSRQHAYLACEVLPAVQCAVRWPAARDLRRTVLASGRVFGPGVFARVEAAHARLYPDAPPLRLCRGANVRYRVRTRFGPDTLVPMSPREYRRAVLPALDGRAAAS (SEQ ID NO: 176).
[0504] In some embodiments, provided herein are polyribonucleotide encodings one or more HSV (for example, HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL54 polypeptide or its antigenic fragment. In some embodiments, the UL54 polypeptide or its antigenic fragment comprises or is made up of the following amino acid sequence: ETLVAHGPSLYRTFAANPRAASTAKAMRDCVLRQENLIEALASADETLAWCKMCIHHNLPLRPQDPIIGTAAAVLENLATRLRPFLQCYLKARGLCGLDDLCSRRRLSDIKDIASFVLVILARLANRVERGVSEIDYTTVGVGAGETMHFYIPGACMAGLIEILDTHRQECSSRVCELTASHTIAPLYVHGKYFYCNSLF (SEQ ID NO: 177).
[0505] In some embodiments, provided herein are polyribonucleotide encodings of one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL29 polypeptide or an antigenic fragment thereof. In some embodiments, the UL29 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: REDIETIAFIKRFSL DYGAINFINLAPNNVSELAMYYMANQILRYCDHSTYFINTLTAVIAGSRRPPSVQAAAAWAPQGGAGLEAGARALMDSLDAHPGAWTSMFASCNLLRPVMAARPMVVLGLSISKYYGMAGNDRVFQAGNWASLLGGKNACPLLIFDRTRKFVL (SEQ ID NO: 178).
[0506] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL39 polypeptide or an antigenic fragment thereof. In some embodiments, the UL39 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: RTFGSAPRLTEDDFGLLNYALAEMRRLCLDLPPVPPNAYTPYHLREYATRLVNGFKPLVRRSARLYRILGVLVHLRIRTREASFEEWMRSKEVDLDFGLTERLREHEAQLMILAQALNPYDCLIHSTPNTLVERGLQSALKYEEFYLKRFGGHYMESVFQMYTRIAGFLA (SEQ ID NO: 179).
[0507] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL49 polypeptide or an antigenic fragment thereof. In some embodiments, the UL49 polypeptide or an antigenic fragment thereof comprises or consists of the following amino acid sequence: KMTRGAPKASATPATDPARGRRPAQADSAVLLDAPAPTASGRTKTPAQGLAKKLHFS TAPPSPTAPWTPRVAGFNKRVFCAAVG (SEQ ID NO: 180).
[0508] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL9 polypeptide or an antigenic fragment thereof. In some embodiments, the UL9 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: LLNNYDVLVLDEVM STLGQLYSPTMQQLGRVDALMLRLLRTCPRIIAMDATANAQLVDFLCSLRGEKNVHVVIGEYAMPGFSARRCLFLPRLGPEVLQAALRRRGPAGGAPPPDAPPDATFFGELEARLAGGDNVCIFSSTVSFAEVVARFCRQFTDRVLLLHSLTPPGDVTTWGRYRVVIYTTVVTVGLSFDPPHFDSMFAYVKPMNYGPDMVSVYQSLGRVRTLRKGELLIYMDGSGARSEPV (SEQ ID NO: 181).
[0509] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL30 polypeptide or an antigenic fragment thereof. In some embodiments, the UL30 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: ISCLLYDLSTTALEHILLFSLGSCDLPESHLSDLASRGLPAPVVLEFDSEFEMLLAFMTF VKQYGPEFVTGYNIINFDWPFVLTKLTEIYKVPLDGYGRMNGRG VFRVWDIGQSHF (SEQ ID NO: 182). In some embodiments, the UL30 polypeptide or its antigenic fragment comprises the amino acid sequence GLLPCLHVAATVTTIGREML LATRAYVHARWAEFDQLLADFPEAAGMRAPGPYSM (SEQ ID NO: 183).
[0510] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL40 polypeptide or an antigenic fragment thereof. In some embodiments, the UL40 polypeptide or an antigenic fragment thereof comprises or consists of the following amino acid sequence: TSQCPDINHLRSLSILNRWLETELVFVGDEEDVSKLSEGELGFYRFLFAFLSAADDLVTENLGGLSGLFEQKDILHYYVEQECIEVVHSRVYNIIQLVLFHNNDQARRAYVARTINHPAIRVKVDWLEARVRECDSIPEKFILMILIEGVFFAASFAAIAYLRTNNLLR (SEQ ID NO: 184).
[0511] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL5 polypeptide or an antigenic fragment thereof. In some embodiments, the UL5 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: HEFGNLMKVLEYGL PITEEHMQFVDRFVVPESYITNPANLPGWTRLFSSHKEVSAYMAK LHAYLKVTREGEFVVFTLPVLTFVSVKEFDEYRRL (SEQ ID NO: 185). In some embodiments, the UL5 polypeptide or its antigenic fragment comprises or consists of the following amino acid sequence: ELFGEVFESAPFSTYVDNVIFRG CELLTGSPRGGLMSVALQTDNYTLMGYTYTRVFAFAEELRRRHA TAGVAEFLEESPLPYIVLRDQHGFMSVVNTNI (SEQ ID NO: 186).
[0512] In some embodiments, provided herein is a polyribonucleotide encoding one or more HSV (for example, HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL52 polypeptide or its antigenic fragment. In some embodiments, the UL52 polypeptide or its antigenic fragment comprises the following amino acid sequence or is made up of the following amino acid sequence: SVAAP VEVTALYATDGCVITSSLALLTNCLLGAEPLYIFSYDAYRSDAPNGPTGAPTEQERFEGSRALYRDAGGLNGDSFRVTFCLLGTEVGVTHHPKGRTRPMFVCRFERADDVAVLQDALGRGTPLLPAHVTATLDLEATFALHANIIMALTVAIVHNAPARIGSGSTAPLYEPGESMRSVV (SEQ ID NO: 187).
[0513] In some embodiments, the polyribonucleotides provided herein encode one or more HSV (e.g., HSV-1 and / or HSV-2) antigens, wherein at least one antigen is a UL1 polypeptide or an antigenic fragment thereof. In some embodiments, the UL1 polypeptide or an antigenic fragment thereof compri...
Claims
1. A polyribonucleotide encoding a polypeptide, wherein the polypeptide comprises one or more herpes simplex virus (HSV) antigens or antigenic fragments thereof, and wherein the one or more HSV antigens or antigenic fragments thereof comprise: (i) one or more HSV RS1 polypeptides or antigenic fragments thereof, (ii) one or more HSV RL2 polypeptides or antigenic fragments thereof, (iii) one or more HSV UL1 polypeptides or antigenic fragments thereof, (iv) one or more HSV UL5 polypeptides or antigenic fragments thereof, (v) one or more HSV UL9 polypeptides or antigenic fragments thereof, (vi) one or more HSV UL19 polypeptides or antigenic fragments thereof, (vii) one or more HSV UL21 polypeptides or antigenic fragments thereof, (viii) one or more HSV UL25 polypeptides or antigenic fragments thereof, (ix) one or more HSV UL27 polypeptides or antigenic fragments thereof, (x) one or more HSV UL29 polypeptides or antigenic fragments thereof, (xi) one or more HSV UL30 polypeptides or antigenic fragments thereof, (xii) one or more HSV UL39 polypeptides or antigenic fragments thereof, (xiii) one or more HSV UL40 polypeptides or antigenic fragments thereof, (xiv) one or more HSV UL46 polypeptides or antigenic fragments thereof, (xv) one or more HSV UL47 polypeptides or antigenic fragments thereof, (xvi) one or more HSV UL48 polypeptides or antigenic fragments thereof, (xvii) one or more HSV UL49 polypeptides or antigenic fragments thereof, (xviii) one or more HSV UL52 polypeptides or antigenic fragments thereof, (xix) one or more HSV UL54 polypeptides or antigenic fragments thereof, or (xx) any combination thereof.
2. polyribonucleotide as claimed in claim 1, wherein said polypeptide comprises one or more HSV antigenic fragments, and said one or more HSV antigenic fragments comprise: (i) one or more HSV RS1 polypeptide antigenic fragments, (ii) one or more HSV RL2 polypeptide antigenic fragments, (iii) one or more HSV UL1 polypeptide antigenic fragments, (iv) one or more HSV UL5 polypeptide antigenic fragments, (v) one or more HSV UL9 polypeptide antigenic fragments, (vi) one or more HSV UL19 polypeptide antigenic fragments, (vii) one or more HSV UL21 polypeptide antigenic fragments, (viii) one or more HSV UL25 polypeptide antigenic fragments, (ix) one or more HSV UL27 polypeptide antigenic fragments, (x) one or more HSV UL29 polypeptide antigenic fragments, (xi) one or more HSV UL30 polypeptide antigenic fragments, (xii) one or more HSV UL39 polypeptide antigenic fragments, (xiii) one or more HSV UL40 polypeptide antigenic fragments, (xiv) one or more HSV UL46 polypeptide antigenic fragments, (xv) one or more HSV UL47 polypeptide antigenic fragments, (xvi) one or more HSV UL48 polypeptide antigenic fragments, (xvii) one or more HSV UL49 polypeptide antigenic fragments, (xviii) one or more HSV UL52 polypeptide antigenic fragments, (xix) one or more HSV UL54 polypeptide antigenic fragments, or (xx) any combination thereof.
3. polyribonucleotide as claimed in claim 1 or 2, wherein said polypeptide comprises one or more HSV RL2 polypeptides or its antigenic fragment, one or more HSV RS1 polypeptides or its antigenic fragment and one or more HSV UL54 polypeptides or its antigenic fragment.
4. The polyribonucleotide of any one of claims 1 to 3, wherein the polypeptide comprises an HSV-1 gD secretion signal, one or more RL2 polypeptides or antigenic fragments thereof, one or more RS1 polypeptides or antigenic fragments thereof, one or more UL54 polypeptides or antigenic fragments thereof, and MITD.
5. The polyribonucleotide of any one of claims 1 to 4, wherein the polypeptide comprises, in N-terminal to C-terminal order, a nucleotide sequence encoding an HSV-1 gD secretion signal, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, a UL54 polypeptide or an antigenic fragment thereof, a linker, and MITD.
6. polyribonucleotide as claimed in claim 5, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:197 or is made up of according to the aminoacid sequence of SEQ ID NO:
197.
7. The polyribonucleotide of any one of claims 1 to 4, wherein the polypeptide comprises, in N-terminal to C-terminal order, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL54 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, and MITD.
8. polyribonucleotide as claimed in claim 7, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:201 or is made up of according to the aminoacid sequence of SEQ ID NO:
201.
9. A polyribonucleotide as described in any one of claims 1 to 4, wherein the polypeptide comprises a nucleotide sequence encoding an HSV-2gD secretion signal, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RL2 polypeptide or an antigenic fragment thereof, a linker, an RS1 polypeptide or an antigenic fragment thereof, a linker, a UL54 polypeptide or an antigenic fragment thereof, a linker and MITD in order from N-terminus to C-terminus.
10. polyribonucleotide as claimed in claim 9, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:205 or is made up of according to the aminoacid sequence of SEQ ID NO:
205.
11. polyribonucleotides as claimed in claim 1 or 2, wherein said polypeptide comprises one or more HSV UL29 polypeptides or their antigenic fragments, one or more HSV UL39 polypeptides or their antigenic fragments, one or more HSV UL49 polypeptides or their antigenic fragments and one or more HSV UL9 polypeptides or their antigenic fragments.
12. The polyribonucleotide of any one of claims 1, 2 and 11, wherein the polypeptide comprises an HSV-1 gD secretion signal, one or more HSV UL29 polypeptides or antigenic fragments thereof, one or more HSV UL39 polypeptides or antigenic fragments thereof, one or more HSV UL49 polypeptides or antigenic fragments thereof, one or more HSV UL9 polypeptides or antigenic fragments thereof and MITD.
13. The polyribonucleotide of any one of claims 1, 2, 11 and 12, wherein the polypeptide comprises, in N-terminal to C-terminal order, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL29 polypeptide or an antigenic fragment thereof, a linker, a UL39 polypeptide or an antigenic fragment thereof, a linker, a UL49 polypeptide or an antigenic fragment thereof, a linker, a UL9 polypeptide or an antigenic fragment thereof, a linker and MITD.
14. polyribonucleotide as claimed in claim 13, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:198 or is made up of according to the aminoacid sequence of SEQ ID NO:
198.
15. The polyribonucleotide of any one of claims 1, 2, 11 and 12, wherein the polypeptide comprises, in N-terminal to C-terminal order, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL9 polypeptide or an antigenic fragment thereof, a linker, a UL49 polypeptide or an antigenic fragment thereof, a linker, a UL39 polypeptide or an antigenic fragment thereof, a linker, a UL29 polypeptide or an antigenic fragment thereof, a linker and MITD.
16. polyribonucleotide as claimed in claim 15, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:202 or is made up of according to the aminoacid sequence of SEQ ID NO:
202.
17. polyribonucleotides as claimed in claim 1 or 2, wherein the polypeptide comprises one or more HSV UL30 polypeptides or their antigenic fragments, one or more HSV UL40 polypeptides or their antigenic fragments, one or more HSV UL5 polypeptides or their antigenic fragments and one or more HSV UL52 polypeptides or their antigenic fragments.
18. The polyribonucleotide of any one of claims 1, 2 and 17, wherein the polypeptide comprises an HSV-1 gD secretion signal, one or more HSV UL30 polypeptides or antigenic fragments thereof, one or more HSV UL40 polypeptides or antigenic fragments thereof, one or more HSV UL5 polypeptides or antigenic fragments thereof, one or more HSV UL52 polypeptides or antigenic fragments thereof, and MITD.
19. The polyribonucleotide of any one of claims 1, 2, 17 and 18, wherein the polypeptide comprises, in order from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL40 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL52 polypeptide or an antigenic fragment thereof, a linker and MITD.
20. polyribonucleotide as claimed in claim 19, wherein said polypeptide comprises according to the amino acid sequence of SEQ ID NO:199 or consists of according to the amino acid sequence of SEQ ID NO:
199.
21. The polyribonucleotide of any one of claims 1, 2, 17 and 18, wherein the polypeptide comprises, in N-terminal to C-terminal order, a nucleotide sequence encoding an HSV-1 gD secretion signal, a UL52 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL5 polypeptide or an antigenic fragment thereof, a linker, a UL40 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker, a UL30 polypeptide or an antigenic fragment thereof, a linker and MITD.
22. polyribonucleotide as claimed in claim 21, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:203 or is made up of according to the aminoacid sequence of SEQ ID NO:
203.
23. The polyribonucleotide of claim 1 or 2, wherein the polypeptide comprises one or more HSV UL1 polypeptides or antigenic fragments thereof, one or more HSV UL19 polypeptides or antigenic fragments thereof, one or more HSV UL21 polypeptides or antigenic fragments thereof, one or more HSV UL27 polypeptides or antigenic fragments thereof, one or more HSV UL46 polypeptides or antigenic fragments thereof, one or more HSV UL47 polypeptides or antigenic fragments thereof, one or more UL48 polypeptides or antigenic fragments thereof, and one or more HSV UL25 polypeptides or antigenic fragments thereof.
24. The polyribonucleotide of any one of claims 1, 2 and 23, wherein the polypeptide comprises an HSV-1 gD secretion signal, one or more HSV UL1 polypeptides or antigenic fragments thereof, one or more HSV UL19 polypeptides or antigenic fragments thereof, one or more HSV UL21 polypeptides or antigenic fragments thereof, one or more HSV UL27 polypeptides or antigenic fragments thereof, one or more HSV UL46 polypeptides or antigenic fragments thereof, one or more HSV UL47 polypeptides or antigenic fragments thereof, one or more UL48 polypeptides or antigenic fragments thereof, one or more HSV UL25 polypeptides or antigenic fragments thereof, and MITD.
25. The polyribonucleotide of any one of claims 1, 2, 23 and 24, wherein the polypeptide comprises, in order from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, an HSV UL1 polypeptide or an antigenic fragment thereof, a linker, an HSV UL19 polypeptide or an antigenic fragment thereof, a linker, an HSV UL21 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL46 polypeptide or an antigenic fragment thereof, a linker, an HSV UL47 polypeptide or an antigenic fragment thereof, a linker, an HSV UL25 polypeptide or an antigenic fragment thereof, a linker, an HSV UL48 polypeptide or an antigenic fragment thereof, a linker and MITD.
26. polyribonucleotide as claimed in claim 25, wherein said polypeptide comprises according to the amino acid sequence of SEQ ID NO:200 or is made up of according to the amino acid sequence of SEQ ID NO:
200.
27. The polyribonucleotide of claims 1, 2, 23 and 24, wherein the polypeptide comprises, in order from N-terminus to C-terminus, a nucleotide sequence encoding an HSV-1 gD secretion signal, an HSV UL48 polypeptide or an antigenic fragment thereof, a linker, an HSV UL25 polypeptide or an antigenic fragment thereof, a linker, an HSV UL47 polypeptide or an antigenic fragment thereof, a linker, an HSV UL46 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL27 polypeptide or an antigenic fragment thereof, a linker, an HSV UL21 polypeptide or an antigenic fragment thereof, a linker, an HSV UL19 polypeptide or an antigenic fragment thereof, a linker, an HSV UL1 polypeptide or an antigenic fragment thereof, a linker and MITD.
28. polyribonucleotide as claimed in claim 26, wherein said polypeptide comprises according to the aminoacid sequence of SEQ ID NO:204 or is made up of according to the aminoacid sequence of SEQ ID NO:
204.
29. polyribonucleotides as described in any one among the claims 1-28, wherein said polyribonucleotides are isolated polyribonucleotides.
30. The polyribonucleotide of any one of claims 1-28, wherein the polyribonucleotide is an engineered polyribonucleotide.
31. polyribonucleotides as described in any one among the claims 1-28, wherein said polyribonucleotides are codon optimized polyribonucleotides.
32. A combination comprising: The first polyribonucleotide according to any one of claims 1 to 31, and a second polyribonucleotide, wherein the second polyribonucleotide encodes a second polypeptide, wherein the second polypeptide comprises one or more herpes simplex virus (HSV) antigens or antigenic fragments thereof, and Wherein the first polyribonucleotide and the second polyribonucleotide are different.
33. A combination comprising: A first pharmaceutical composition comprising a first polyribonucleotide, wherein the first polyribonucleotide is a polyribonucleotide according to any one of claims 1 to 31; and A second pharmaceutical composition comprising a second polyribonucleotide, wherein the polyribonucleotide encodes a second polypeptide, wherein the second polypeptide comprises one or more herpes simplex virus (HSV) antigens or antigenic fragments thereof, Wherein the first polyribonucleotide and the second polyribonucleotide are different.
34. A combination as described in claim 32 or 33, wherein the one or more HSV antigens or antigenic fragments thereof of the second polypeptide comprise one or more HSV glycoproteins.
35. The combination of claim 34, wherein the one or more HSV glycoproteins comprise HSV glycoprotein B (gB), HSV glycoprotein E (gE), HSV glycoprotein G (gG), HSV glycoprotein H (gH), HSV glycoprotein I (gI), HSV glycoprotein L (gL), or a combination thereof.
36. The combination of claim 32 or 33, wherein the second polypeptide comprises a single HSV antigen.
37. The combination of 36, wherein the single HSV antigen is an HSV glycoprotein.
38. The combination of claim 37, wherein the HSV glycoprotein is a full-length HSV glycoprotein.
39. The combination of claim 37 or 38, wherein the HSV glycoproteins are HSV gB, HSV gE, HSV gG, HSV gH, HSV gI and HSV gL.
40. An RNA construct comprising, in 5' to 3' order: (i) 5'UTR; (ii) a polyribonucleotide as claimed in any one of claims 1 to 31; (iv) 3'UTR; and (v) Poly A tail sequence.
41. The RNA construct of claim 40, further comprising a 5' cap.
42. A composition comprising: (i) one or more polyribonucleotides according to any one of claims 1 to 31, and (ii) lipid nanoparticles, polyplexes (PLX), lipidated polyplexes (LPLX) or liposomes, Wherein the one or more polyribonucleotides are completely or partially encapsulated in the lipid nanoparticle, polyplex (PLX), lipidated polyplex (LPLX) or liposome.
43. a pharmaceutical composition comprising one or more polyribonucleotides as described in any one of claims 1-31 and at least one pharmaceutically acceptable excipient.
44. A method comprising administering to a subject a polyribonucleotide according to any one of claims 1-31.
45. A method comprising administering to a subject an RNA construct according to claim 40 or 41.
46. A method comprising administering to a subject the pharmaceutical composition of claim 43.
47. A method comprising administering to a subject a combination according to any one of claims 32 to 39.
Citation Information
Patent Citations
Method and apparatus for base station controller relocation in wireless communication system
EP1725062A1
Lipid formulation
US20100324120A1
Pegylated lipids and their use for drug delivery
US20140200257A1
Lipids for the delivery of active agents
US20140308304A1
Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents
US20150005363A1
